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Abstract 
The Rip2 kinase contains a caspase recruitment domain (CARD) and has been 
implicated in the activation of the transcriptional factor NF-B downstream of Nod-like 
receptors.  However, how Rip2 mediates innate immune responses is still largely unclear. 
We show that Rip2 and IKK- become stably polyubiquitinated upon treatment of cells 
with the Nod2 ligand, muramyl dipeptide. We demonstrate a requirement for the E2 
conjugating enzyme Ubc13, the E3 ubiquitin ligase Traf6 and the ubiquitin activated 
kinase Tak1 in Nod2-mediated NF-B activation. We also show that M. tuberculosis 
infection stimulates Rip2 polyubiquitination. Collectively, this study revealed that the 
Nod2 pathway is ubiquitin regulated and that Rip2 employs a ubiquitin-dependent 
mechanism to achieve NF-B activation. 
We also demonstrate that intraphagosomal M. tuberculosis stimulates the 
cytosolic Nod2 pathway. We show that upon Mtb infection, Nod2 recognition triggers the 
expression of type I interferons in a Tbk1- and Irf5-dependent manner. This response is 
only partially impaired by the loss of Irf3 and therefore, differs fundamentally from those 
stimulated by bacterial DNA, which depends entirely on this transcription factor. This 
difference appears to result from the unusual peptidoglycan produced by mycobacteria, 
which we show is a uniquely potent agonist of the Nod2/Rip2/Irf5 pathway. Thus, the 
Nod2 system is specialized to recognize bacteria that actively perturb host membranes 
and is remarkably sensitive to Mycobacteria, perhaps reflecting the strong evolutionary 
pressure exerted by these pathogens on the mammalian immune system. 
v 
 
 
 
Table of Contents  
 
Acknowledgement iii 
 
Abstract iv 
 
List of Figures vii 
 
Chapter I      Introduction 1 
 
Chapter II      NOD2 pathway activation by MDP or Mycobacterium tuberculosis 
infection involves the stable polyubiquitination of Rip2 39 
 
Introduction 40 
 
Results 42 
 
Discussion 51 
 
Materials and Methods 54 
 
Figures and Legends 58 
 
Chapter III      NOD2, RIP2 and IRF5 Play a Critical Role in the Type I Interferon 
Response to Mycobacterium Tuberculosis 67 
 
Introduction 68 
 
Results 72 
 
Discussion 81 
 
Materials and Methods 88 
vi 
 
 
 
Figures and Legends 94 
 
Chapter IV      Discussion 110 
 
References 123 
 
Appendix I       Additional data (not shown in Chaper II and III) 139 
 
Appendix II      A cytosolic NEMO/RIP1 complex recruits TAK1 to mediate the 
NF-B and p38 MAP kinase/MAPKAP-2 responses to DNA 
damage 145 
vii 
 
 
 
List of Figures 
Figure 1. RIP family of proteins 34 
 
Figure 2. 
 
Schematic representation of three NF-B signaling 
pathways 35 
 
Figure 3. 
 
Model of IKK activation by TNF. 
 
36 
 
Figure 4.  
 
Model of IKK activation by MDP. 37 
 
Figure 5. 
 
Overview of the IRF family members and their 
expression patterns and transcriptional roles 38 
 
Figure 6. 
 
Rip2-deficient macrophages are impaired in their 
response to NOD2 ligand MDP, but respond normally to 
the TLR4 ligand, LPS  58 
 
Figure 7. 
 
NOD2 pathway activation stimulates the stable 
K63-linked polyubiquitination of Rip2  59 
 
Figure 8. 
 
 
MDP treatment stimulates the K63-specific ubiquitin 
modification of endogenous Rip2. 60 
 
Figure 9. 
 
MDP-induced Rip2 polyubiquitination is dependent on 
the expression of the E2 conjugating enzyme Ubc13 and 
the E3 ubiquitin ligase Traf6 61 
 
Figure 10. 
 
Rip2 and the ubiquitin activated kinase Tak1 interact 
upon MDP stimulation and Tak1 expression is required 
for MDP-induced IKK activation  63 
 
Figure 11. 
 
Live Mycobacterium tuberculosis infection stimulates Rip2 
polyubiquitination 64 
 
Figure 12. 
 
Identification of critical lysine residues critical for Rip2 
polyubiquitination. 65 
 
Figure 13. 
 
Rip2 polyubiquitin modification is required for 
Nod2-mediated IKK activation. 66 
viii 
 
 
 
Figure 14. Live, intracellular Mycobacterium tuberculosis stimulates 
Rip2 polyubiquitination 94 
 
Figure 15. 
 
Rip2 polyubiquitination upon Mtb infection requires 
ESX-1 96 
 
Figure 16. 
 
Membrane damage allows Nod2-mediated recognition of 
ESX1 mutants 97 
 
Figure 17. 
 
Type I Interferon production upon Mtb infection is 
reduced in Rip2- and Nod2-deficient macrophages 98 
 
Figure 18. 
 
Type I Interferon production upon Mtb infection is 
reduced in Rip2- and Nod2-deficient macrophages but 
not in Nod1-deficient macrophages 99 
 
Figure 19. 
 
Multiple cytosolic pathways lead to IFN induction 100 
 
Figure 20. 
 
Nod2 stimulation is sufficient for type I IFN induction 101 
 
Figure 21. 
 
Mtb-induced type I IFN response is Tbk1-dependent and 
mediated through both Irf3 and Irf5 102 
 
Figure 22. 
 
Mtb-induced type I IFN response is only partially 
mediated through Irf3 104 
 
Figure 23. 
 
Irf5 is required for an optimal type I IFN response upon 
Mtb infection 105 
 
Figure 24. 
 
Irf3 and Irf5 expression levels in Irf3-/- and Irf5-/- 
macrophages 106 
 
Figure 25. 
 
The N-Glycolyl-MDP-induced type I IFN response is 
Irf5-dependent and Irf3 independent 107 
 
Figure 26. 
 
Rip2 polyubiquitination is required for the Mtb-induced 
Type I IFN response 108 
 
Figure 27. 
 
Mtb infection fails to elicit type I IFN production in the 
absence of IRF3 and IRF5 109 
  
 
 
 
Chapter I       
 
 
Introduction 
 
 
 
 
 
 
2 
 
 
 
Cells within an organism face constant stresses from both outside and inside the 
cell. These stresses allow communications between cells and signal changes in the 
environment to which the cells must adapt. To respond to these stresses, cells activate a 
series of pathways which ultimately lead to changes in gene expression, enzyme activity, 
or the localization of cellular components. For example, binding of pro-inflammatory 
cytokines to their receptors, stimulation of pathogen recognition receptors by 
pathogen-associated molecular patterns, or events that induce DNA damage activate the 
transcription factors NF-B and AP-1, as well as mitogen-activated protein kinases and 
interferon regulatory factors, resulting in specific cellular responses [1,2]. 
However, these cellular stress pathways must be precisely regulated, since they 
regulate cell proliferation, motility, communication and survival. Deregulation of these 
pathways can result in chronic inflammatory diseases such as inflammatory bowel 
disease (IBD), Crohn's disease (CD), autoimmune disease, etc [3,4]. This dissertation 
focuses on the receptor-interacting protein (RIP) family, which are critical 
regulators/mediators of several cellular stress pathways.   
 
I. Overview of the Rip protein family 
The human genome contains about 500 protein kinase genes, which transmit 
signals and control complex processes in cells [5,6]. One branch of the serine/threonine 
kinase family includes the receptor-interacting proteins (RIP). Rip kinases are closely 
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related to members of the interleukin-1-receptor-associated kinase (IRAK) family. IRAK 
family members mediate interleukin-1β (IL-1β) and Toll-like receptor (TLR) signaling 
pathways [7], suggesting that the Rip family proteins may also be involved in the 
response to cell stress induced signaling pathways. 
Receptor interacting protein (RIP) kinases constitute a family of seven members 
(Figure 1), all of which contain a serine/threonine kinase domain (KD) but diverge at 
their C-termini. Rip kinases mediate cellular responses to infection, inflammation, 
differentiation and DNA damage. Although these stimuli are diverse, they activate 
similar pathways including activation of the transcription factors NF-κB or AP-1 [8]. 
      Rip1 and Rip2 are the Rip family members which have been most extensively 
studied. Besides the serine/threonine kinase domain, Rip1 and Rip2 (CARDIAK/RICK) 
contain a C-terminal domain belonging to the death domain (DD) superfamily, namely, a 
DD and a caspase recruitment domain (CARD), respectively. Both the DD domain and 
CARD domains recruit large protein complexes through domain oligomerization, 
initiating different signaling pathways. Rip1 and Rip3 also contain a RIP homotypic 
interaction motif (RHIM). This RHIM domain is sufficient for the interaction of Rip1 
with the TLR3/4 adapter protein Trif and Rip3 [9], which suggests that Rip3 and Rip1 
may regulate Trif dependent anti-viral responses. Rip4 (DIK/PKK) and Rip5 (SgK288) 
are characterized by the presence of ankyrin repeats in their C-terminal domains, which 
are required for keratinocyte differentiation[10,11]. Rip6 (LRRK1) and Rip7 (LRRK2) 
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contain a leucine-rich repeat (LRR) motif in the N-terminal domain, which may be 
involved in recognition of pathogen-, damage- or stress-associated molecular patterns 
(PAMP, DAMP, SAMP). In addition, they contain Roc/COR domains (Ras of complex 
proteins/C-terminal of Roc) adjacent to the LRR motif. Binding of GTP to the 
GTPase-like Roc domain leads to the stimulation of Rip6 kinase activity. Mutational 
analysis indicated that the COR domain might be important for transmitting an 
stimulating signal to the kinase domain. The function of Rip6 and Rip7 remains unclear, 
though, mutations in the human Rip7 gene are associated with both familial and sporadic 
Parkinson's disease[12,13]. 
 
II. Protein Ubiquitination and Signal Transduction  
Protein ubiquitination is an essential and ubiquitous mechanism used by 
eukaryotic cells to regulate responses to cellular stress [14]. This process involves a 
covalent modification of cellular proteins by ubiquitin, a highly conserved, 
76-amino-acid protein [15]. Ubiquitin is linked to specific lysine residues of the substrate, 
and the long polyubiquitin chains are formed as additional ubiquitins are attached to a 
lysine residue in ubiquitin itself. Originally, ubiquitin modification was primarily 
considered a mechanism of targeting proteins for proteasomal degradation. In the past 
several years, a number of new cellular functions have been associated with stable protein 
ubiquitination. 
The protein ubiquitination process initiates with ubiquitin activation by an E1 
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(ubiquitin-activating enzyme), followed by the transfer of an activated ubiquitin to an E2 
(ubiquitin-conjugating enzyme, also known as Ubc), and ends with the conjugation of 
ubiquitin to a target protein through the activity of a ubiquitin-protein ligase (E3) to form 
an isopeptide bond between the carboxyl terminus of ubiquitin and an epsilon amino 
group of a lysine residue on the protein substrate. The E3 ubiquitin ligase, sometimes 
together with E2s, usually determines substrate specificity. E3 ubiquitin ligases are a 
large protein family that can be divided into three categories, depending on the nature of 
the E3 ligase domain: HECT (homology to E6AP C-terminus), RING (really interesting 
new gene) domain and U Box domain. The HECT domain E3s contain an active-site 
cysteine, which can accept ubiquitin from an E2 and transfer the ubiquitin to a target 
protein. In contrast, the RING domain E3s do not contain a conventional enzyme active 
site, but they promote ubiquitination by binding to both protein substrates and E2s, 
facilitating the conjugation of ubiquitin to specific protein targets. Also, similar to 
phosphorylation, the ubiquitination reaction is a reversible covalent modification, 
regulated by a large family of deubiquitination enzymes (DUBs, also known as 
isopeptidases) [16].  
There are seven lysines in ubiquitin, each of which can be conjugated by 
another ubiquitin to form a polyubiquitin chain [17]. Recent evidence suggests that the 
topology of polyubiquitin chains may have specific functions. Generally speaking, 
polyubiquitin chains linked through lysine 48 (K48) of ubiquitin normally target a protein 
for proteasomal degradation, whereas K63-linked polyubiquitin chains have functions 
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independent of proteolysis, and are usually involved in responses to cellular stress [18]. 
Monoubiquitination, where a protein substrate is modified with a single ubiquitin, usually 
does not lead to proteasomal degradation, but appears to regulate chromatin remodeling, 
vesicle trafficking and cellular localization. 
A recent study showed that a ubiquitin ligase complex composed of two RING 
domain proteins, RNF31 (also known as HOIP) and RBCK1 (also known as HOIL-1L), 
and UbcH5C catalyze the synthesis of linear ubiquitin chains. These linear ubiquitin 
chains can bind NEMO and are believed to be important for IKK activation [19,20]. This 
study suggests that in addition to K63-linked ubiquitin chains, linear ubiquitin chains 
may also have the specific function of mediating signaling pathways. However, another 
report indicated that the RNF31-RBCK1 synthesized linear polyubiquitin chains did not 
activate IKK or Tak1 and only K63-linked ubiquitin chain can activate IKK and Tak1. 
Furthermore, the results from this report indicate that unanchored polyubiquitin chains 
directly activate IKK and Tak1 in vitro, suggesting a potentially new mechanism of 
kinase activation [21].     
 
III. The NF-B pathway 
Both proteolytic and nonproteolytic protein ubiquitinition reactions contribute to 
the regulation of nuclear factor kappa B (NF-κB). There are five different Rel family 
members that have been identified in mammals: RelA (p65), RelB, c-Rel, NF-B1 (p50 
and its precursor p105) and NF-B2 (p52 and its precursor p100), which can form either 
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hetero- or homodimers. Active NF-B transcription factors are composed of dimeric 
combinations of members of the Rel transcription factor family [22,23]. Rel family 
members have a 300-amino-acid long N-terminal domain, called the Rel homology 
domain (RHD), which is responsible for DNA binding, dimerization and interaction with 
inhibitor of B (IB) proteins. Interaction with IB blocks the nuclear localization signal 
(NLS) present in the RHD and sequesters NF-B in an inactive form in the cytoplasm. In 
addition, RelA/p65, RelB and c-Rel also have transcriptional activation domains (TAD) 
which are required for their transcriptional activity. In most cells, the p50/p65 (p50/RelA) 
heterodimer is the major transcriptional activator which regulates diverse gene expression. 
p50 and p52 lack a TAD domain and p50 or p52 homodimers are thought to repress 
transcription of NF-B-dependent target genes. The NF-B transcription factor family is 
involved in the host response to diverse cellular stresses, including cytokines, bacteria, 
viruses, oxidative, genotoxic, physiological or chemical stress factors [24]. Three major 
NF-B activating pathways have been identified [23,25,26] (Figure 2).  
The canonical or classic NF-B pathway, is typically activated in response to 
pathogen-associated molecular patterns (PAMPs) or pro-inflammatory cytokines. During 
infection or an inflammatory response, the IKK signalosome complex, consisting of two 
kinases (IKK and IKK) and a regulatory scaffolding subunit IKK/NEMO (NF-B 
essential modifier), is activated by an upstream kinase. The activation of the IKK 
complex results in phosphorylation, ubiquitination, and degradation of NF-B inhibitor 
IB, which releases the prototypical NF-B dimer RelA/p50 from its inhibitor IkB. 
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IkB degradation exposes the NLS of NF-B, allowing the nuclear translocation of the 
RelA/p50 heterodimer and subsequent induction of specific gene transcription. The 
canonical NF-B pathway can be activated rapidly in response to acute stress situations. 
The noncanonical or alternative pathway is predominantly active in B cells and is 
induced by a particular subset of TNFR family ligands, such as B-cell-activating factor of 
the tumour necrosis factor (TNF) family (BAFF), CD40 or lymphotoxin (LT) . In this 
pathway, the IKK signalosome complex consists exclusively of IKK homodimers, 
without IKK and IKK/NEMO. Upon stimulation, NF-B-inducing kinase (NIK), a 
kinase implicated in the phosphorylation of IKK, is recruited to the receptor and 
activates IKK. IKK then targets p100 for phosphorylation and K48 linked 
ubiquitination, resulting in the limited proteolysis of its ankyrin-like C-terminus, 
generating the mature p52 subunit. p52 dimerizes with RelB, and the dimeric complex 
enters the nucleus to activate the expression of genes important for B-cell maturation and 
activation. 
The third NF-B activation pathway, also known as the atypical pathway is 
induced by stimuli such as DNA damage or oxidative stress. Compared to the canonical 
pathway, which usually induces a rapid and strong NF-B-activating signal, the atypical 
NF-B activators induce a slower and weaker NF-B signal (with peak activities reached 
after 2–4 hours). The detailed mechanism of how genotoxic stress activates NF-B 
remains unclear, and each different stimulus may use a completely unrelated mechanism. 
For example, in the case of DNA damage induced NF-B activation, ultraviolet 
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(UV)-induced NF-B signaling appears to be IKK-independent [27], while most other 
genotoxic stress agents activate a pathway that require classic IKK activation and IB 
degradation. No consensus has been reached as to how oxidative stress induces NF-B 
activation, but most likely this involves phosphorylation of IB [28].  
 
IV. Rip1 and TNF-induced NF-B Activation 
Rip1, the first member of the Rip family, was identified in a yeast two-hybrid 
screen in 1995 as an interaction partner of the Fas death receptor through a homotypic 
DD–DD interaction [29]. Subsequent work revealed that Rip1 interacted with other death 
receptors, such as tumor necrosis factor (TNF)-R1, TRAIL-R1 and TRAIL-R2, and other 
DD-containing adaptor proteins such as TNF-receptor-associated death domain (TRADD) 
and FADD. The recruitment of Rip1 to the TNFR1 complex upon TNF stimulation 
indicated that Rip1 plays an important role in TNF-induced signaling [29,30].     
Rip1 is constitutively expressed in many tissues, and also shows inducible 
expression upon T-cell activation or after stimulation with TNF [29]. Rip1 expression in 
HEK293 cells activates an NF-κB–luciferase reporter plasmid and induce apoptosis, 
suggesting that Rip1 may regulate both survival and death via the TNF pathway[30]. 
These dual functions of Rip1 can be explained by the observation of a 
caspase-8-dependent cleavage of Rip1 in treated cells, which generates a C-terminal 
cleavage product during stimulation by TNF, Fas or TNF-related apoptosis-inducing 
ligand (TRAIL) [31]. The C-terminal cleavage product of Rip1 blocks NF-κB activation 
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and promotes cell death, whereas a Rip1 non-cleavable mutant activates NF-κB and 
protects the cells against TNF-induced apoptosis [31]. Thus, the cleavage of Rip1 
controls the survival/death decision.   
The physiological role of Rip1 in the TNF pathway was addressed with the 
generation of Rip1-deficient cells. A Rip1 deficient Jurkat leukemic T cell line was 
selected for its inability to activate NF-B. When these cells were stimulated with TNF, 
they failed to active NF-B [32]. Reconstitution of the Rip -deficient Jurkat T cell line 
with a Rip1 expression plasmid restored TNF signaling. Similarly, studies of Rip1 
-deficient MEFs revealed that Rip1 mediates the TNF induced NF-B pathway [33]. 
Rip1 deficient mice die during the postnatal period and display massive cell death of 
lymphoid and adipose tissues [33]. Although the NF-B response to TNF stimulation is 
impaired in the absence of Rip1, TNF induced c-Jun N-terminal kinase (JNK) activation 
appears less affected [33]. Rip1 deficiency also sensitizes to TNF-induced cell death [33]. 
The kinase activity of Rip1 is not required for the activation of NF-κB because 
reintroduction of a kinase-dead form of Rip1 into the Rip1-deficient Jurkat cells or MEFs 
restored full NF-κB activation [32,34].  
      More recent studies have demonstrated that Rip1 is ubiquitin modified in TNF 
stimulated cells and its polyubiquitination appears essential for TNF induced NF-B 
activation. Upon TNF stimulation, Rip1 is polyubiquitinated in lipid rafts [35]. Rip1 can 
be modified by both K48 and K63 linked polyubiquitin chains [34,36]. K63-linked 
polyubiquitination of Rip1 is required for TNF-induced activation of NF-B. Although 
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K63-linked ubiquitination can occur on several lysine residues in the intermediate region 
of Rip1, a critical lysine residue in the intermediate region of Rip1 (Lys377 in hRip1 and 
Lys376 in mRi1) was shown to be critical for the function of Rip1 in TNF pathway [37]. 
Expression of a Rip1 K377R mutant in Rip1-deficient cells failed to activate NF-B upon 
TNF treatment. Rip1 ubiquitination may stimulate recruitment of the Tak1-binding 
protein 2 (Tab2) and thereby recruit Tak1-Tab2 complex to TNFR1 associated 
polyubiquitinated Rip1. K63-linked polyubiquitinated Rip1 also binds polyubiquitinated 
NEMO and thereby brings the IKK complex and activated Tak1 into close proximity with 
IKK [37]. Some studies suggest that K63 polyubiquitin chains are able to directly 
activate Tak1 by binding to the ubiquitin receptor Tab2. This binding leads to 
autophosphorylation and activation of Tak1 [21]. Thus, binding to K63 polyubiquitinated 
Rip1 stimulates formation of NEMO/Tak1/IKK complex and ensures Tak1 and IKK 
activation [37] (Fig. 3).  
Multiple E3 ubiquitin ligases have been implicated in the ubiquitin 
modification of Rip1. The Traf2 and Traf5 Ring domain-containing E3 ligases have been 
suggested to be required for Rip1 K63-linked ubiquitination following TNF stimulation 
[34,36]. In the absence of Traf2 and Traf5, Rip1 polyubiquitination and NF-B activation 
is impaired. cIAP1 and cIAP2, another group of Ring domain containing E3 ligases, have 
also been shown to be required for Rip1 polyubiquitination in the TNF pathway [38]. 
Whether these E3 ligases cooperate to regulate Rip1 polyubiquitination remains unclear 
and requires further investigation.  
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The deubiquitinating enzyme (DUB) A20 terminates the TNF-induced NF-B 
response by regulating Rip1 polyubiquitination [36]. The amino-terminal domain of A20, 
which is a de-ubiquitinating (DUB) enzyme of the OTU (ovarian tumour) family, 
removes K63-linked ubiquitin chains from Rip1. The carboxy-terminal domain of A20, 
composed of seven C2/C2 zinc fingers, then functions as a ubiquitin ligase to 
polyubiquitinating Rip1 with K48-linked ubiquitin chains, thereby targeting Rip1 for 
proteasomal degradation, terminating signaling to NF-B. The polyubiquitin chain 
editing on Rip1 in the TNF pathway has been confirmed by using the linkage-specific 
polyubiquitin antibodies [39]. Consistently, binding of NEMO to polyubiquitinated Rip1 
stabilizes Rip1 by inhibiting its degradation, possibly by interrupting the interaction of 
Rip1 with A20. 
 
V. Rip1 and necroptosis 
Patterns of cell death have been divided into apoptosis, which is actively 
executed by caspases, and programmed necrosis. Although death receptor ligands 
predominantly induce apoptosis, a form of programmed necrosis called necroptosis 
occurs in the absence of caspase activation [40]. Necroptotic cells lack chromatin 
condensation and form large lysosome-derived cytosolic vacuoles which lead to cellular 
disintegration and release of cytoplasmic materials. Caspase 8-deficient Jurkat leukemic 
cells undergo cell death upon TNF treatment, suggesting that TNFR1 activation 
stimulates an alternative form of cell death [41]. Furthermore, treatment with TNF or 
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FasL induced cell death in Jurkat T cells and L929 murine fibroblasts pretreated with the 
caspase inhibitor zVAD-fmk [42]. Although the mechanism for this necroptotic pathway 
is unknown, Rip1-deficient Jurkat cells are resistant to TNF and FasL- induced cell 
death in the presence of the caspase inhibitors, suggesting that Rip1 may regulate 
necroptosis [43].  
Recent studies demonstrate that Rip1, as well as another Rip family member 
Rip3, play essential roles in the decision between tumor necrosis factor (TNF)-induced 
necroptosis and survival when apoptotic signaling is blocked [44,45,46]. Indeed, both 
Rip1 and Rip3 are activated catalytically by phosphorylation, and interact with each other 
via the RIP homotypic interaction motif, RHIM.  This phosphorylation and interaction is 
essential for the initiation of programmed necrosis in vitro and in vivo. In cells that 
express Rip3 and cannot properly activate caspases due to the presence of the pancaspase 
inhibitor zVAD-fmk, TNF stimulation leads to the assembly of a multiprotein complex 
that contains caspase-8, FADD, Rip1 and Rip3. In this complex, Rip1 and Rip3 are 
phosphorylated in an interdependent manner. Phosphorylated Rip3 then interacts with 
several bioenergetic enzymes including glycogen phosphorylase (PYGL), 
glutamate-ammonia ligase (GLUL) and glutamate dehydrogenase 1 (GLUD1), thereby 
enhancing their catalytic activity. Enhanced glycogenolysis and glutaminolysis provide 
additional respiratory substrates and ultimately result in an increase of reactive oxygen 
species (ROS). Excess ROS, in turn, can trigger mitochondrial membrane 
permeabilization (MMP), thereby mediating TNF-induced programmed necrosis. 
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VI. Rip1 and the anti-viral innate immune response 
In addition to a kinase and death domain, a short region of 35 amino acids 
located in the intermediate region of Rip1 was also identified in the 
TIR-domain-containing adaptor protein Trif (also called TICAM-1), known to mediate 
TLR3 and TLR4 signaling [47]. This region is called the RIP homotypic interaction motif 
(RHIM) and also present in the intermediate region of Rip3 and DAI (DNA-Dependent 
Activator of IFN Regulatory Factors) [47]. Trif binds to TLR3 and TLR4, two 
TIR-domain-containing receptors that recognize double stranded RNA (dsRNA) from 
viruses and lipopolysaccharide (LPS) from Gram-negative bacteria, respectively. Rip1 
has been shown to interact with Trif through the RHIM domain, implicating Rip1 in 
TLR3 and TLR4 signaling [9,48]. Studies in Rip1 deficient cells demonstrated that the 
activation of NF-B and MAPKs, induced by TLR3 and TLR4 ligands, depends on Rip1 
[9,48]. TRIF-induced activation of NF-B can also proceed independently of the RHIM 
domain, through N-terminal binding of Traf6. Upon TLR3 activation, Rip1 is also 
modified by polyubiquitin chains and is recruited to TLR3 along with Traf6 and the 
ubiquitin-activated kinase Tak1 [49]. Rip1 polyubiquitination is aslo been observed in 
TLR3 stimulated cells, and the E3 ubiquitin ligase Peli1 has been reported to mediate 
ubiquitin modification of Rip1 in the TLR3 pathway [50]. These studies suggest that 
Rip1 uses a similar, ubiquitin-dependent mechanism to activate IKK in response to 
TNF- and TLR3 ligands. Rip1 is dispensable for TRIF-dependent activation of IRF3, 
which occurs in a TRIF/TRAF3/TBK1/IKK-dependent manner.  
15 
 
 
 
Viral replication intermediates, including dsRNA, are potent stimuli that trigger 
host responses when they are recognized and engaged by specific pathogen recognition 
receptors (PRRs). TLR3, TLR7 and TLR9 participate in anti-viral innate immunity and 
recognize dsRNA, ssRNA and CpG DNA, respectively.  However, dsRNA is also 
recognized by the cytoplasmic RNA helicases retinoic acid-inducible gene I (Rig-I) [51] 
and melanoma differentiation-associated gene (Mda) 5 [52,53].  These helicases mediate 
the activation of NF-B, ATF2-c-Jun, IRF-3 and IRF-7 via recruitment of a 
CARD-like-domain-containing adapter, IFN promoter stimulator (IPS-1) [54] (also called 
MAVS, CARDIF, VISA). The IPS-1 adapter interacts with Fadd and Rip1 to activate 
NF-B and type I IFN promoters. Cells deficient for FADD or Rip1 are impaired in their 
type I IFN response to infection with VSV (vesicular stomatitis virus) [55]. A Fadd-Rip1 
pathway has also been described in Drosophila where the Rip1 homolog Imd binds 
dFadd to activate an NF-B-like pathway and induce expression of anti-microbial genes 
[56].  
How do Rip1 and FADD the mediate anti-viral innate immune response? It has 
been implied that Rip1 mediates Rig-I anti-viral signaling by facilitating IRF-7 activation. 
Rip1 interacts with IRF7 and LMP1 (latent membrane protein 1) in EBV-positive 
Burkitt's lymphoma cells [57]. LMP1 stimulates the K63-linked ubiquitin modification of 
Rip1 and IRF7. Although the IPS-1 adapter interacts with Rip1, it does not associate with 
TBK-1 or IKK-, suggesting that Rip1 may link TBK-1/IKK- kinase to IRF-7.  Thus, 
Rip1 may contribute to Rig-I anti-viral signaling by mediating both NF-B and IRF-7 
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activation.   
Most recently, Rip1 has been implicated in DAI (DNA-dependent activator of 
IFN regulatory factors) mediated NF-B activation [58]. DAI is a cytosolic DNA sensor 
that stimulates the IRF3 and NF-B pathways leading to type I IFN and cytokine 
production. DAI, also contains a RIP homotypic interaction motif (RHIM), and binds to 
and colocalizes with endogenous Rip1 in characteristic cytoplasmic granules. Rip1 
deficient cells are impaired in their NF-B activation mediated through DAI. The role of 
Rip1 in DAI-mediated NF-B activation in response to immunostimulatory DNA appears 
analogous to the sensing of dsRNA by TLR3. Both pathways involve RHIM-dependent 
signaling, reinforcing a central role for Rip1 in anti-viral innate immune responses.     
 
VII Overview of Rip2 and the NLR pathway 
The Rip1-related Rip2 protein also responds to cellular stress brought on by 
bacterial infection. Rip2, also called RIP-like-interacting CLARP kinase (RICK) and 
caspase-recruitment domain (CARD)-containing IL-1β converting enzyme 
(ICE)-associated kinase (CARDIAK), is a novel Rip1-like kinase also capable of 
inducing NF-B activation and cell death [59,60,61]. Similar to Rip1, Rip2 is expressed 
in many tissues and the kinase activity of Rip2 appears dispensable for the NF-B 
response [61]. Rip2 also contains an N-terminal kinase domain followed by an 
intermediate region.  Instead of a DD domain, Rip2 contains a C-terminal CARD 
domain in the C-terminal. Rip2 interacts with many CARD-domain containing proteins. 
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In tranfected cells, Rip2 also interacts with several TRAF family members, including 
TRAF1, TRAF2, TRAF5, TRAF6 and the anti-apoptotic proteins cFLIP and cIAP1 
(cellular inhibitor of apoptosis 1) [59,60,61].  
        Overexpression of Rip2 stimulates the NF-B, p38 MAP kinase, JNK and 
ERK2 pathways [61,62]. Upon overexpression, the CARD domain of Rip2 interacts with 
the CARD domain of caspase-1, a pro-inflammatory caspase implicated in IL-1β 
maturation [63]. Rip2 was therefore proposed to play a role in the generation of active 
IL-1β, but this could not be confirmed in a mouse model, as caspase-1 activation occurs 
normally in Rip2 deficient macrophages [64]. It remains to be seen whether Rip2 itself 
might be regulated by the activity of caspase-1, since Rip1 itself might be a caspase 
target. 
An important hint regarding the physiological function of Rip2 came from the 
observation that the CARD of Rip2 interacts with CARDs of Nod1 and Nod2 (also called 
CARD-4 and CARD-15, respectively), two cytoplasmic pathogen-recognition receptors 
that sense intracellular peptidoglycans [65]. In a model of invasive Shigella infection, 
Nod1 was shown to sense the presence of intracellular bacteria and to subsequently 
activate JNK and NF-B. Shigella infection or self-association of Nod1 induces the 
transient formation of a complex containing Nod1, Rip2, and the IKKs [66]. Rip2 also 
interacts with the second Nod family member, Nod2 [67]. Mutations in NOD2 or 
CARD15 are associated with a subset of Crohn's disease patients [68,69]. Hence, Rip2 is 
likely to participate in the elaboration of the innate immune response to pathogens, 
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downstream of the intracellular Nod receptors.  
 
VIII. NLR and innate immunity 
As the first line of defense, the innate immune system is involved in the initial 
detection and removal of harmful microbes. While immune reactions induced through the 
adaptive immune system may take days, innate immune responses are activated 
immediately or within several hours following an encounter with an invading organism. 
Thus the signaling pathways triggered by innate immune system must be regulated with 
exquisite precision [70].  
Unlike adaptive immunity, the innate immune system does not have the 
capability to recognize specific antigens. Rather, it is designed to recognize molecules 
shared by groups of related microbes that are essential for the survival of those organisms 
and are not found associated with mammalian cells. These unique microbial molecules 
are called pathogen-associated molecular patterns or PAMPS [71].  These PAMPs 
include lipopolysaccharide (LPS), a major component of the outer layer of 
Gram-negative bacteria, peptidoglycan (PGN), the main component of the cell wall of 
Gram-positive bacteria, flagellin, and microbial nucleic acids. In order to recognize 
PAMPs, cells express a variety of pattern-recognition receptors or PRRs capable of 
binding specifically to conserved portions of these molecules. PRRs comprise an array of 
proteins present at the plasma membranes, endosomes, and cell cytosol. A single 
microorganism can be detected by multiple sensors. The existence of multiple PRRs 
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capable of recognizing a single microorganism ensures the induction of immune 
responses when one signaling pathway is blocked by the pathogen. In addition, the 
activation of multiple PRRs in response to a pathogen often results in a combinatorial 
activation that specifically stimulates the host response to a particular class of microbes 
[72,73]. There is evidence that certain PRRs are involved not only in recognizing 
microorganisms but also in recognizing endogenous non-microbial 'danger' signals such 
as uric acid, ATP and HSP70 [74]. The activation of PRRs by microbial or endogenous 
danger stimuli results in the activation of multiple signaling pathways including nuclear 
factor-κB (NF-κB), mitogen-activated protein kinases (MAPKs), and IRF family proteins 
to induce production of cytokines and type I interferon (IFN) [75]. 
There are two major groups of PRRs in the cells: membrane-bound PRRs and 
cytoplasmic PRRs. The first group usually refers to Toll-like receptors (TLRs), the first 
class of cellular PRRs identified. TLRs monitor the extracellular environment and 
endosomal compartments, and recognize a variety of microbial components including 
bacterial lipoprotein, peptidoglycan, CpG DNA, and double- and single-stranded RNA 
[75,76]. In contrast, the nucleotide oligomerization domain (Nod)-like receptors (NLRs) 
and the retinoic acid-inducible gene I (RIG-I)-like receptors (RLRs) are intracellular 
cytosolic sensors. NLRs were first identified in plants where they play a critical function 
in disease resistance (R genes) against microbial and parasitic pathogens [77,78]. RLRs 
are helicases that sense viruses [79]. Homologues of the NLRs are present in vertebrates 
(at least 22 was been found) as well as in primitive organisms, such as the sea urchin, 
20 
 
 
 
indicating that NLR responses are conserved through evolution [80]. 
       NLRs are multi-domain proteins and all have a centrally located NOD domain 
that is critical for activation. The NOD domain (also referred as the NACHT cassette) is 
closely related to the oligomerization module found in the AAA+ family of adenosine 
triphosphatases (ATPases). The NOD domain mediates NLR protein oligomerization and 
may also contain ATPase activity [81]. The NLR N-terminal domain is composed of a 
variable effector region consisting of caspase recruitment domain (CARD), pyrin domain 
(PYD), acidic domain, or baculovirus inhibitor repeats (BIRs). Based on the class of 
N-terminal effector domain, the NLR family has been divided into five subfamilies 
including the caspase-recruiting domain (CARD)-containing NODs, the pyrin (PYR) 
domain-containing NALPs and the baculovirus-inhibitor-of-apoptosis-repeats 
(BIRs)-containing NAIPs.  
 
VIIII. Rip2 and Nod signaling  
First discovered as mammalian members of the Ced4/Apaf-1 family of 
apoptosis regulators, Nod1 and Nod2 are critical pathogen-recognition receptors that 
sense intracellular peptidoglycans [67,82].  Nod1 and Nod2 are multi-domain proteins 
consisting of one or two CARD domains in the N-terminal region, a centrally located 
NOD domain followed by a number of C-terminal LRRs. Nod1 and Nod2 are found 
expressed in almost all higher vertebrates but not in insects or worms. Nod2 expression is 
restricted to macrophages, dendritic cells, Paneth cells, keratinocytes, and epithelial cells 
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of the intestine, lung, and oral cavity [67,83,84,85].  Nod1 is more widely expressed in 
many cell types and organs. Both Nod1 and Nod2 are expressed in the cytosol, but more 
recently Nod1 and Nod2 proteins have been found associated with the plasma membrane 
[86,87]. In the case of Nod2, point mutants that prevent membrane association are 
impaired in their ability to activate downstream signaling [87]. However, the same 
mutations are also known to affect microbial recognition and secondarily Nod2 activation; 
therefore, the role of membrane localization in Nod2 signaling remains unclear. 
In cells, Nod1 and Nod2 are thought to be kept in an inactive state by 
intra-molecular interactions. Truncation or mutation of the C-terminal LRR region of a 
variety of NLRs results in a constitutively active form of the proteins [88]. When 
co-expressed in cells, the Nod2 C-terminal fragment consisting of only the LRRs 
interacts with an N-terminal fragment consisting of the CARD and NOD domains. The 
LRR/CARD interaction can be disrupted by the presence of the Nod2 ligand MDP [89]. 
Collectively, these results suggest a model whereby ligand recognition results in a 
conformational change in the Nod1/2 protein, relieving the autoinhibitory intramolecular 
interactions and allowing NOD domain-dependent nucleotide binding and 
oligomerization. However, evidence for a direct interaction between NLRs including 
Nod1 and Nod2 and their putative ligands is still lacking; so, it is possible that the 
activation of Nod1 and Nod2 by microbial stimulation is indirect. Clearly, more structural, 
biochemical, and functional studies are needed to test these models. 
While the functions of most NLR’s remain undefined, the Nod1 and Nod2 
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proteins have been shown to respond to bacterial cell wall fragments. The Nod1 protein 
recognizes a fragment of peptidoglycan (PGN) containing the dipeptide 
-d-glutamyl-meso-diaminopimelic acid (iE-DAP) produced by Gram-negative and some 
Gram-positive bacteria [90,91]. Nod2 recognizes muramyl dipeptide (MDP) present on 
most types of PGN [90,91,92,93]. While the recognition of these common forms of 
peptidoglycan has been extensively studied, bacteria modify their cell walls in a myriad 
of ways and the effects of these modifications on Nod1/2 recognition are only beginning 
to be appreciated [94,95,96].  For example, Listeria monocytogenes removes a common 
N-acetyl moiety from the glucosamine of its peptidoglycan, which renders the cell wall 
resistant to host lysozyme and thereby inhibits bacterial recognition by Nod1 [97].  In 
contrast, mycobacteria, replace the N-acetyl group of the muramic acid of MDP with an 
N-glycolyl moiety [98,99], and this modification significantly increases the potency of 
this compound as a Nod2 agonist.  
Nod1- and Nod2- deficient cells are unable to activate NF-κB and produce 
cytokines and chemokines in response to ligand stimulation [100,101]. Rip2, known to 
interact with Nod1 and Nod2, has been implicated in the pathway. The original work on 
Rip2 deficient mice suggests that Rip2 may mediate multiple adaptive and innate immune 
pathways. Rip2-deficient cells displayed an impaired cytokine response to the TLR 
ligands LPS, lipoteichoic acid and poly(I:C), but not bacterial DNA, suggesting a role for 
Rip2 downstream of TLR-4, -2, and -3, respectively [100,101]. Rip2-deficient cells also 
appeared hyporesponsive to signaling through interleukin (IL)-1, IL-18 and Nod1/2 
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ligands [64,102]. While studies implicating Rip2 in multiple TLR pathways appear to 
reflect the presence of contaminating peptidoglycan [103], the role of Rip2 in Nod 
signaling was the subject of this thesis research.  
Following microbial detection, Rip2 is directly recruited to Nod1 or Nod2 
proteins through CARD–CARD interactions [67,82]. Our work presented in charpter II 
demonstrated that Rip2 is modified with K63-linked ubiquitin chains in MDP treated 
cells [104]. Although the E3 of Rip2 is still unclear, it is clear that the polyubiquitination 
of Rip2 is critical for Nod1/2 response. A Rip2 lysine mutant (K209R) can not restore 
NF-B activation in Nod stimulated cells [104]. Our work demonstrated that K63-linked 
ubiquitin modification of Rip2 recruits the ubquitin activated transforming growth factor 
β-activated kinase (Tak1), which is essential for IKK activation [105,106]. Tak1, a 
serine–threonine kinase that forms a complex with the ubiquitin-binding proteins 
Tak1-binding protein 1 (Tab1), Tab2, and/or Tab3, activates IKK by phosphorylating 
IKK. Tak1 binds to polyubiquitinated Rip2 via its N-terminal ubiquitin-binding CUE 
domain [107]. Rip2 also binds NEMO and promotes its ubiquination, and thereby brings 
the IKK complex and Tak1 into close proximity [108]. IKK activation results in 
phosphorylation, ubiquitination and degradation of NF-B inhibitor IB, exposes the 
NLS of NF-B, and allows its nuclear translocation (Fig. 4).  
Both Rip2 and Tak1 also contribute to Nod1- and Nod2-mediated p38 MAPK 
and JNK1/2 activation, although the intermediate steps in this pathway are less well 
characterized [105,106]. Stimulation of Nod1 or Nod2 results in the secretion of 
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proinflammatory cytokines and chemokines including IL-6, IL-8, KC, macrophage 
inflammatory protein-2 (MIP-2), CCL2, CCL5, and presumably secreted (RANTES) 
[109,110]. Nod1 activation induces neutrophil recruitment in vivo [110], and both Nod1 
and Nod2 signaling lead to the production of anti-microbial peptides [111]. 
The deubiquitinase A20, known to remove K63-ubquitin chains from Rip1 
protein, also regulates Rip2 polyubiquitination and downregulates Nod- induced NF-κB 
signaling [112]. A20 has a conserved role in the regulation of Rip proteins in the TNF and 
NLR pathways [36], indicating that A20 acts broadly to suppress proinflammatory 
pathways. Also, caspase-12 and MEKK4 have been shown to downregulate Nod2 
signaling by disrupting the Nod2/Rip2 CARD–CARD interaction [113,114]. Additionally, 
an alternatively transcribed CARD domain-only isoform of Nod2 appears to function as a 
dominant negative regulator of Nod2 signaling and woks by similar mechanisms to 
inhibit the Nod2/Rip2 interaction [115]. Recently, a negative regulatory role for the cell 
polarity protein, Erbin, has been proposed based on its ability to associate with Nod2 and 
inhibit NF-κB activation and subsequent inflammatory cytokine secretion [116]. Whether 
Rip2 and Erbin associate is unclear.  
 
X. Nod mediated pathogen recognition 
The Rip2 and Nod proteins are involved in the sensing of numerous pathogenic 
bacteria. Although TLRs might be the primary sensor of a bacterial infection, several 
studies suggest that Nod1 and Nod2 play non-redundant roles with TLRs in pathogen 
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recognition and production of proinflammatory and anti-microbial molecules [70]. 
Consistently, the functions of Nod1 and Nod2 appear to be important when TLR 
signaling is absent or reduced. 
Nod1 detects a variety of Gram-negative pathogens including Shigella flexneri, 
Chlamydia, Pseudomonas aeruginosa, enteroinvasive Escherichia coli, Campylobacter 
jejuni, and Helicobacter pylori [66,109,111,117,118,119]. However, most of the evidence 
that Nod1 mediates pathogen sensing comes from in vitro experiments. For example, 
while Nod1 senses Chlamydia in vitro, studies using vaginally infected mice fail to reveal 
a requirement for Nod1 in vivo [109].  Nod1 has been implicated in the host defense 
against a human enteric pathogen, H. pylori, which is involved in the development of 
gastritis, duodenal ulcers, and gastric cancer. Following intragastric infection with H. 
pylori, Nod1 deficient mice exhibit decreased expression of the anti-microbial peptide 
β-defensin 4 and an increased bacterial load. Although H. pylori is a non-invasive 
bacterium, it activates the Nod1 pathway by injecting PGN fragments into epithelial cells 
via a bacterial type IV secretion system. Consistently, mutant H. pylori lacking the cag 
pathogenicity island that encodes the secretion apparatus are not sensed by Nod1 [119]. 
The requirement of the bacterial secretion system for cytosolic Nod activation revealed a 
possible mechanism whereby PGN fragments enter the host cells cytosol to induce Nod1 
and Nod2 activation. This feature will be discussed in greater detail in Charpter III.  
Similar to Nod1, in vitro studies have identified a variety of pathogens that 
activate Nod2, including S. pneumoniae, S. aureus, Salmonella typhimurium, and S. 
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flexneri and Mycobacterium tuberculosis [120,121,122,123]. Oral infection of 
Nod2-deficient mice with Yersinia pseudotuberculosis, revealed in a slight increase in 
susceptibility [124]. Differences were observed in the cytokine responses of infected 
wildtype and Nod2-deficient macrophages with Yersinia pseudotuberculoss in vitro [125].  
Meanwhile, when Nod2-deficient mice were orally infected with Gram-positive L. 
monocytogenes, the infected mice had increased bacterial loads, and exhibited diminished 
expression of certain anti-microbial α-defensin peptides relative to wildtype controls 
[100]. 
Nod1 and Nod2 are primarily located in the cytosol. How do the PGN 
fragments gain access to the cytosol to induce Nod1 and Nod2 activation, especially 
when the bacterium is located in membrane-bound vesicles such as a phagosome? One 
way is through the bacterial secretion system, discussed in the case of H. pylori infection 
[119]. Another potential mechanism could involve the pore-forming toxins produced by 
bacteria. For example, Staphylococcus aureus, Bacillus anthracis, and Streptococcus all 
produce toxins that mediate cytosolic sensing of Nod1 agonists [126].  Nod1 or Nod2 
ligands produced by bacteria may also enter the cell via endocytosis or via epithelial 
transporters. For example, the Nod2 ligand MDP is internalized by macrophages and 
localized to acidified vesicles, suggesting that MDP uptake can occur via endocytosis 
[127], although the precise mechanism involved remains unclear. The epithelial 
transporters PepT1 and PepT2 have been shown to selectively deliver Nod1/2 ligands 
iE-DAP and MDP to the cytosol [128]. However, the expression of PepT1 is largely 
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confined to intestinal epithelial cells, while Nod2 is also expressed in monocytes and 
macrophages [128]. So, it is unclear whether this transporter regulates MDP uptake in 
cells of the innate immune system.  
 
XI. The Nod pathway and Mycobacterium tuberculosis 
Mycobacterium tuberculosis (Mtb), the causative agent of human tuberculosis, 
is thought to persist within as many as one billion individuals worldwide [129]. Mtb is an 
extremely successful intracellular pathogen that infects and causes disease by 
manipulating the host immune response [130,131]. Following uptake by phagocytic cells 
such as macrophages and dendritic cells (DC), Mtb resides in a modified phagosomal 
compartment with the characteristics of an early endosome. Mtb inhibits phagosomal 
maturation and lysosomal fusion, and survives within modified phagosomal 
compartments. The ability of Mtb to survive and replicate inside a modified phagosomal 
compartment of host macrophages is central to the pathogenesis of this disease [132]. 
Thus, like many other pathogens that cause chronic infections, the long-term survival of 
Mtb depends on a delicate balance between bacterial virulence and host immunity. 
The immunity to Mtb depends on both the host innate and adaptive response. 
During infection, Mtb triggers an innate immune response mediated by pattern 
recognition molecules (PRMs) [133]. Genetic studies in mice have shown that multiple 
TLRs have important roles in protective immunity to mycobacterial  infection, including 
TLR2, TLR4, TLR6 and TLR9 [133,134,135,136,137]. Moreover, in the absence of 
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MyD88, the common adaptor for two IL-1R and most TLRs pathways, mice were 
profoundly susceptibile to Mtb infection, indicating that instead of one TLR, multiple 
TLR pathways are required for the innate immune response to Mtb [138]. However, a 
large fraction of the transcriptional response to Mtb, including many immunologically 
important proteins, such as the chemokines RANTES and IP-10, and the inducible nitric 
oxide synthase enzyme NOS2 that are critical for mycobacterial immunity, are induced 
independently of TLR2/4 and the adapter proteins MyD88, MAL and TRIF. Instead, these 
responses rely on autocrine or paracrine signaling via type I interferons (IFN), which 
are induced largely through undefined pathways [139]. Also, the adaptive immune 
response is not significantly impaired in Mtb infected MyD88 deficient mice [140,141]. 
These findings suggest that other PRMs, signaling through a MyD88-independent 
pathway, are involved in shaping the adaptive immune response to mycobacterial 
infection.  
         The cytosolic Nod pathway has been implicated in the MyD88-independent 
Mtb response. Several studies have shown that Nod2  pathway activation results in an 
optimal Mtb response in both human and murine derived macrophages in vitro 
[121,142,143]. Also, human NOD2 variants were found to be associated with 
susceptibility to tuberculosis in an African American population [144]. Moreover, the 
Nod2 ligand MDP has been shown to synergize with cytosolic DNA to enhance type I 
IFN production during both L. monocytogenes and Mtb infection [143]. Collectively, 
these studies indicate that the Nod pathway may mediate immune responses upon Mtb 
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infection. Also, in light of these findings, the importance of Nod-mediated immunity in 
Mtb pathogenesis requires further study and is a focus of the work described in charpter 
III.  
 
XII. Type I Interferon and Interferon regulatory factors 
Interferons, so called because of their activity to interfere with (inhibit) virus 
replication in a cell [145,146], are divided into at least three distinct groups (types): types 
I, II, and III [147]. Type I IFNs include IFN-α, -β [148], and others, such as IFN-ω, -ε, 
and –κ [147]. In human and mouse cells, the IFN- genes are composed of multiple 
subfamily genes (13 in humans and 14 in mice), whereas only a single IFN-β gene has 
been found [149].  
Type I IFN production is primarily controlled at the gene transcription level. 
The promoter region of the IFN-β gene contains at least four regulatory cis elements, 
called the positive regulatory domains (PRDs) I, II, III, and IV [150], whereas the 
promoter regions of IFN-α genes contain PRD I- and PRD III-like elements (PRD-LEs) 
[151]. PRD I and PRD III contain the binding sites for IRF family members, whereas 
PRD II and PRD IV elements are the sites for NF-κB and the activating transcription 
factor 2 (ATF2) / c-JUN heterodimer (AP-1) binding, respectively. Upon viral infection, 
PRDs direct the assembly of IRFs, NF-κB, AP-1, and the high-mobility group protein 
HMG-I (Y) to form a complex known as the ―enhanceosome‖ [150] to stimulate IFN-β 
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gene expression. However, the IFN-β promoter is activated only weakly, if not at all, by 
tumor necrosis factor-α (TNF-α), which strongly activates NF-κB and AP-1, but not the 
IRFs [152], suggesting that activation of IRFs is the major mediator of robust type I 
interferon induction. 
The IRF family of transcription factors is comprised of nine members: IRF1, 
IRF2, IRF3, IRF4 (also known as PIP or ICSAT), IRF5, IRF6, IRF7, IRF8 (also known as 
ICSBP), and IRF9 (also known as ISGF3γ) [153,154] (Figure 5). These family members 
are characterized by a well-conserved amino (N)-terminal DNA binding domain (DBD). 
The DBD is a helix-turn-helix DAN binding domain. The DBDs of all IRFs recognize 
very similar DNA sequences. Except of IRF1 and IRF2, the carboxy (C)-terminal regions 
of all the IRFs have an IRF association domain (IAD) that is responsible for homo- and 
heteromeric dimmer formation/interaction with other family members or transcription 
factors such as PU.1 and signal transducer and activator of transcription (STAT) 
[153,154]. Mouse genetic studies of most of the IRF genes have revealed that IRFs have 
distinct roles in development and immune responses [154,155,156].  
Among the IRFs, four IRFs—IRF1, IRF3, IRF5, and IRF7—have been 
implicated as positive regulators of type I IFN gene transcription. IRF3 and IRF7, which 
are highly homologous, have been well established as the key regulators of type I IFN 
gene expression induced upon viral infection. IRF3 is constitutively expressed and 
resides in the cytosol in the inactive form. Upon viral infection, IRF3 is phosphorylated 
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in the C-terminal region by TBK1/IKK. Phosphorylated IRF3 interacts with the 
hydrophobic pocket within the IAD of another IRF3 or potentially IRF7, resulting in the 
formation of either an IRF3 homodimer or an IRF3/IRF7 heterodimer [157]. The IRF3 
homodimer or an IRF3/IRF7 heterodimer then translocates to the nucleus, forms a 
complex with the coactivators CBP and/or p300, and binds to the target DNA promotor 
sequence in type I IFN genes as well as certain cytokine and chemokine genes [158,159]. 
Unlike IRF3, constitutive expression of IRF7 is limited to peripheral blood lymphocytes 
and dendritic cells and is strongly induced upon type I IFN mediated signaling [160,161]. 
Similar to IRF3, IRF7 resides in the cytosol and, on viral infection, undergoes serine 
phosphorylation in its C-terminal region, allowing its dimerization and nuclear 
translocation. IRF7 forms a homodimer or a heterodimer with IRF3, and each of these 
dimers differentially acts on the type I IFN gene family members. IRF3 is more potent in 
activating the IFN-β gene than the IFN-α genes, whereas IRF7 efficiently activates both 
IFN-α and IFN-β genes [160,161]. The cellular events controlling the activity of IRF3 
and IRF7 have been studied in recent years. They mediate essential antiviral pathways 
that are triggered by the detection by at least two PRRS derived from viruses: 
transmembrane TLRs and cytosolic retinoic acid-inducible gene I (RIG-I) and melanoma 
differentiation-associated gene 5 (MDA5).  
IRF1 is the first family member discovered to activate type I IFN gene 
promoters [162]. The overexpression of IRF1 results in the induction of endogenous type 
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I IFN genes. However, the induction of type I IFN was unaffected in viral-infected 
irf1−/− fibroblasts, although IRF1 participates in type I IFN gene induction in some 
facets of TLR signaling [163]. Mouse genetic studies also revealed that IRF5 is 
dispensable for type I IFN gene induction by viruses or TLR agonists and that IRF5 
regulates the expression of inflammatory cytokine genes, such as interleukin (IL)-12 and 
TNF-α [164]. Hence, the precise role of IRF1 and IRF5 in type I IFN induction still 
remains unclear. In this thesis work, we reveal a specific role for IRF5 in the Nod2 
mediated anti-bacterial type I IFN response. 
 
XIII. Overview of work to be presented in this thesis 
Despite recent advances in our understanding of cellular stress responses, a 
number of questions remain. This thesis research reveals detailed mechanisms whereby 
Rip2 mediates Nod pathway activation. Furthermore, the role of the Nod-Rip2 pathway 
in the innate immune response to Mycobacterium tuberculosis infection will be 
extensively examined.  
In chapter 2, we demonstrate that Rip2 and the IKK regulatory subunits 
NEMO/IKK- become stably polyubiquitinated upon treatment of cells with the NOD2 
ligand, muramyl dipeptide.  We demonstrate a requirement for the E2 conjugating 
enzyme Ubc13, the E3 ubiquitin ligase Traf6 and the ubiquitin-activated kinase Tak1 in 
Nod2-mediated NF-B activation.  We also show that bacterial infection stimulates 
Rip2 polyubiquitination. Collectively, this study revealed that the NOD2 pathway is 
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ubiquitin regulated and that Rip2 employs a ubiquitin-dependent mechanism to achieve 
NF-B activation. 
In chapter 3, we demonstrate that infection with the bacterial pathogen M. 
tuberculosis stimulates the cytosolic Nod2 pathway. We show that upon Mtb infection, 
Nod2 recognition triggers the expression of type I interferons in a Tbk1- and 
Irf5-dependent manner.  This response is only partially impaired by the loss of Irf3 and 
therefore, differs fundamentally from those stimulated by bacterial DNA, which depends 
entirely on this transcription factor.  This difference appears to result from the unusual 
peptidoglycan produced by mycobacteria, which we show is a uniquely potent agonist of 
the Nod2/Rip2/Irf5 pathway.  Thus, the Nod2 system is specialized to recognize bacteria 
that actively perturb host membranes and is remarkably sensitive to Mycobacteria, 
perhaps reflecting the strong evolutionary pressure exerted by these pathogens on the 
mammalian immune system. 
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Figure 1. RIP family of proteins. A. Domain organization of RIP family members. 
All members share a homologous N-terminal kinase domain. RHIM: RIP homotypic 
interaction motif;  DD: death domain;  CARD: caspase recruitment domain; ANK: 
ankyrin repeats; LRR: leucine-rich repeat; Roc/COR: Ras of complex proteins/C-terminal 
of Roc domain; WD40: WD40 repeats. B. Phylogenic tree of the kinase domain of human 
RIPs and IRAKs. RIP5-7 are not represented here. 
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Figure 2. Schematic representation of three NF-B signaling pathways. The 
canonical or classic NF-B pathway (depicted in the middle) is typically activated in 
response to pathogen-associated molecular patterns (PAMPs) or proinflammatory 
cytokines. The noncanonical or alternative pathway (depicted on the right) is 
predominantly active in B cells and is induced by a particular subset of TNFR family 
ligands, such as B-cell-activating factor of the tumour necrosis factor (TNF) family 
(BAFF), CD40 or lymphotoxin (LT) . The third NF-B activation pathway, also known 
as the atypical pathway (depicted on the left) is induced by stimuli such as DNA damage 
or oxidative stress. 
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Figure 3. Model of IKK activation by TNFα. Trimeric TNFα stimulation leads to 
the trimerization of TNF-R1 (TNF receptor). Multiple signaling proteins, including 
TRADD, TRAF2, TRAF5, and RIP1 recruit to the TNF-R1 after stimulation. The TRAF 
proteins TRAF2/TRAF5, together with Ubc13/Uev1A polyubiquitinate RIP1 at 
K377. Polyubiquitinated RIP1 then recruits the TAK1 kinase complex through the 
interaction between the polyubiquitin chains and the NZF domain of TAB2. 
The polyubiquitin chains on RIP1 can also bind to NEMO, resulting in recruitment of 
the IKK complex. IKKβ in the complex is then phosphorylated and activated by TAK1, 
leading to the phosphorylation, ubiquitination, and degradation of IκB. NF-κB 
subsequently translocates into the nucleus to activate gene expression. 
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Figure 4. Model of IKK activation by MDP. Stimulation of cells with MDP leads to 
the conformational change of NOD2 and subsequent recruitment of signaling 
protein RIP2 through its CARD domain. RIP2 is polyubiquitin modified by cIAP1/2 in 
the complex. Polyubiquitinated RIP2 then recruits the TAK1 kinase complex. RIP2 can 
also bind to NEMO, resulting in recruitment of the IKK complex. IKKβ in the complex is 
then phosphorylated and activated by TAK1, leading to the phosphorylation, 
ubiquitination, and degradation of IκB. NF-B subsequently translocates into the nucleus 
to activate gene expression. 
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Figure 5. Overview of the IRF family members and their expression patterns and 
transcriptional roles. The conserved tryptophan repeats in the DNA binding domain 
(DBD) (black bar) are represented by W. Certain IRF family members possess a 
proline-rich domain shown by Pro. IAD presents an IRF association domain, hatched bars 
present a C-terminal autoinhibition domain, and phosphorylation sites designated by P.  
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Chapter II       
 
NOD2 pathway activation by MDP or 
Mycobacterium tuberculosis infection involves the 
stable polyubiquitination of Rip2 
 
 
 
 
 
 
 
 
 
 
This chapter is based on work from the following publications: 
 
Yang Y, Yin C, Pandey A, Abbott D, Sassetti C, Kelliher MA.  NOD2 pathway activation by MDP or 
Mycobacterium tuberculosis infection involves the stable polyubiquitination of Rip2. J Biol Chem. 2007 
Oct 18; PMID: 17947236  
 
Abbott DW, Yang Y, Hutti JE, Madhavarapu S, Kelliher MA, Cantley LC.  Coordinated regulation of 
Toll-like receptor and NOD2 signaling by K63-linked polyubiquitin chains. Mol Cell Biol. 2007 
Sep;27(17):6012-25. PMID: 17562858 
 
Yang Y contributed the work of Fig. 7, 8, 9, 10B, 10C, 11, 12, 13; Yin C contributed the work of Fig. 6; 
Abbott DW contributed the work of Fig. 10A; Pandey A contributed the work of Fig. 11. 
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Introduction 
Conserved structures on pathogens are recognized by specific host receptors such 
as Toll-like receptors (TLRs) or nucleotide binding oligomerization domain (NOD)-like 
receptors (NLRs). In contrast to TLRs which recognize pathogens at the cell surface or 
within the endosome, NLRs induce innate immune responses by recognizing bacterial 
products released into the cytosol. Several NLRs, including Nod1 and Nod2 proteins, 
induce cytokine production by activating the transcription factor NF-B and by 
stimulating MAP kinase activation [165]. The Nod1 protein recognizes a form of 
peptidoglycan (PGN) containing the amino acid meso-diaminopimelic acid (IE-DAP) 
produced by Gram-negative and some Gram-positive bacteria [91]. The Nod2 pathway 
recognizes muramyl dipeptide (MDP) present on most types of PGN [93]. Transfection 
studies have shown that expression of Nod proteins stimulates NF-B activity and the 
ability to stimulate NF-B reporter activity is dependent on the co-expression of the 
adapter protein Rip2 [67].  Yet how Rip2 proteins achieve Nod-mediated NF-B or 
MAP kinase activation remains undefined. 
 We found Rip2 required for Nod2 pathway activation in macrophages, however we 
did not find Rip2 required for TLR 2, 3 or 4-mediated IKK activation.  Similar data 
have recently been published by Gabriel Nunez and colleagues who find Rip2 required 
for cytokine production induced through NLRs, but not TLRs [103].  We show that 
treatment of macrophages with the Nod2 ligand MDP stimulates the ubiquitin 
modification of endogenous Rip2 and IKK-.  The ubiquitin modification of Rip2 is 
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stable and involves the conjugation of K63-linked polyubiquitin chains.  MDP-induced 
Rip2 polyubiquitination and NF-B activation requires the E2 conjugating enzyme 
Ubc13, the E3 ubiquitin ligase Traf6 and the ubiquitin activated kinase Tak1.  
The Nod2 pathway has been implicated in the innate immune response to 
Mycobacterium tuberculosis (Mtb) infection, as Nod2-deficient macrophages are 
impaired in their cytokine response to infection with Mtb [121]. Moreover, a 
quantitatively small fraction of the transcriptional changes induced by Mtb infection of 
macrophages can be attributed to TLR2/4- or MyD88-dependent pathways [139].  
Collectively, these studies suggest nonredundant roles for NOD2 and TLR in the innate 
immune recognition of Mtb.  We find that infection with live, but not heat killed, Wt 
strains of Mtb stimulates Rip2 polyubiquitination.  Therefore, we hypothesize that Nod 
proteins recognize Mtb components that are translocated into the cytosol and consistent 
with this model, Rip2 polyubiquitination induced by live Mtb infection appears MyD88 
independent, implicating NLRs in the cytosolic recognition of Mtb. 
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Results 
Rip2-deficient macrophages are impaired in their response to the NOD2 ligand 
MDP, but respond normally to the TLR4 ligand, LPS. 
The CARD domain kinase Rip2 has been implicated in signaling from multiple 
TLRs including TLR 2, 3 and 4, the T cell receptor and the cytosolic NOD1/2 pathways.  
To understand how Rip2 mediates such diverse signals, we isolated macrophages from 
Rip2-deficient mice and stimulated the cells with the NOD2 ligand muramyl dipeptide 
(MDP) or with purified LPS to stimulate the TLR4 pathway.  We found that MDP and 
LPS induced NF-B, p38 MAP kinase and JNK1/2 activation when wild type 
macrophages were stimulated (Figure 6A and 6B).  Rip2-deficient macrophages also 
respond upon LPS stimulation, but appear impaired in their ability to mediate NF-B 
activation when treated with MDP (Figure 6A).  Similarly, the MDP-induced 
phospho-p38 and phospho-JNK1/2 activity was consistently impaired but not abrogated, 
suggesting that Rip2 contributes to MAP kinase activation but is not absolutely required 
(Figure 6A and 6B).  This data suggests that Nod-mediated MAP kinase activation may 
involve other CARD domain containing adapter proteins.  One possibility may be 
CARD9, as Card9-deficient mice exhibit defects in p38 MAP kinase and JNK activation 
in Nod stimulated cells.  
 
NOD2 pathway activation stimulates the stable K63-linked polyubiquitination of 
Rip2. 
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We hypothesized that Nod mediated IKK activation may involve the ubiquitin 
modification of Rip2 or IKK-/NEMO and tested this possibility by stimulating the 
mouse macrophage cell line RAW 264.7 with the Nod2 ligand MDP and assayed for the 
presence of polyubiquitinated Rip2 or NEMO/IKK-.  We observed a ligand-dependent 
induction of Rip2 and NEMO/IKK- polyubiquitination and interestingly, Rip2 
polyubiquitination appears to precede the ubiquitin modification of NEMO/IKK-
pathway activation by MDP appears to induce the stable modification of Rip2 and IKK-, 
suggesting that Rip2 and IKK- may be conjugated by K63-linked polyubiquitin chains 
(Figure 7A).  To test this possibility, HEK293 cells were transfected with epitope-tagged 
versions of Rip2 and NOD2 in the presence of wild type or mutant forms of ubiquitin 
where only the lysine(s) at positions 63 or 48 are available for conjugation.  In this 
setting, Rip2 appeared preferentially modified by K63-linked polyubiquitin chains and 
this activity appeared dependent on the presence of NOD2 (Figure 7B). The K63-specific 
polyubiquitin modification of Rip2 in MDP-NOD2 patyway was confirmed by using the 
linkage-specific polyubiquitin antibodies [39] (Figure 8).  These data suggest that 
physiologic activation of the NOD2 pathway might stimulate the stable K63-linked 
polyubiquitination of Rip2.   
 
MDP-induced Rip2 polyubiquitination is dependent on the expression of the E2 
conjugating enzyme Ubc13 and the E3 ubiquitin ligase Traf6.  
Our studies suggest that NOD2-induced NF-B activation may be mediated by 
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the ubiquitin conjugation of Rip2 and IKK- and the transfection studies suggest that 
K63-linked polyubiquitin chains may stably modify both proteins.  Therefore, we were 
interested in testing whether MDP-induced NF-B activation and Rip2/IKK- 
polyubiquitination require expression of the E2 conjugating enzyme Ubc13, known to 
conjugate K63-linked polyubiquitin chains.  To address a requirement for Ubc13, we 
infected the MDP responsive mouse macrophage cell line RAW 264.7 with lentiviruses 
expressing shRNAs specific for the Ubc13 enzyme.  These stable pools of RAW 264.7 
macrophages were impaired in their ability to phosphorylate IB in response to MDP 
(data not shown).  Rip2 polyubiquitination was detected in RAW 264.7 macrophages 
expressing a control shRNA, however, treatment with the Nod2 ligand MDP failed to 
stimulate Rip2 polyubiquitination when the Ubc13-deficient cells were stimulated 
(Figure 9A).  The level of Rip2 polyubiquitination and MDP-induced NF-B activation 
correlated with the reduction of Ubc13 expression achieved in the RAW 264.7 pools. 
In transfected cells, Rip2 has been shown to interact with Traf 2, 5 and 6 proteins 
[60], suggesting that one of these Traf proteins may modify Rip2 upon Nod2 pathway 
stimulation.  To identify the E3 ubiquitin ligase responsible for the modification of Rip2, 
we transfected HEK293 cells with epitope-tagged versions of NOD2 and Rip2 and tested 
whether MDP- or NOD2-dependent Rip2 polyubiquitination is observed in cells where 
Traf2 or Traf6 expression was reduced.  In HEK293 cells transfected with NOD2 and 
stimulated with MDP, Rip2 polyubiquitination was detected, as expected (Figure 9B).  
Similarly, in cells where Traf2 expression is reduced via transfection of siRNAs specific 
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for Traf2, MDP stimulated Rip2 polyubiquitination and this modification appeared 
NOD2-dependent.  In contrast, Rip2 polyubiquitination was reduced in MDP-stimulated 
HEK293 cells in which Traf6 expression was reduced (Figure 9B), thereby implicating 
Traf6 as a potential Rip2 E3 ubiquitin ligase in the Nod2 pathway.  We also examined 
whether MDP or NOD2 pathway activation stimulates an association between Rip2 and 
Traf6.  Using co-immunoprecipitation, MDP treatment stimulated interaction between 
endogenous Rip2 and Traf6 between 30 and 60 min following MDP treatment.  
Consistently, polyubiquitinated Rip2 proteins are detected at similar time periods 
following MDP treatment (Figure 7A).   
To further test a requirement for Traf6, we attempted to knock down the 
expression of Traf6 in the RAW 264.7 mouse macrophage cell line and then stimulated 
the cells with IL-1 or MDP.  As expected [166], no IL-1-induced NF-B activation is 
detected in the Traf6 knocked down cells, however, the control shRNA treated cells 
activate NF-B upon IL-1 treatment.  MDP-induced NF-B activation is clearly 
impaired in cells where Traf6 expression is reduced, suggesting that Traf6 is required for 
optimal NF-B responses to MDP (Figure 9D).  These data are consistent with a model 
whereby Traf6 modifies Rip2 upon activation of the Nod2 pathway, raising the possibility 
that this enzyme may be targeted in human inflammatory disease. 
 
Rip2 and the ubiquitin activated kinase Tak1 interact upon MDP stimulation and 
Tak1 expression is required for MDP-induced IKK activation. 
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Our data suggest that Rip2 polyubiquitination may contribute to NOD2-mediated 
NF-B activation by recruiting the ubiquitin activated kinase Tak1.  Therefore, we 
tested whether Rip2 interacts with Tak1 and whether MDP stimulates an endogenous 
Rip2/Tak1 interaction.  A Rip2/Tak1 interaction could be readily demonstrated in 
transfected cells (Figure 10A) and an endogenous Rip2/Tak1 interaction was detected 
following MDP treatment (Figure 10B), during a time period when a Rip2/Traf6 
interaction was also observed (Figure 9C).  Collectively, these data suggest that MDP 
stimulation or NOD2 pathway activation stimulates the formation of a 
 
These data predict that MDP-induced NF-B activation will be dependent on the 
expression of the ubiquitin-dependent kinase Tak1.  We reduced Tak1 expression level 
in the RAW 264.7 macrophage cell line and tested its effects on MDP- and TNF-induced 
NF-B activation.  Consistent with the transfection studies, NF-B activation was 
reduced in both the MDP- and TNF-stimulated Tak1 silenced cells, whereas it remained 
unaffected when the control cells were stimulated with either MDP or TNF- (Figure 
10C).  These data led us to propose that Tak1 is critical for NOD2 signaling to NF-B.  
Thus, stimulation of the NOD2 pathway results in the recruitment and subsequent 
ubiquitin modification of Rip2 by an Ubc13/Uev1a and Traf6 complex.  
Polyubiquitinated Rip2 then signals the recruitment and activation of the Tak1 kinase.  
  
Live Mycobacterium tuberculosis infection stimulates Rip2 polyubiquitination. 
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Although MDP stimulates NOD2-mediated NF-B activation and mutations in 
the CARD15 gene are associated with human inflammatory disease, MDP has not, as yet, 
been shown to bind to the NOD2 protein [122].  Hence, we were interested in testing 
whether infection with live bacteria stimulates the ubiquitin modification of Rip2.  The 
cytosolic NOD2 pathway has been implicated in the cytokine response to Mycobacterium 
tuberculosis (Mtb) infection in vitro and recent studies reveal important, nonredundant 
roles for NOD2 and TLRs in the in vivo recognition of Mtb [121,140].  To test whether 
Mtb infection stimulates Rip2 polyubiquitination, we infected bone marrow derived 
macrophages with a wt strain of Mtb (H37Rv) or with heat-killed Mtb and assayed for 
polyubiquitinated Rip2 proteins at 1 and 4 hours post infection.  Infection with live Mtb 
stimulated Rip2 polyubiquitination, whereas heat killing destroyed the ability of Mtb to 
induce the modification of Rip2 (Figure 11A).  
TLR2/4 have been implicated in the innate immune recognition of Mtb and 
published studies place Rip2 downstream of TLR2/4 [64,102,167].  Thus, it was 
important to test whether Mtb-induced Rip2 polyubiquitination was TLR-dependent.  To 
test this idea, we isolated wild type and MyD88-deficient macrophages and left the cells 
uninfected or infected them with Mtb.  Rip2 polyubiquitination was observed in 
Mtb-infected wild type and MyD88-deficient macrophages, suggesting that Mtb 
recognition is TLR independent (Figure 11B).  We also examined Rip2 
polyubiquitination in macrophages lacking both TLR2 and TLR4 to directly test the 
contribution of the TLR4, MyD88 independent pathway, but observed no differences in 
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the ability of Mtb infection to stimulate Rip2 polyubiquitination (Figure 11B).  Although 
it remains unclear precisely how the cytosolic NOD2 pathway is activated by Mtb 
infection, several observations suggest that the Mycobacterial phagosome may be 
permeable to some compounds [168,169,170], suggesting a mechanism whereby Mtb 
products are released into the cytosol where they stimulate Rip2 recruitment and 
polyubiquitination. 
 
Identification of critical lysine residues critical for Rip2 polyubiquitination.   
     It remains unclear from our studies, however, whether polyubiquitinated Rip2 is 
required for Nod2-mediated IKK activation.  To map the ubiquitination site(s) on Rip2,  
we focused on the intermediate domain of Rip2, since like Rip1, expression of the 
intermediate domain of Rip2 activates an NF-B reporter construct, whereas expression 
of the kinase domain does not [171]. To identify the activated lysine residue(s) within the 
intermediate domain, we aligned the sequence of the intermediate domains of human, rat 
and mouse Rip2 and found that lysines 310, 311, 313, 326, 327 and 383 are conserved 
among the different species (Fig. 12A).  We hypothesized that the critical ubiquitin site 
is likely to be conserved among species and therefore constructed 2 mutant forms of Rip2. 
One in which the lysine residues 310/311/313 (Rip2 3K) were mutated to arginines, 
designated Rip2 3K. The other mutant was designated Rip2 2K since lysine residues 
326/327 were mutated to arginines. 
      To test if these lysine residues are critical for Rip2 polyubiquitination in the Nod2 
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pathway, wild type Rip2 and the Rip2 lysine mutants were overexpressed in HEK293 
cells. Wild type and mutant Rip2 protein were immunoprecipitated and Rip2 
polyubiquitination measured by blotting with ubiquitin antibody. Compared to wild type 
Rip2 protein, the Rip2 K326/327R form failed to be ubiquitin modified in this assay 
(Figure 12B). Polyubiquitination of Rip2 3k protein was detected, suggesting that 
K310/311 and K313 may not be essential. Co-expression of Rip2 wild type and Rip2 2K 
with Nod2 followed by MDP stimulation revealed that the Rip2 2k mutant unable to 
undergo stable polyubiquitination compare to wild type Rip2 (Figure 12C). This 
experiment suggested that Rip2 lysine 326/327 might be critical for Rip2 
polyubiquitination in MDP pathway.  
 
Rip2 polyubiquitination is required for Nod2-mediated IKK activation. 
      Recently, Inohara and colleagues identified lysine 209 in Rip2 kinase domain 
required for Nod1-mediated NF-B activation in MEFs [104], suggested that lysine at 
position 209 may contribute to Rip2 polyubiquitination. To determine whether 
polyubiquitinated Rip2 is required for Nod2-mediated IKK activation, we generated 
rip2-/- macrophage cell lines stably express wild type Rip2, Rip2 K209R, Rip2 
K326/327R (Rip2 2K) and Rip2 K310/311/313 (Rip2 3K).  We cloned wild type Rip2 
and the lysine mutants into the MSCV2.2.IRES-GFP retroviral vector and prepared high 
titer, replication incompetent retroviral stocks. The rip2-/- transformed macrophage cell 
line was infected with the retroviral vector alone or with retroviruses expressing wild 
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type or mutant forms of Rip2. Transduction efficiency was reported as percentage of GFP 
positive cells for each reconstituted line (Figure 13A). Rip2 proteins in reconstituted 
macrophage cell line were measured by immuno blotting of Rip2 antibody to ensure that 
comparable levels of Rip2 expression were achieved (Figure 13A). 
      Using this approach, we found conserved lysines 326 and 327 (Rip2 2K) required 
for MDP-induced NF-B activation and cytokine production (Fig 13B and 13C).  
Expression of this Rip2 2K lysine mutant in our rip2-/- macrophage cell line failed to 
restore responsiveness to MDP.  In contrast, expression of wild type Rip2 or Rip2 3K 
restores Nod2-mediated NF-B activity and cytokine production. The Rip2 K209R 
mutant also failed to restore IKK activation upon MDP treatment (Figure 13D), 
suggested that Rip2 K209 and K326/327 might all contribute to Rip2 function in Nod 
pathway. Together with our previous results that Rip2 2K protein cannot be ubiquitin 
modified upon MDP stimulation (Figure 12C), these results indicate that Rip2 
polyubiquitination is essential for MDP or Nod2 mediated IKK activation.  
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Discussion 
Our work demonstrates that Rip2 primarily mediates NF-B activation but is 
not required for MAP kinase activation in MDP-stimulated peritoneal macrophages.  
MDP treatment of macrophages or infection with the human pathogen Mycobacterium 
tuberculosis stimulates Rip2 polyubiquitination, suggesting that Rip2 polyubiquitination 
may be required for NF-B activation by NLRs.  Our work also implicates the E2 
conjugating enzyme Ubc13, the E3 ubiquitin ligase Traf6 and the ubiquitin-activated 
kinase Tak1 in Nod2-mediated NF-B activation.  In collaboration with Abbott and 
Cantley, we also recently showed that IKK- is ubiquitin modified in NOD2 transfected 
cells [172].  These studies are limited however, as they involve transfected proteins and 
the NOD2 pathway is activated not by ligand, but rather by NOD2 or Rip2 
overexpression.  In the work herein, macrophages are stimulated with ligand (MDP) or 
infected with the intracellular pathogen Mtb, and the endogenous Rip2 and IKK- 
proteins were examined for evidence of polyubiquitination.  Collectively, both studies 
provide strong evidence that the NOD2 pathway is ubiquitin regulated and that IKK- 
and Rip2 polyubiquitination is mediated by an Ubc13/Traf6/Tak1 complex.  Abbott et al 
also suggest that in contrast to wild type NOD2, expression of the Crohn’s disease (CD) 
associated NOD2 allele, L2007insC fails to stimulate IKK- polyubiquitination [172].  
Yet NOD2 L2007insC is impaired in its ability to stably interact with Rip2 ([108] and 
Yang and Kelliher, unpublished data), suggesting that Rip2 and potentially 
polyubiquitinated Rip2 stimulates IKK- recruitment and its subsequent ubiquitination. 
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These findings also raise the intriguing possibility that human inflammatory diseases like 
Crohn’s Disease or Blau syndrome may reflect deregulated ubiquitin mediated signaling, 
a hypothesis that remains to be tested by asking whether polyubiquitinated IKK- or Rip2 
proteins are detected in the relevant cell types isolated from patients. 
Although we observed a defect in MDP-induced NF-B activation in 
Rip2-deficient macrophages, MDP-induced p38 MAP kinase or JNK1/2 activation 
appears only modestly affected. These data suggest that other CARD containing adapter 
proteins may contribute to NOD2-mediated MAP kinase activation.  One possibility 
may be CARD9, that is expressed in RAW 264.7 macrophages and whose expression has 
been shown to preferentially activate the p38 MAP kinase and JNK1/2 pathways.  
Consistent with this model, MDP-induced MAP kinase responses and cytokine 
production are impaired in CARD9-deficient cells, whereas MDP-induced NF-B 
activation appears unaffected [173].   
The cytosolic Nod2 pathway has been implicated in innate immune responses to 
Streptococcus pneumoniae, Listeria monocytogenes and Mycobacterium tuberculosis 
(Mtb) [100,120,121].  Rip2-deficient mice have been shown to be susceptible to Listeria 
infection [102], however the contribution of Rip2 to the innate immune response to Mtb 
has not yet been examined.  We demonstrate that Mtb infection results in the ubiquitin 
modification of Rip2.  Rip2 polyubiquitination is observed in macrophages infected 
with wt strains of Mtb, but is not observed if the bacilli are killed prior to infection (with 
heat,) (Figure 11A).  These data indicate that Rip2 polyubiquitination and Nod2 
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pathway ―activation‖ requires bacterial viability and suggests that Mtb components may 
gain entry into the host cell cytosol to stimulate the Nod2/Rip2 pathway.  
Although Rip2 and NLRs have been implicated in the innate immune 
recognition of Listeria monocytogenes, we did not observe Rip2 polyubiquitination 
following Listeria infection.  It remains unclear why Listeria infection did not stimulate 
Rip2 polyubiquitination, but recent work by Girardin and colleagues suggests that the 
Listeria monocytogenes genome encodes a peptidoglycan N-deacetylase (pgdA) gene and 
inactivation of the bacterial pgdA gene results in reduced bacterial growth and a massive 
host IFN- response [97]. Thus, our inability to detect Rip2 polyubiquitination in 
Listeria-infected macrophages may reflect the ability of the bacteria to deacetylate 
peptidoglycan and thereby avoid NLR recognition. 
In summary, this study provides genetic and biochemical evidence that 
Nod2-mediated bacterial recognition is mediated by the stable ubiquitin modification of 
Rip2, raising the possibility that the enzymes responsible for the ubiquitin modification 
of Rip2 may serve as potential therapeutic targets in certain infectious diseases and 
potentially in chronic inflammatory disease. 
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Materials and Methods 
 
Isolation of Macrophages and Mycobacterium tuberculosis infection   
To isolate peritoneal activated macrophages, wild type and rip2-/- mice (gift of 
Dr. Vishva M. Dixit, Genentech, Inc. South San Francisco, CA) were injected with 3ml of 
thioglycolate by intraperitoneal injection.  Three days later, macrophages were isolated 
by gentle flushing of the peritoneal cavity.  Peritoneal macrophages were left 
unstimulated or treated with MDP or purified LPS (Sigma).  NF-B activation was 
measured using phospho-IB antibodies (Cell Signaling Technology), p38 MAP kinase 
and JNK1/2 activity was measured using anti-phospho-p38 and phospho-JNK1/2 
antibodies (Cell Signaling Technology), respectively.  Bone marrow derived 
macrophages for Mycobacterium tuberculosis (Mtb) infection were harvested from wild 
type or MyD88-deficient mice as described in [174]. Mtb (strain H37Rv) was cultivated 
in 7H9 broth to exponential phase and washed thoroughly in phosphate buffered saline 
prior to infection.  Bacterial clumps were removed by passing the washed suspension 
through a 5M syringe filter.  ―Heat-killed‖ bacteria were inactivated by heating to 80ºC 
for 30 minutes.  Macrophages were infected for 1 or 2 hours after which filtered cell 
lysates were immunoprecipitated with anti-Rip2 antibody (Santa Cruz) or immunoblotted 
with anti-phospho-IB antibody (Cell Signaling Technology).   
 
Plasmids and Constructs   
The full-length Rip2 constructs was provided by Dr. Vishva M. Dixit (Genentech, 
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South San Francisco, California). The wild type NOD2 construct has been described 
previously [108]. The HA-ubiquitin, HA-K48-only ubiquitin and HA-K63-only ubiquitin 
constructs were generously provided by Dr. Zhijan James Chen (University of Texas 
Southwestern, Dallas, TX). 
 
Antibodies, siRNA and Reagents  
Anti-Rip2 (Rabbit), anti-Nemo (Rabbit), anti-Traf2 (Rabbit), 
anti-Traf6(Mouse), anti-Ubiquitin (Mouse), anti-Omni (Rabbit), anti-Tak1 (Rabbit), 
anti-p38 (Goat) and anti-JNK (rabbit) antibody were obtained from Santa Cruz 
Biotechnology. Anti-phospho-IB-, anti-phospho-p38 and anti-phospho-JNK antibodies 
were obtained from Cell Signaling Technology. Anti-UBC13 antibody was obtained from 
Zymed, anti-FLAG, and anti--actin antibody were obtained from Sigma and anti-HA 
antibody was obtained from Boehringer Mannheim. Human Traf2 and Traf6 siRNA and 
mouse Tak1 siRNA were obtained from Santa Cruz Biotechnology. MDP was obtained 
from InvivoGen. Mouse TNF-
Escherichia coli strain 0111.B4 was purchased from Sigma, dissolved in deoxycholate, 
and re-extracted with phenol/chloroform as described in [175]. 
 
Cell Culture, DNA transfection and SiRNA transfection   
HEK293T cells and the mouse RAW 264.7 macrophage cell lines were 
obtained from ATCC and were grown in DMEM containing 10% FBS. For all 
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transfection studies, HEK293T cells were plated at 5x105 cells/plate on 60mm plates. 
Constructs were transfected to HEK293T cells using FuGENE 6 transfection reagent 
(Roche Applied Science) according to the manufacturer’s instructions. SiRNAs were 
transfected to HEK293T cells using Lipofectamine 2000 (Invitrogen).  Mouse control 
and Tak1 specific siRNAs were transiently transfected into the mouse RAW 264.7 
macrophage cell line using a two step transfection procedure and Lipofectamine 2000 
(Invitrogen).        
 
Generation of Ubc13 stably knock down RAW246.7 cell lines    
The mouse macrophage cell line RAW264.7 was infected with lentiviruses 
containing shRNA sequences specific for Ubc13 (Open Biosystems) and selected with 
2.5g/ml puromycin.  Selected puromycin resistant pools of cells were left unstimulated 
or treated with MDP and Rip2 polyubiquitination assayed by immunoprecipitation with 
anti-Rip2 antibody (Santa Cruz) followed by immunoblotting with anti-ubiquitin 
antibodies.  The expression of the E2 conjugating enzyme Ubc13 in the lentiviral 
infected pools was determined by immunoblotting with an anti-Ubc13 antibody (Zymed). 
 
Immunoprecipitation and Western Blot Analysis   
For all immunoprecipitation and ubiquitination assays, cell lysates were 
prepared in radioimmune precipitation assay (RIPA) buffer (150mM NaCl, 50mM 
Tris-HCl (pH 7.5), 1% NP40, 0.25% deoxycholate, 0.1% SDS, 1mM EDTA), 
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supplemented with a protease mixture inhibitor (Roche Applied Science) and 5mM 
N-ethylmaleimide (Sigma), immunoprecipitated with anti-Rip2 or anti-NEMO antibody 
(Santa Cruz), Polyubiquitinated Rip2 or NEMO/IKK-
immunoblotting with an anti-ubiquitin antibody (Santa Cruz).  To examine endogenous 
protein interactions, cells were lysed in an endogenous lysis buffer (0.5 M Tris (pH 7.6), 
0.5 M NaCl, 0.1 M EDTA, 1% Triton X-100, 0.5 M NaF, and 0.5 M sodium 
pyrophosphate) supplemented with a protease mixture inhibitor (Roche Applied Science), 
immunoprecipitated with anti-Rip2 antibody, and then immunoblotted with either 
anti-Tak1 or anti-Traf6 antibody (Santa Cruz Biotechnology).  Expression of 
epitope-tagged, transfected proteins or endogenous proteins was detected by 
immunoblotting with corresponding antibodies.  
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Figures and Legends 
Figure 6.  Rip2-deficient macrophages are impaired in their response to NOD2 
ligand MDP, but respond normally to the TLR4 ligand, LPS.  A.  Rip2 is required 
for NF-B and p38 MAP kinase activation in response to MDP or NOD2 pathway 
stimulation. Macrophages from wild type and rip2-/- mice were grown to confluence on 
6 well plates and treated with 10g/ml MDP or 10ng/ml LPS for the indicated times. The 
IKK and p38 MAPK activity were measured by immunoblotting with anti-phospho-IB 
and anti-phospho-p38 MAP kinase antibody (Cell signaling). Total p38 protein level was 
measured by immunoblotting with anti-p38 antibody (Santa Cruz).  B.  MDP-induced 
JNK1/2 activation is modestly impaired in the absence of Rip2.  Macrophages from 
wild type and rip2-/- mice were grown to confluence on 6 well plates and treated with 
10g/ml MDP or 10ng/ml LPS for the indicated periods of time. The JNK MAPK 
activity was measured by immunoblotting with anti-phospho-JNK antibody (Cell 
signaling). Total JNK protein level was measured by immunoblotting with anti-JNK 
antibody (Santa Cruz). 
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Figure 7.  NOD2 pathway activation stimulates the stable K63-linked 
polyubiquitination of Rip2.  A.  MDP treatment stimulates the ubiquitin 
modification of endogenous Rip2 and NEMO/IKK-.  The RAW 264.7 macrophage 
cell line was left untreated or treated with the NOD2 ligand, MDP (10g/ml) for the 
indicated times.  Cells were lysed, and an equal amount of total protein was 
immunoprecipitated with anti-Rip2 or anti-NEMO antibody (Santa Cruz).  To detect 
ubiquitinated proteins, immunoprecipitated proteins were immunoblotted with an 
anti-ubiquitin antibody (Santa Cruz).  Total immunoprecipitated Rip2 or 
NEMO/IKK- protein was measured by immunoblotting with anti-Rip2 or anti-NEMO 
antibodies (Santa Cruz).  B.  NOD2 expression stimulates the stable, K63-linked 
polyubiquitination of Rip2.  Omni-tagged NOD2 and FLAG-tagged Rip2 constructs 
were expressed in HEK293T cells in the presence of HA-tagged K63-only or HA-tagged 
K48-only forms of ubiquitin. Rip2 was immnoprecipitated with anti-Rip2 antibody 
(Santa Cruz), and western blots were performed with the indicated antibodies.  
Expression levels of both Flag-Rip2 and Omni-NOD2 was measured by immunoblotting 
total cell lysates with anti-Flag or anti-Omni antibodies. 
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Figure 8. MDP treatment stimulates the K63-specific ubiquitin modification of 
endogenous Rip2. The RAW 264.7 macrophage cell line was left untreated or treated 
with the NOD2 ligand, MDP (10g/ml) for the indicated times. Cells were lysed, and an 
equal amount of total protein was immunoprecipitated with anti-Rip2 antibody (Santa 
Cruz). To detect K63-specific ubiquitinated proteins, immunoprecipitated proteins were 
immunoblotted with an anti-K63-ubiquitin antibody (Millipore and original from 
Genentech). Total immunoprecipitated Rip2 protein was measured by immunoblotting 
with anti-Rip2 antibody (Santa Cruz). 
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Figure 9.  MDP-induced Rip2 polyubiquitination is dependent on the expression of 
the E2 conjugating enzyme Ubc13 and the E3 ubiquitin ligase Traf6.  A.  MDP 
fails to stimulate Rip2 polyubiquitination in Ubc13-deficient RAW 264.7 
macrophages. The mouse macrophage cell line RAW 264.7 was infected with 
lentiviruses containing shRNA sequences specific for Ubc13 or GFP as a control and 
stable puromycin resistant pools selected.  These lines were left untreated or stimulated 
with MDP (10g/ml) for the time periods indicated.  Cells were lysed, and an equal 
amount of total protein was immunoprecipitated with anti-Rip2 antibody (Santa Cruz) 
followed by immunoblotting with an anti-ubiquitin antibody (Santa Cruz).  Total 
immunoprecipitated Rip2 protein was measured by immunoblotting with anti-Rip2 
antibody (Santa Cruz).  Expression of Ubc13 level was determined by immunoblotting 
with an anti-Ubc13 antibody (Zymed).  B.  Rip2 polyubiquitination requires the 
expression of the E3 ubiquitin ligase Traf6, but not Traf2.  Omni-tagged NOD2 was 
expressed in HEK293T cells in the presence of either a control siRNA or siRNA specific 
for Traf2 or Traf6.  Rip2 was immunoprecipitated with anti-Rip2 antibody (Santa Cruz) 
followed by immunoblottting with anti-ubiquitin to detect polyubiquitinated Rip2 
proteins.  Expression levels of Omni-NOD2 and Traf2 or Traf6 protein levels was 
measured by immunoblotting the total cell lysates with anti-Omni, anti-Traf6 and 
anti-Traf2 antibodies (Santa Cruz).  C.  MDP stimulates interaction between 
endogenous Rip2 and Traf6.  RAW 264.7 macrophages were left untreated or treated 
with 10g/ml MDP for the indicated periods of time.  Cells were lysed, and an equal 
amount of total protein was immunoprecipitated with anti-Rip2 antibody (Santa Cruz) 
followed by immunoblotting with an anti-Traf6 antibody (Santa Cruz).  The total 
immunoprecipitated Rip2 protein was measured by immunoblotting with anti-Rip2 
antibody (Santa Cruz).  D. Traf6 expression is required for MDP- and IL-1 induced 
NF-B activation.  The RAW 264.7 macrophage cell line was transfected with control 
siRNA or a pool of Traf6 siRNAs.  Forty-eight hours later, the cells were left untreated 
or stimulated with MDP (10g/ml) for the time periods indicated or with IL- (5ng/ml) 
for 10 minutes.  NF-B activation was measured by immunoblotting with a 
phospho-IB antibody (Cell Signaling Techology).  Traf6 and -actin levels were 
determined by immunoblotting with the indicated antibodies. 
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Figure 10.  Rip2 and the ubiquitin activated kinase Tak1 interact upon MDP 
stimulation and Tak1 expression is required for MDP-induced IKK activation.  A.  
Rip2 and Tak1 interact in transfected cells.  Flag-tagged Tak1 and HA-tagged Rip2 
were either co-expressed or expressed alone in HEK293T cells.  Tak1 was 
immunoprecipitated with an anti-Flag antibody and Rip2 detected by immunoblotting 
with anti-HA antibody or Rip2 was immunoprecipitated with an anti-HA antibody 
followed by immunoblotting with anti-Flag antibody to detect associated Tak1 proteins.  
Relative expression of each construct was measured by immunoblotting the total cell 
lysate with anti-HA or -Flag antibodies.  B.  MDP stimulates interaction between 
Rip2 and Tak1.  The RAW 264.7 macrophage cell line was left untreated or treated 
with 10g/ml MDP for the indicated periods of time.  Cells were lysed, and an equal 
amount of total protein was immunoprecipitated with anti-Rip2 antibody (Santa Cruz) 
followed by immunoblotting with an anti-Tak1 antibody (Santa Cruz).  Total 
immunoprecipitated Rip2 protein was measured by immunoblotting with anti-Rip2 
antibody (Santa Cruz).  C. Tak1 expression is required for TNF- and MDP-induced 
NF-B activation.  Mouse RAW 264.7 macrophages cell line was transfected with 
control siRNA or a pool of Tak1 siRNAs.  Forty-eight hours later, the cells were left 
untreated or stimulated with MDP (10g/ml) for the time periods indicated or with 
TNF- (10ng/ml) for 10 minutes.  NF-B activation was measured by immunoblotting 
with a phospho-IB antibody (Cell Signaling).  Tak1 and -actin levels were 
determined by immunoblotting with the indicated antibodies. 
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Figure 11.  Live Mycobacterium tuberculosis infection stimulates Rip2 
polyubiquitination.  A.  Live, wt strains of Mtb (Rv) stimulate Rip2 
polyubiquitination but heat killed strains fail to stimulate Rip2 polyubiquitination.  
Wildtype bone marrow-derived macrophages were infected with live virulent (Rv) or heat 
killed (HK-Rv) strains of M. tuberculosis (Mtb H37Rv).  Polyubiquitinated Rip2 
proteins were detected by immunoprecipitating the cell lysates with an anti-Rip2 
antibody followed by immunoblotting with an anti-ubiquitin antibody.  
Immunoprecipitates were immunoblotted with a Rip2 antibody to insure that equal 
amounts of Rip2 protein were immunoprecipitated.  B.  Mtb-induced Rip2 
polyubiquitination is MyD88 and TLR2/4 independent.  Wildtype, MyD88-/- and 
TLR2/4-/- bone marrow-derived macrophages were left uninfected (-) or infected with 
live wt M. tuberculosis (H37Rv) for 1 hour.  Polyubiquitinated Rip2 proteins were 
detected by immunoprecipitating the cell lysates with an anti-Rip2 antibody followed by 
immunoblotting with an anti-ubiquitin antibody. 
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Figure 12. Identification of critical lysine residues critical for Rip2 
polyubiquitination. A. Sequence alignment of the intermediate domains of human, 
rat and mouse Rip2. Lysines 310, 311, 313, 326, 327 (in Red Box) are conserved among 
the different species. B. Rip2 2K mutant is unable to undergo polyubiquitination 
when overexpressed in HEK293 cells.  FLAG-tagged Rip2 wt, 3K or 2K constructs 
were expressed in HEK293T cells. Rip2 was immunoprecipitated with anti-FLAG 
antibody and western blots were performed with the indicated antibodies.  Expression 
levels of Flag-Rip2 was measured by immunoblotting total cell lysates with anti-Flag 
antibodies. C. Rip2 2k polyubiquitination is impaired in MDP treated cells.   
FLAG-tagged Rip2 wt or 2K constructs and Omni-tagged NOD2 were expressed in 
HEK293T cells. Cells were treated with MDP (10g/ml) for the indicated time.  Rip2 
was immunoprecipitated with anti-FLAG antibody (Santa Cruz) followed by 
immunoblottting with anti-ubiquitin to detect polyubiquitinated Rip2 proteins.   
 
3k 2k 
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Figure 13. Rip2 polyubiquitin modification is required for Nod2-mediated IKK 
activation. A. Generation of rip2-/- reconstituted macrophage cell lines stably 
expressing wild type Rip2, Rip2 2K, Rip2 Rip2 3K and Rip2K209R.  Rip2 wild type 
and lysine mutants was cloned into an MSCV2.2.IRES-GFP retroviral vector. The rip2-/- 
transformed macrophage cell line was infected with the retroviral vector alone or with 
retroviruses expressing Rip2. Rip2 protein expression level was measured by GFP 
positive cells and Rip2 immuno blot to ensure comparable levels of Rip2 expression were 
achieved. B and C. Conserved lysines 326 and 327 (Rip2 2K) are required for 
MDP-induced NF-kB activation and cytokine production. rip2-/- reconstituted 
macrophage cell lines were left untreated or stimulated with MDP (10g/ml) for the time 
periods indicated. NF-B activation was measured by immunoblotting with a 
phospho-IB antibody (B).  TNF expression was measured by TNF ELISA (C).  
D. Rip2 K209R mutant reconstituted cell line also failed to restore IKK activation 
upon MDP treatment. rip2-/- reconstituted macrophage cell lines were left untreated or 
stimulated with MDP (10g/ml) for the time periods indicated. NF-B activation was 
measured by immunoblotting with a phospho-IB antibody. 
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Chapter III       
 
NOD2, RIP2 and IRF5 Play a Critical Role in the 
Type I Interferon Response to Mycobacterium 
Tuberculosis 
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Introduction  
Mycobacterium tuberculosis (Mtb), the causative agent of human tuberculosis, is 
an exquisitely adapted obligate human pathogen that is thought to persist within as many 
as one billion individuals worldwide [129]. While residing inside a modified phagosomal 
compartment of host macrophages, Mtb is able to persist for decades.  However, a 
robust cell-mediated immune response effectively inhibits bacterial replication in 
approximately 90% of otherwise healthy individuals, and the infection can be controlled 
indefinitely.  Deficits in this immune response result in progressive bacterial replication, 
necrosis of infected lung tissue, and spread to other individuals.  Thus, like many other 
pathogens that cause chronic infections, the long-term survival of Mtb, depends on a 
delicate balance between bacterial virulence and host immunity. 
Immunity to tuberculosis depends on both the innate and adaptive responses of 
the host. Initial recognition of the bacterium is mediated by pattern recognition receptors 
(PRR) such as Toll-like receptors (TLRs) [74,165] or nucleotide binding oligomerization 
domain (NOD)-like receptors (NLRs) [176,177], both of which recognize conserved 
microbial structures known as pathogen associated molecular patterns (PAMPs).  
Although the functions of most NLR’s remain undefined, the Nod1 and Nod2 proteins 
have been shown to respond to bacterial cell wall fragments. While the recognition of 
these common forms of peptidoglycan have been extensively studied, bacteria modify 
their cell walls in a myriad of ways and the effects of these modifications on Nod1/2 
recognition are only beginning to be appreciated (reviewed in [94,95,96]).  For example, 
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Listeria monocytogenes removes a common N-acetyl moiety from the glucosamine of its 
peptidoglycan, which renders the cell wall resistant to host lysozyme and thereby inhibits 
bacterial recognition by Nod1 [97].  In contrast, mycobacteria, replace the N-acetyl 
group of the muramic acid of MDP with an N-glycolyl moiety[98,99], and this 
modification significantly increases the potency of this compound as a Nod2 agonist 
(Coulombe et al, unpublished data). 
 Nod1 and Nod2 functions depend on the serine threonine kinase Rip2. Rip2 has 
been shown to be essential for cytosolic Nod1/2 signaling, and its overexpression 
stimulates NF-B activity and induces apoptosis [60,67]. We have shown that Rip2 is 
stably modified with ubiquitin in cells treated with the Nod2 agonist MDP (Figure 7).  
This modification is required for Nod1-mediated NF-B activation [104], indicating that 
stable polyubiquitination is a critical component of this signaling cascade.  
Intact Mtb bacilli are recognized by both TLRs and NLRs, which cooperatively 
respond to infection and synergistically induce NF-B activation [121].  However, a 
large fraction of the transcriptional response to Mtb, including many immunologically 
important proteins are induced independently of TLR2/4 and the adapter proteins MyD88, 
MAL and TRIF. Instead these responses rely on autocrine or paracrine signaling via type 
I interferons (IFN/), which are induced through largely undefined pathways [139].  
Despite the ability of cell surface localized TLR4 to trigger IFN and 
IFN transcription, existing evidence indicates that during genuine bacterial infections, 
this response instead requires the recognition of bacterial products in the cytosol. This has 
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been most clearly demonstrated for Listeria monocytogenes, which must disrupt the 
phagosomal membrane and escape into the cytosol in order to trigger the type I IFN 
response in resting macrophages [178,179]. Despite its residence in the phagosome, Mtb 
still induces rapid and robust IFN/ transcription, and this response depends on a 
specialized secretion system of the bacterium, ESX1 [169].  This system has been 
suggested to contribute to the perturbation of the phagosomal membrane [180,181,182], 
indicating that cytosolic recognition might be critical for IFN/ responses to diverse 
bacterial pathogens including Mtb.  
The primary pathways leading to IFN/ induction upon bacterial infection 
remain obscure. Since transfection of DNA into the cytosol of macrophages can induce a 
Tbk-1 and Irf3-dependent IFN/ response similar to that seen upon L. monocytogenes 
infection, bacterial DNA has been implicated as the eliciting stimulus [183].  Two 
different cytosolic DNA sensors have been identified, DAI [184] and AIM2 [185], but 
their importance during bacterial infections remains to be demonstrated.  While Nod2 
recognition of MDP is not absolutely required for IFN/ production [186], it has been 
shown to synergize with the cytosolic DNA response and enhance IFN production during 
both L. monocytogenes and Mtb infection [143]. However, Nod2 stimulation alone is 
thought to be insufficient to induce type I IFN production [143].   
In sum, while a large fraction of the macrophage response to Mtb infection 
depends on type I IFN [139], and therefore is likely to rely on a cytosolic signaling 
pathway, the bacterial products recognized and the pathways involved remain unknown.  
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We previously found that Mtb infection of macrophages triggers Rip2 polyubiquitination 
in a TLR and MyD88 independent manner [187].  We now show that this stimulation is 
due to the ESX1-dependent entry of bacterial products into the cytosol where they are 
recognized by Nod2, implicating MDP as the relevant PAMP.  Unexpectedly, this results 
in IFN/ production that is dependent on a novel pathway consisting of Nod2, Rip2, 
Tbk1, and Irf5. This work is the first to implicate NLRs in IRF activation and to suggest a 
role for Irf5 in anti-bacterial innate immune responses.  Furthermore, we found that the 
unusual N-glycolyl MDP produced by Mtb was 10-100 fold more potent than the 
commonly studied N-acetylated MDP produced by most bacteria, and that only 
N-glycolyl MDP could stimulate Rip2-dependent IFN/ transcription in the absence of 
other stimulants.  Thus, the mammalian Nod2 pathway appears to be remarkably 
sensitive to mycobacterial MDP and responds to infection by triggering the production of 
type I interferon, which is responsible for a significant component of the transcriptional 
response to Mtb infection. 
72 
 
 
 
Results  
Mycobacterium tuberculosis infection stimulates the ubiquitin modification of Rip2 
via the Nod2 protein. 
The ability of Mtb to rapidly modify macrophage signaling and vesicular sorting 
pathways [132] suggests that bacterial products gain access to the cytosol soon after 
phagocytosis. These products are, in turn, likely to be sensed by the host and trigger the 
innate immune response.  Previously, we demonstrated that Mtb rapidly induces the 
TLR2/4 independent polyubiquitination of the Rip2 protein [187], an event that could 
represent the initiation of cytosolic recognition.  To characterize these events in more 
detail, we infected the mouse macrophage cell line RAW 264.7 or primary bone marrow 
derived macrophages (BMDM) with live or heat killed Mtb. In both cell types, we 
observed that infection with live, but not heat-killed, Mtb stimulated the rapid 
polyubiquitination of Rip2.  The Mtb-induced ubiquitin modification reached maximal 
levels within 1 hour post-infection and declined by 4 hours (Figure 14A).  Furthermore, 
pretreatment of cells with cytochalasin D to inhibit phagocytosis reduced Rip2 
polyubiquitination in a dose-dependent manner (Figure 14B), indicating that the bacteria 
must be both live and intracellular to initiate this response. 
Since Nod1 and Nod2 have been implicated in the cytosolic recognition of 
mycobacterial components [121], we sought to determine if Rip2 polyubiquitination 
depended on these proteins.   In contrast to cells from wild type mice, inducible Rip2 
polyubiquitination was not observed in macrophages derived from mice lacking Nod1 
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and Nod2, and was greatly reduced in cells lacking only Nod2 (Figure 14C).  These data 
confirmed that intracellular Mtb is recognized by a Nod2-dependent pathway and that 
this protein is required for the stable ubiquitination of Rip2.  
 
The mycobacterial ESX1 system is required for Nod recognition. 
Live intracellular Mycobacteria were required to stimulate the Nod-Rip2 pathway, 
indicating that the bacterium actively participated in this process, likely via the 
translocation of bacterial products into the cytosol. A specialized protein secretion system, 
encoded by the ESX1 locus, has been implicated in the perturbation of the host 
membranes [180,181,188] and for stimulation of the type I IFN response [169] and 
inflammasome activation [189], suggesting that this system might contribute to cytosolic 
recognition via Nod proteins.  In order to test this hypothesis, we infected the mouse 
macrophage cell line RAW 264.7 with wild type Mtb or mutants lacking ESX1 function.  
No induction in Rip2 polyubiquitination was observed upon infection with a strain of 
Mtb harboring the ―RD1‖ mutation, which deletes a portion of the ESX1 locus [190].  
Similarly, a mutant lacking espA, a distally-encoded gene that is required for 
ESX1-mediated secretion [191], also failed to elicit this response (Figure 15).  The 
phenotype of the latter mutant could be complemented by the expression of espA from a 
plasmid vector, demonstrating that the inability to stimulate Rip2 polyubiquitination was 
linked to the espA mutation.  Furthermore, M. bovis BCG, an attenuated vaccine strain 
carrying the RD1 deletion and therefore lacking ESX1 function [190], was unable to 
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stimulate Rip2 polyubiquitination.  While all of these ESX1 mutants are less virulent 
than wild type bacteria, the lack of Nod2-Rip2 stimulation did not appear to be a 
nonspecific effect of attenuation.  Two unrelated bacterial mutants that are unable to 
grow intracellularly, a biotin auxotroph (∆bioF [192]) and a small molecule efflux mutant 
(TN::rv1410c [193]), robustly stimulated this response (Figure 15).  Taken together, 
these observations indicate that a functional ESX1 secretion system is specifically 
required for Nod2 stimulation. 
 
Membrane damage allows Nod2-mediated recognition of ESX1 mutants. 
    Since the Mtb-induced Rip2 polyubiquitination required ESX1, we hypothesized 
that this system might be responsible for the release of Nod2 ligands into the cytosol, 
perhaps via the disruption of vacuolar membrane integrity.  However, it also remained 
possible that ESX1-deficient strains simply lacked a critical PAMP or other Nod2 
stimulating activity.  To distinguish between these possibilities, we investigated whether 
ESX1 function could be complemented by two exogenous membrane-disruptive activities.  
Streptolysin O (SLO) is a cholesterol-dependent toxin that introduces pores directly into 
mammalian membranes.  Pores can also be introduced by adding ATP to macrophages, 
resulting in stimulation of the P2X7 receptor and the subsequent opening of the 
hemichannel, pannexin-1 (PANX1) [194].  We observed that membrane perturbation by 
either of these two methods resulted in robust Rip2 polyubiquitination upon infection 
with espA-deficient bacteria, which were otherwise unable to induce this response (Figure 
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16A).  The involvement of PANX1 in the ATP-facilitated Rip2 ubiquitination was 
verified by the addition of a competitive inhibitory peptide of the PANX1 pore.  This 
peptide, but not a scrambled control peptide, inhibited Rip2 polyubiquitination to levels 
observed in cells infected with the ∆espA mutant (Figure 16).  While the K+ flux 
subsequent to membrane damage has been found to stimulate NLRs in some 
circumstances [176], we found that the addition of ATP or SLO alone resulted in a 
minimal response.  These data indicate that SLO, PANX1 and ESX1 are all likely to 
promote Nod2 pathway activation via a similar mechanism, by facilitating the release of a 
stimulatory mycobacterial component into the cytosol.  Since this pathway appears to be 
specific for peptidoglycan fragments, mycobacterial MDP-containing fragments were the 
most likely candidates. 
 
The cytosolic Nod2-Rip2 pathway contributes to type I IFN production upon Mtb 
infection. 
   The inability of ESX1 mutants to stimulate either the Nod2-Rip2 pathway or the 
type I IFN response [169] led us to hypothesize that the Nod2 pathway may mediate type 
I IFN expression in this system.  To investigate a potential link between Nod2 and 
IFN/, we infected Nod2- or Rip2-deficient macrophages with Mtb, and measured the 
induction of IFN and IFN mRNAs using real time PCR (qRT-PCR).  In the absence 
of Rip2, IFN induction was reproducibly reduced approximately 3-fold, whereas 
IFN induction was almost completely abrogated (Figure 17A and B). Nod2 deficiency 
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had a similar effect on both IFN and IFN transcription, consistent with its requirement 
for Rip2 polyubiquitination.  Nod1 appears to play no role in this pathway, as nod1-/- 
macrophages produced wild type levels of IFN (Figure 18).  The decreases in mRNA 
abundance observed in rip2-/- and nod2-/- cells were reflected in a similar decrease in 
protein production, as measured by ELISA (Figure 17C and D). 
In order to assess the importance of Nod2 and Rip2 to the downstream 
IFN/-dependent macrophage response, we quantified the induction of RANTES 
mRNA, which depends on type I IFN secretion and signaling via the IFN receptor 
(IFNAR1) in this infection model [139].  We found that in the absence of Rip2 or Nod2, 
Mtb infection failed to induce RANTES expression (Figure 17E). These data suggest that 
the effect of a Rip2 deficiency on downstream type I IFN responses may be even more 
pronounced than the IFN mRNA levels indicate. In contrast, TNF mRNA levels were 
unaffected by Nod2- or Rip2-deficiency (Figure 17F) indicating that other pattern 
recognition pathways remained responsive to Mtb in these cells.  
 Consistent with previous work [169], we found that infection with ESX1 mutant 
bacteria induced significantly less IFN and RANTES expression than wild type bacteria 
(Figure 19).  To test whether ESX1-mediated type I IFN expression was mediated solely 
via Rip2, we infected Rip2-deficient macrophages with ESX1 mutants and quantified 
IFN and RANTES mRNA levels. We found that in the absence of Rip2, the loss of 
ESX1 function resulted in a further decrease in IFN mRNA levels (Figure 19A), 
suggesting the presence of an additional host pathway(s) that contribute to IFN 
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induction.   However, Rip2 deletion had no effect in the absence of ESX1 (Figure 19B), 
supporting our biochemical evidence that NOD2 stimulation depends entirely on the 
ESX1-dependent delivery of stimulants into the cytosol.  
 
The N-glycolylated MDP produced by Mtb is a potent stimulator of the 
Nod2-mediated type I IFN response. 
   While our data indicated that a significant fraction of the IFN/ response could 
be attributed to the Nod2-Rip2 pathway, it has been suggested that MDP stimulation 
alone is unable to induce type I IFNs and can only augment responses triggered by other 
pathways [143].  Indeed, we also found that the N-acetylated MDP that is commonly 
used to stimulate Nod2 was a very poor inducer of IFN and RANTES expression 
(Figure 20A and B).  However, our preliminary studies investigating Rip2 
polyubiquitination indicated that Mtb was a particularly potent stimulator of this response 
[187], and therefore we reasoned that this could be due to the N-glycolylated form of 
MDP produced by Mtb.  To determine if this form of MDP was sufficient to induce type 
I IFN responses, we compared the ability of N-acetyl- and N-glycolyl-MDP to stimulate 
IFN expression. In contrast to N-acetyl MDP, treatment with the N-glycolylated form 
stimulated a robust IFN response, which was entirely dependent on Rip2 and Nod2 
(Figure 20).  In addition, at least 30-fold less N-glycolyl-MDP was necessary to 
stimulate the IFN transcription.  Thus, the Nod2/Rip2 pathway alone is sufficient to 
induce the production of the IFN response when stimulated with this potent form of 
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MDP. 
 
Induction of the host type I IFN response upon Mtb infection requires the Tbk1 
kinase and Irf5. 
Listeria monocytogenes infection induces a potent host type I IFN response 
mediated by the Tbk1 kinase and Irf3 [179,183,186,195]. To test whether Mtb infection 
triggered similar pathways, we infected Irf3-deficient and Tbk1/Tnfr1-deficient 
macrophages with Mtb and measured IFN induction. The Tnfr1 deficiency was necessary 
to suppress the embryonic lethality of Tbk1 deletion [196].  Similar to the L. 
monocytogenes model, we found that IFN induction by Mtb infection was completely 
dependent upon Tbk1, and the loss of Tnfr1 had little effect (Figure 21A).  However, in 
contrast to the complete dependence on Irf3 observed for L. monocytogenes 
[179,183,186], we found IFN expression was reduced, but not ablated when 
Irf3-deficient macrophages were infected with M. tuberculosis (Figure 21A).  This 
partial dependence on Irf3 was not changed by varying the multiplicity of infection 
(Figure 22). These data prompted us to test whether other IRFs mediate Nod2-dependent 
type I IFN responses. 
    Induction of IFN expression is dependent on the formation of the enhancesome 
which includes the NF-B, ATF-2, c-jun, Irf3 and Irf7 transcription factors [197].  Irf5 is 
a related family member that has also been shown to contribute to induction of type I IFN 
responses triggered by TLRs, and overexpression of MyD88 has been shown to synergize 
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with Irf5 to induce IFN expression [198]. Based on these studies, we tested whether 
RIP2 collaborates with IRF5 or IRF3 to stimulate IFN luciferase reporter activity. 
HEK293 cells were transfected with an IFN-luciferase reporter construct, along with 
increasing amounts of expression plasmids encoding RIP2, MyD88, IRF3 or IRF5. RIP2 
and IRF5 coexpression stimulated IFN promoter activity in a dose dependent manner 
and to a similar extent as MyD88 and IRF5 (Figure 21B).  In contrast, RIP2 and IRF3 
expression failed to induce this robust response (Figure 21C). RIP2 and IRF5 expression 
also stimulated IFN4 promoter activity as well as a reporter construct containing 
multimerized ISRE elements (data not shown). 
     To further investigate the contribution of Irf5 to the anti-bacterial type I IFN 
response, we infected macrophages from Irf5-deficient mice and control littermates with 
either Mtb or L. monocytogenes, and measured IFN expression. Consistent with the 
luciferase reporter studies, we found that Mtb-induced IFN (Figure 21D) and IFN 
(Figure 23) expression was impaired in the absence of Irf5.  In contrast, the response to 
Listeria was unaffected by the loss of Irf5 (Figure 21D and Figure 23).  While the 
related Rip1 adaptor protein regulates Irf7 activity in innate anti-viral signaling [57], we 
found that IFN induction after Mtb infection was unaffected by Irf7 deficiency (data not 
shown).  To rule out the possibility that Irf3 expression levels may also be affected in 
irf5-/- macrophages, we verified that the Irf3 protein level was unchanged in 
Irf5-deficient cells (Figure 24).  These results indicated that Mtb infection stimulates 
type I IFN expression via a pathway that depends on Nod2, Rip2, Tbk1, and Irf5.  This 
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contrasts with the pathway triggered by L. monocytogenes, which depends entirely on 
Irf3 and not Irf5.  We reasoned that this dependence on different Irf proteins might be 
explained by the preferential stimulation of a Nod2-Rip2-Irf5 pathway by mycobacterial 
peptidoglycan.  Consistent with this model, we found that the IFN induction triggered 
by N-glycolyl MDP was entirely dependent on Irf5 and independent of Irf3 (Figure 25), 
functionally linking Irf5 with the Nod2 pathway. 
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Discussion 
   Mammals first detect microbial infections via an array of PRRs that include both 
cell surface TLRs and cytosolic NLRs.  However, not all microbial interactions 
represent a pathological state, and the immune system must be able to discriminate to 
some degree between colonization by commensal organisms and dangerous infection.  
One level of discrimination is provided by the desensitization or anatomical sequestration 
of TLRs at sites of chronic stimulation, such as the gut, which presumably allows for 
tolerance to normal flora [199,200].  Bacterial pathogens can still be recognized at these 
sites via NLRs, since these systems rely on the specific ability of pathogens to translocate 
PAMPs into the host cytosol. 
 The concept that NLRs are specific for pathogenic organisms that disrupt host 
membranes is supported in a number of bacterial systems in which the loss of specific 
virulence functions abrogates NLR signaling.  For example, in resting macrophages, 
cytosolic recognition of L. monocytogenes requires the pore-forming toxin, listeriolysin O 
[178,179].  Similarly, Helicobacter pylori [119] and Legionella pneumophila [183] 
mutants lacking a functional type IV secretion system (T4SS), and Shigella flexneri [201] 
or Salmonella enterica serovar typhimurium [201] mutants lacking a functional type III 
secretion system (T3SS) fail to stimulate NLR pathways.  In each case, the virulence 
system in question is responsible for host membrane damage and the likely translocation 
of bacterial products into the cytosol where they can be recognized by NLRs and/or other 
cytosolic surveillance systems.  
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Similarly, we found that the ESX1 specialized protein secretion system of Mtb is 
required for Nod2 recognition.  While it has been suggested that type I IFN induction 
via ESX1 might represent a specific immunomodulatory virulence strategy [169], 
analogies to these other pathogens suggests that perhaps NLR recognition is simply a 
byproduct of a membrane damaging function that allows bacterial products to enter the 
cytosol.  This model is supported by our observations that other membrane perturbing 
agents, such as SLO and PANX1 can substitute for ESX1 function and allow cytosolic 
recognition.  Thus, in a number of cases it appears that NLRs can be considered as 
sentinels for pathogens that rely on membrane damage as a pathogenic strategy.   
   Based on their common role in protein secretion and in facilitating cytosolic 
recognition, it is tempting to speculate that ESX1 and Gram-negative T3SS and T4SS 
function analogously to deliver effector proteins into the host cytosol.  Despite these 
similarities, the role played by ESX1 during infection remains unclear, since no 
translocated effectors have been identified to date.  In both Mtb and M. marinum, a 
related pathogen of ectotherms, ESX1 has been implicated in host membrane disruption 
and one of the major substrates of this system, EsxA, has been proposed to possess a 
membrane-lytic activity [181,188].  This single activity could be sufficient to account 
for the delivery of MDP and other PAMPs to the cytosol.  It remains to be determined 
whether perturbing host membranes is the only role played by ESX1 during infection, or 
if this system also serves additional functions analogous to the specialized secretion 
systems of other pathogens. 
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 A major consequence of the cytosolic recognition of Mtb is the induction of type I 
IFN.  While the importance of this response in viral defense is clear and virtually 
universal, its role in antibacterial immunity appears to vary.  Mice deficient in the type I 
IFN receptor, Ifnar1, are significantly more susceptible to several Gram-positive and 
-negative bacterial infections [202,203,204,205], indicating that IFN/ are important for 
immunity to many bacteria.  However, Ifnar1 mutation has the opposite effect on the 
outcome of L. monocytogenes infection [206], suggesting that IFN/ can also 
exacerbate disease.  The role played by IFN/ in Mtb infection remains somewhat 
uncertain.  The induction of several immunologically important genes, including NOS2, 
depend on IFN/, suggesting a protective role.  Initial studies of mouse and human 
infections appeared to support this view [207,208].  However, like the L. monocytogenes 
system, mutation of the IFN/ receptor has in most cases been associated with 
decreased bacterial burden in mouse models of tuberculosis [169,208,209,210,211].  
IFN/ may fail to protect against disease because Mtb inhibits the response to these 
cytokines in infected macrophages [212].  Despite these differences however, some 
important themes emerge from these studies.  Most importantly, the effect of IFN/ is 
most apparent after the onset of adaptive immunity and not before, which we will discuss 
in detail in chapter IV.  
    A variety of bacterial pathogens trigger the type I IFN response, and a paradigm 
has begun to emerge regarding the induction of this response by bacteria.  The current 
model suggests that bacterial DNA translocated into the host cytosol is the major eliciting 
84 
 
 
 
agent. Other PAMPs, such as MDP, can provide a synergistic IFN-inducing stimulus, but 
have not appeared to be sufficient for induction of IFN in the absence of other triggers 
[143].  In contrast, our data support a model whereby Nod2 stimulation by Mtb infection 
induces the polyubiquitination of Rip2, which acts via the Tbk1 kinase to stimulate the 
activity of Irf5 and induce transcription of IFN/.  The detailed discussion of this 
difference will be presented in chapter IV. Furthermore, we found that unlike the 
N-acetylated MDP found in many bacteria, stimulation with the N-glycolylated MDP 
derivative found in mycobacteria was sufficient to stimulate the IFN response in the 
absence of other stimuli.    
   A significant component of IFN induction remains intact upon Mtb infection of 
Rip2-deficient macrophages (Figures 17 and 19), indicating that additional pathways are 
also involved.  Since virtually all IFN expression is ESX1-dependent, it appears that 
the residual induction observed in rip2-/- macrophages also depends on cytosolic 
recognition pathways.  These pathways could certainly include a DNA sensor that acts 
via Irf3, as proposed for other infections, since Irf3 deficiency had a moderate effect on 
IFN expression in our experiments (Figure 21A and 22).  Thus, our data do not imply 
that Mtb is stimulating IFN/ in a fundamentally different manner from other bacteria.  
Instead, it is likely that bacterial pathogens stimulate the IFN response via multiple, 
partially redundant pathways, and that the relative importance of each is determined by 
the unique biology of the infection. In the case of Mtb, we speculate that the 
N-glycolylation of its peptidoglycan, and perhaps a paucity of other stimulants such as 
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DNA, favor recognition via Nod2.  It is also possible that the balance of these pathways 
might be affected by the activation state of the macrophage.  When resting macrophages 
are infected with L. monocytogenes, the IFN response requires LLO and is completely 
Irf3 dependent.  In contrast, IFNstimulated cells are able to deliver this bacterium to 
the lysosome, where the cell wall is degraded to produce abundant peptidoglycan 
fragments.  In this situation, a significant component of the IFN induction depends on 
Nod2 and not Irf3 [213].  While Irf5 was not investigated in this study, it is possible that 
this represents another situation in which robust Nod2 signaling promotes a Nod2- and 
Irf5- dependent type I IFN response. 
    While we found that loss of Nod2-Rip2 signaling only partially reduces the 
induction of IFN, Rip2 deletion completely abrogated IFN and RANTES expression.  
These results can be explained by the structure of the IFN regulatory circuit.  Initially, 
only IFN is expressed, and subsequently IFN and other interferon regulated genes 
(IRGs), such as RANTES, are induced via an Ifnar1 and Irf7-dependent 
autocrine/paracrine signaling pathway [214].  Thus, it appears that the decrease in IFN 
expression that we observe is sufficient to severely impair downstream IRG induction, at 
least in this cell culture model.   
    Multiple steps of this pathway are likely to depend on stable ubiquitin 
modifications.  Not only did we observe that Rip2 is polyubiquitinated upon infection, 
but we also found that a Rip2 point mutant that cannot be stably ubiquitin modified is 
unable to mediate IFN/ induction in response to Mtb infection (Figure 26). 
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Collectively, these data suggest that polyubiquitinated Rip2 is required for Mtb-induced 
type I IFN expression via Irf5.  Interestingly, MyD88-dependent activation of Irf5 
involves formation of a tertiary complex that includes the E3 ubiquitin ligase, Traf6 
[164,215]. This E3 ubiquitin ligase associates with Rip2 upon MDP stimulation, raising 
the possibility that a Rip2-Traf6-Irf5 complex might exist and that the activity of Irf5 
might also be regulated by ubiquitin. 
   The specificity of the innate immune system has been shaped by the very powerful 
natural selection imposed by microbial pathogens.  Our work suggests that upon 
infection with Mtb, a particularly potent form of MDP is translocated into the host cell 
cytosol where it triggers a novel signaling pathway leading to the robust induction of the 
type I IFN response.  It is unlikely to be coincidental that the active component of our 
most potent adjuvant, complete Freund's adjuvant (CFA), consists of mycobacterial cell 
fragments.  The specific pathway described in this work might play a major role in this 
adjuvant's effectiveness, since IFN/ production is required for CFA to promote 
antigen-specific immune responses (55).  Thus, while PAMPs are often regarded as 
invariant microbial components, it is clear that functionally important pathogen-specific 
differences exist in the composition of these molecules, and that the immune system can 
differentiate these subtly distinct structures. 
Given the potent adjuvant activity of mycobacterial components, it is somewhat 
surprising that the attenuated vaccine strain M. bovis BCG, which produces the same 
PAMPs present in CFA, provides poor protection against pulmonary TB in adults 
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[216,217].  The lack of ESX1 function in this strain appears to be at least partially 
responsible, since the reconstitution of ESX1 improves the efficacy of this vaccine 
[218,219].  While this effect has previously been attributed to either the secretion of 
additional antigens or altered antigen presentation, it is also possible that ESX1 activity 
improves immunity by delivering crucial PAMPs into the cytosol where they are 
optimally recognized.  Understanding both the details of PAMP trafficking, as well as 
the precise specificity of PAMP recognition, promises to aid in both the design of 
improved adjuvants and more effective tuberculosis vaccines. 
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Materials and Methods 
Mice 
C57BL/6 mice ages 8-12 weeks were obtained from the Jackson Laboratory.  
rip2-/- mice were a kind gift from Dr. Vishva M. Dixit (Genentech, Inc. South San 
Francisco, CA). nod2-/- mice were provided by Dr. Peter J. Murray (Department of 
Infectious Diseases, St. Jude Children’s Research Hospital, Memphis, TN). Nod1 and 
Nod2 double knockout macrophages were isolated from nod1-/-nod2-/- mice provided by 
Dr. Gabriel Nunez (University of Michigan Medical School, Ann Arbor, MI). irf3-/-, 
irf5-/-, tbk1+/+tnfr1-/- and tbk1-/-tnfr1-/- mice and their littermate controls were 
provided by Dr. Kate A. Fitzgerald (University of Massachusetts Medical School, 
Worcester, MA). Mice were housed under specific pathogen-free conditions, and in 
accordance with the University of Massachusetts Medical School, IACUC guidelines.  
Bacteria  
The WT strain of M. tuberculosis used in these studies was the H37Rv strain. All 
the mutants were derived from the wild type strain. ∆ESX-1 was obtained from D. 
Sherman (SBRI, Seattle.WA) [190]. ∆BioF, ∆Rv3616 and ∆Rv3616-complemented 
strains have been described previously [191,192]. TN::Rv1410 contains a himar-1 
transposon inserted at nucleotide #688 of the 1557bp predicted open reading frame [220]. 
All strains were cultured in 7H9 medium containing 0.05% Tween 80  and OADC 
enrichment (Becton Dickinson).  Pre-titered stocks of Listeria monocytogenes  strain 
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10403 stored at -80oC (kindly provided by Victor Boyartchuk) were recovered for 1hr at 
37oC in 9ml of Tryptic Soy Broth (BD Biosciences). Bacteria were then washed and 
resuspended in PBS prior to infection. 
 
Antibodies and Reagents   
Anti-Rip2 (Rabbit) and anti-ubiquitin (Mouse) antibodies were obtained from 
Santa Cruz Biotechnology. Anti-Irf3 antibody was obtained from Zymed. Anti-Irf5 
antibody was obtained from Abcam. Anti--actin antibody was obtained from Sigma. 
MDP was obtained from InvivoGen. Mouse TNF- was obtained from Sigma. LPS 
derived from Escherichia coli strain 0111.B4 was purchased from Sigma, dissolved, 
treated with deoxycholate, and re-extracted with phenol/chloroform as described in [175]. 
The pannexin-1 mimetic blocking peptides panx1 (WRQAAFVDSY) and the scrambled 
peptide control were synthesized by GeneScript Corporation (Piscataway, NJ) and have 
been described previously [221].  Streptolysin O (SLO) a pore forming protein derived 
from Streptococcus and Adenosine 5’- triphosphate (ATP) were purchased from Sigma.  
N-glycolyl muramyl dipeptide (N-glycolyl MDP) was custom synthesized (Carbohydrate 
Synthesis, Oxford, UK) and shown to be more than 95% pure by NMR spectrometry. 
This preparation was found to be free of endotoxin contamination using the Limulus 
amebocyte lysate assay (Pyrotell, Cape Cod Inc., MA). 
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Macrophage infections 
Bone marrow from 8- to 10-week-old mice was harvested from femurs and 
differentiated into macrophages for 7 days in Dulbecco's modified Eagle medium 
(DMEM) supplemented with 10% L929-cell conditioned medium, 10% fetal bovine 
serum, 2 mM L-glutamine and 1 mM sodium pyruvate. After 7 days in culture, bone 
marrow derived macrophages (BMDMs) were washed with phosphate-buffered saline 
(PBS) and seeded into tissue culture plates for infection. RAW 264.7 macrophage cell 
line was cultured in Dulbecco's modified Eagle medium (DMEM) supplemented with 
10%  fetal bovine serum. All Mtb strains were cultivated in 7H9 broth, grown to 
exponential phase and washed thoroughly in DMEM media prior to infection. Bacterial 
clumps were removed by passing the washed suspension through a 5
For the peptide blocking studies, the cells were pre incubated with the desired peptides 
for 30 minutes followed by ATP or SLO for additional 15 minutes. Macrophages were 
infected at an MOI of 10 for 1 or 2 hours after which filtered cell lysates were 
immunoprecipitated with anti-Rip2 antibody (Santa Cruz). Heat inactivation was 
achieved by incubating the bacteria at 80oC for 30 minutes.  Immortalized macrophage 
cell lines from wild type, rip2-/-, nod2-/- and nod1-/-nod2-/- mice were established by 
infecting bone marrow cells with a v-raf/mil and v-myc retrovirus in the presence of 
GM-CSF and polybrene [222,223]. These rip2-/-, nod2-/- and nod1-/-nod2-/- macrophage 
cell lines express CD11b and Gr-1 and are capable of phagocytosing antibody coated 
beads.  To determine the effect of cytochalasin D on the phagocytic function of the 
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macrophages, we used the Vybrant phagocytosis assay kit to quantify the uptake of 
fluorescent E. coli.  This assay was performed according to the protocol provided by the 
manufacturer. 
 
Immunoprecipitation and Western Blot Analysis  
For the immunoprecipitation and ubiquitination assays, cell lysates were prepared 
in radioimmune precipitation assay (RIPA) buffer (150mM NaCl, 50mM Tris-HCl (pH 
7.5), 1% NP40, 0.25% deoxycholate, 0.1% SDS, 1mM EDTA), supplemented with 
protease inhibitors (Roche Applied Science) and 5mM N-Ethylmaleimide (Sigma), 
immunoprecipitated with anti-Rip2 antibody (Santa Cruz).  Polyubiquitinated Rip2 
proteins were detected by immunoblotting with an anti-ubiquitin antibody (Santa Cruz). 
Total immunoprecipitated Rip2 protein was measured by immunoblotting with anti-Rip2 
antibodies (Santa Cruz). 
 
Luciferase reporter assay  
HEK293 cells (2 x104) seeded in 96 well plates were transfected with 40ng of the 
IFN luciferase reporter plasmid together with a total of 100 ng of various expression 
plasmids using GeneJuice (Novagen).  The total amounts of transfected DNA were kept 
constant in all experiments by adjustment with empty vector.  Luciferase activity was 
measured 24h later using Dual Luciferase reporter assay system (Promega).  The Renilla 
luciferase gene (40ng) was co-transfected and used as an internal control plasmid. IFN 
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luciferase reporter activity was normalized to Renilla luciferase reporter activity. Each 
experiment was repeated three times. Data are expressed as mean ± s.d. of three 
replicates. 
Real time quantitative PCR analysis  
To measure IFN/ mRNA levels upon MDP treatment or Mtb infection, total 
RNA was extracted from the macrophage cultures using Trizol reagent (Invitrogen) 
according to the manufacturer’s directions.  cDNA was prepared from 2 µg of total 
RNA and quantitative real-time PCR performed using SYBR green as a label with the 
following primers: mIFN-F, 5'-AAGATGCCCTGCTGGCTG; mIFN-R, 
5'-TTCTGCTCTGACCACCTCCC; mIFN-F, 5’-CGTCTCCTGGATGAACTCCAC; 
mIFN-R, TGAGGACATCTCCCACGTCA; -actin-F, 
5'-CGAGGCCCAGAGCAAGAGAG -actin-R, 5'-CGGTTGGCCTTAGGGTTCAG; 
mTNF-F, CAGTTCTATGGCCCAGACCCT; 
mTNF-R,  CGGACTCCGCAAAGTCTAAG; mRANTES-F, 
GCCCACGTCAAGGAGTATTTCTA; mRANTES-R, ACACACTTGGCGGTTCCTTC. 
Results shown are representative of more than three separate infection experiments, with 
each PCR performed in triplicate. All values reported were in the linear range of the 
experiment and were normalized to -actin values. Standard curves were generated by 
linear dilution of a cDNA sample generated from poly I:C-stimulated macrophages.  
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ELISA 
IFN protein in cell culture supernatants was performed using a custom ELISA as 
described previously [224]. IFN concentrations were calculated using a recombinant 
IFN (HyCult, Biotechnology, Uden, Netherlands) standard curve performed in 
quadruplicate using linear regression, and expressed in units per ml. IFN protein in cell 
culture supernatants was measured similarly using a custom ELISA as described in [225].  
 
94 
 
 
 
Figures and Legends 
 
Figure 14.  Live, intracellular Mycobacterium tuberculosis stimulates Rip2 
polyubiquitination.  A. Live, but not heat killed Mtb (Rv) stimulates Rip2 
polyubiquitination. Bone marrow-derived macrophages (BMDM) were infected with 
live wt (Rv) or heat killed (HK-Rv) strains of M. tuberculosis (strain H37Rv) for the 
indicated times.  Polyubiquitinated Rip2 protein was detected by immunoprecipitating 
the cell lysates with an anti-Rip2 antibody followed by immunoblotting with an 
anti-ubiquitin antibody.  Immunoprecipitates were also immunoblotted with a Rip2 
antibody (lower panel) to insure that equal amounts of protein were immunoprecipitated. 
B. The cell permeable mycotoxin Cytochalasin D inhibits Rip2 polyubiquitination 
upon Mtb infection.  The murine RAW 264.7 macrophage cell line was pretreated with 
Cytochalasin D for 1 hour at the indicated concentrations before being infected with wt 
Mtb H37Rv (Rv) for 1 hour. Polyubiquitinated Rip2 proteins were detected as described 
above.  1µM cytD caused a 95% decrease in phagocytosis, as described in the Materials 
and Methods section. C. Mycobacterium tuberculosis-induced Rip2 polyubiquitination 
is Nod2-dependent.  Wildtype, nod1/nod2-/- or nod2-/- bone marrow-derived 
macrophages cell lines were generated (see material and methods) and either left 
uninfected (-) or infected with live wt M. tuberculosis (H37Rv) for the indicated times. 
Polyubiquitinated Rip2 proteins were detected as described above.   
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Figure 15.   Rip2 polyubiquitination upon Mtb infection requires ESX-1.  The 
murine RAW  264.7 macrophage cell line was left uninfected (UI), infected with Mtb 
H37Rv (Rv), with ESX1 mutant strains of Mtb (∆ESX1, ∆espA), with a complemented 
∆espA-C strain, with the attenuated vaccine strain Mycobacterium bovis BCG or with the 
unrelated attenuated mutants Tn::rv1410 and ∆bioF. Cell lysates were 
immunoprecipitated with an anti-Rip2 antibody followed by immunoblotting with an 
anti-ubiquitin antibody. Immunoprecipitates were also immunoblotted with a Rip2 
antibody to insure that equal amounts of protein were immunoprecipitated. 
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Figure 16. Membrane damage allows Nod2-mediated recognition of ESX1 mutants. 
A. The mouse RAW 264.7 macrophage cell line was left untreated or pre-treated with 
either blocking (P) or control (scramble) peptide (S) for 30 minutes followed by 
H37Rv (Rv), ESX1 mutant strains of Mtb (∆espA) or with a complemented ∆espA-C 
strain for 1 hour. Cell lysates were immunoprecipitated with an anti-Rip2 antibody 
followed by immunoblotting with an anti-ubiquitin antibody. Immunoprecipitates were 
immunoblotted with a Rip2 antibody to insure that equal amounts of protein were 
immunoprecipitated. B. Relative abundance of Rip2 polyubiquitination in each 
sample as determined by densitometry of the results in panel A. All values were 
calculated relative to the uninfected sample (UI). 
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Figure 17.  Type I Interferon production upon Mtb infection is reduced in Rip2- 
and Nod2-deficient macrophages.   A, B, E, and F. BMDM derived from wt, rip2-/- 
and nod2-/- mice were left uninfected (UI) or infected with Mtb (MOI 10) for 4h. RNA 
was harvested, and IFN, IFN, RANTES and TNF mRNA levels were quantified 
using real time PCR. Gene expression is reported as copy number per 1,000 copies of 
-actin. Samples were assayed in triplicate; error bars represent the standard deviation. 
The experiment shown is representative of at least three. C and D. BMDM derived from 
wt, rip2-/- and nod2-/- mice were infected with Mtb (MOI 10) for 18h, the amount of 
IFN and IFN released in the supernatant was quantified by ELISA. Samples were 
assayed in triplicate; error bars represent the standard deviation. N.D. represents not 
detected, the actual value is below zero in standard curve. 
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Figure 18.  Type I Interferon production upon Mtb infection is reduced in Rip2- 
and Nod2-deficient macrophages but not in Nod1-deficient macrophages.   BMDM 
derived from wt, nod1-/-, rip2-/- and nod2-/- mice were left uninfected (UI) or infected 
with Mtb (MOI 10) for 4h. RNA was harvested, and IFN mRNA levels were quantified 
using real time PCR. Gene expression is reported as copy number per 1,000 copies of 
-actin. Samples were assayed in triplicate; error bars represent the standard deviation. 
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Figure 19.   Multiple cytosolic pathways lead to IFN induction.  A. BMDM 
derived from wt and rip2-/- mice were left uninfected (UI) or infected with ESX1 wt Mtb 
H37Rv (Rv) or with an ESX1 mutant (∆ESX1) at an MOI of 10 for 4h. RNA was 
harvested, and IFN mRNA levels were quantified using real time PCR. Gene expression 
of IFN is reported as copy number per 1,000 copies of -actin. Samples were assayed in 
triplicate; error bars represent the standard deviation. The experiment shown is 
representative of at least three.   B. BMDM derived from wt and rip2-/- mice were 
infected with ESX1 wt Mtb H37Rv (Rv) or with an ESX1 mutant (∆ESX1) at an MOI of 
10 for 4h. RNA was harvested, and RANTES mRNA levels were quantified using real 
time PCR. Gene expression of RANTES is reported as copy number per 1,000 copies of 
-actin. Samples were assayed in triplicate; error bars represent the standard deviation. 
The experiment shown is representative of at least three. 
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Figure 20.  Nod2 stimulation is sufficient for type I IFN induction. A and B. 
N-Glycolyl MDP is more potent than the more common N-Acetylated derivative.   
The macrophage cell line RAW 264.7 was treated with the indicated concentrations of 
N-Glycolyl-MDP or N-Acetyl-MDP for 4h. RNA was harvested, and IFN and RANTES 
mRNA levels were quantified using real time PCR. Gene expression of IFN (A) and 
RANTES (B) were normalized to actin then mormalized to untreated contral for fold 
induction. Samples were assayed in triplicate; error bars represent the standard deviation. 
The experiment shown is representative of at least three.  C and D.  The 
N-Glycolyl-MDP-induced type I IFN response is Rip2- and Nod2- dependent. Wt, 
rip2-/- and nod2-/- transformed macrophage stable cell lines were treated for 4 hours with 
increasing concentrations of N-Glycolyl-MDP. RNA was harvested, and IFN and 
RANTES mRNA levels were quantified using real time PCR. Gene expression of IFN 
(C) and RANTES (D) were normalized to actin then normalized to untreated control to 
establish fold induction. Samples were assayed in triplicate; error bars represent the 
standard deviation. The experiment shown is representative of at least three. 
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Figure 21.   Mtb-induced type I IFN response is Tbk1-dependent and mediated 
through both Irf3 and Irf5.  A. M. tuberculosis-induced type I IFN response is 
Tbk1-dependent and only partially mediated through Irf3. BMDM derived from wt, 
irf3-/- and tbk1-/-tnfr1-/- mice and littermate controls were infected with ESX1 wt Mtb 
H37Rv (Rv) at an MOI of 10 for 4h. RNA was harvested, and IFN mRNA level was 
quantified using real time PCR. Gene expression is reported as copy number per 1,000 
copies of -actin. Samples were assayed in triplicate; error bars represent the standard 
deviation. The experiment shown is representative of at least three.  B. Co-expression 
of RIP2 and IRF5 stimulate IFN luciferase reporter activity. HEK293T cells were 
co-transfected with IFN-luciferase reporter plasmid (40ng) together with the indicated 
concentrations of MyD88, IRF5 and RIP2 expression plasmids.  Luciferase activity was 
measured 24h later using Dual Luciferase reporter assay system (Promega).  Renilla 
luciferase gene (40ng) was co-transfected and used as an internal control.  Each 
experiment was repeated three times. Data are expressed as mean ± s.d. of three 
replicates. C. Co-expression of RIP2 and IRF3 does not stimulate IFN luciferase 
reporter activity. HEK293T cells were co-transfected with IFN-luciferase reporter 
plasmid (40ng) together with the indicated concentrations of IRF5, IRF3 and RIP2 
expression plasmids.  Luciferase activity was measured 24h later using Dual Luciferase 
reporter assay system (Promega).  Renilla luciferase gene (40ng) was co-transfected and 
used as an internal control.  Each experiment was repeated three times. Data are 
expressed as mean ± s.d. of three replicates. D. Irf5 is required for an optimal type I 
IFN response upon Mtb infection. BMDM from irf5-/- or control littermates were 
infected with ESX1 wt Mtb H37Rv (Rv) at an MOI of 10, or with Listeria 
monocytogenes (Lm) strain 10403S (MOI 10) for 4 hours. RNA was harvested, and IFN 
mRNA level was quantified by real time-PCR. Gene expression of IFN is reported as 
copy number per 1,000 copies of -actin. Samples were assayed in triplicate; error bars 
represent standard deviation. Data shown is representative of at least three independent 
experiments. 
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Figure 22.   Mtb-induced type I IFN response is only partially mediated through 
Irf3. BMDM derived from wt and irf3-/- mice were infected with ESX1 wt Mtb H37Rv 
(Rv) at an MOI of 1, 3 and 10 for 4h. RNA was harvested, and IFN mRNA level was 
quantified using real time PCR. Gene expression is reported as copy number per 10,000 
copies of -actin. Samples were assayed in triplicate; error bars represent the standard 
deviation.  
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Figure 23. Irf5 is required for an optimal type I IFN response upon Mtb infection. 
BMDM from irf5-/- mice or control littermates were left uninfected (UI) or infected with 
ESX1 wt Mtb H37Rv (Rv) at an MOI of 10, or with Listeria monocytogenes (Lm) strain 
10403S (MOI 10) for 4 hours. RNA was harvested, and IFN mRNA level was 
quantified by real time-PCR. Gene expression of IFN is reported as copy number per 
1,000 copies of -actin. Samples were assayed in triplicate; error bars represent standard 
deviation. 
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Figure 24. Irf3 and Irf5 expression levels in irf3-/- and irf5-/- macrophages. BMDM 
derived from irf3-/- and irf5-/- mice and their littermate controls were lysed in RIPA 
buffer and the Irf3 and Irf5 expression levels was determined by immunoblotting of anti  
Irf3 (Zymed) and Irf5 (Abcam) antibodies. Protein loading level was measured by -actin 
antibody (Sigma). 
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Figure 25. The N-Glycolyl-MDP-induced type I IFN response is Irf5-dependent and 
Irf3 independent. BMDM derived from irf3-/- and irf5-/- mice and their littermate 
controls were left untreated or treated for 6 hours with 10g/ml of N-Glycolyl-MDP. 
RNA was harvested, and IFN mRNA levels were quantified using real time PCR. Gene 
expression of IFN is reported as copy number per 1,000 copies of -actin. Samples were 
assayed in triplicate; error bars represent the standard deviation.  
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Figure 26. Rip2 polyubiquitination may be required for the Mtb-induced Type I IFN 
response. The rip2-/- transformed macrophage cell line was infected with the retroviral 
vector alone or with retroviruses expressing wild type Rip2 or a form of Rip2 (K209R) 
that cannot be ubiquitin modified [104]. The rip2-/- reconstituted macrophage cell lines 
were then infected with Mtb (MOI 10) for 4h. RNA was harvested, and IFN mRNA 
levels were quantified using real time PCR. Gene expression is reported as copy number 
per 1,000 copies of -actin. Samples were assayed in triplicate; error bars represent the 
standard deviation. Rip2 expression levels in each of the rip2-/- reconstituted macrophage 
cell lines were examined by immunoblotting to insure that equivalent expression levels of 
Rip2 were achieved. 
 
 
 
109 
 
 
 
Figure 27. M. tuberculosis infection fails to elicit type I IFN production in the 
absence of IRF3 and IRF5.   BMDM derived from Irf3+/+Irf5+/+, Irf3-/-Irf5-/-, 
Tbk1+/+Tnfr1-/- and Tbk1-/-Tnfr1-/- mice were left uninfected (UI) or infected with 
ESX1 wt Mtb H37Rv (Rv) at an MOI of 10 for 4h. RNA was harvested, and IFN 
mRNA level was quantified using real time PCR. Gene expression is reported as copy 
number per 1,000 copies of -actin. Samples were assayed in triplicate; error bars 
represent the standard deviation. The experiment shown is representative of at least three. 
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First discovered as the second member of the RIP protein family, Rip2 has critical 
functions in NF-B activation and cell death regulation. The original mouse knockout 
study implicated Rip2 in signaling from multiple TLRs including TLR 2, 3 and 4, the T 
cell receptor, as well as the cytosolic Nod1/2 pathways [64,102]. Our work in this thesis, 
as well as the work from other groups, demonstrates that Rip2 participates in the 
Nod-mediated innate immune response to pathogens, but does not mediate TLR or TCR 
signaling ([103], Figure 6). However, how Rip2 mediates these innate immune responses 
remains largely unclear. 
The work described in this thesis demonstrates a crucial role for Rip2 in Nod2 
mediated NF-B activation and induction of the Type I interferon response.  We provide 
evidence that the Nod2 pathway is ubiquitin-regulated and that the K63-linked ubiquitin 
modification of Rip2 is required for cytosolic recognition of bacterial products.  IKK 
activation in the Nod2 pathway is mediated by a complex consisting of Rip2, 
Ubc13/Uerla, Traf6 and Tak1; whereas, the Rip2-mediated Type I interferon response 
dependents on TBK1, and involves the stable ubiquitin modification of Rip2. We provide 
additional evidence for the expanding role of ubiquitin in the regulation of innate immune 
pathways. Polyubiquitination is not only important for terminating immune responses 
through the destruction of immune regulatory proteins, but also for initiating and 
amplifying immune responses, as exemplified by the role of K63-linked 
polyubiquitination in the activation of protein kinases and immune signaling in the 
NF-B and IRF pathway [14,226]. 
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      However, the precise mechanisms whereby polyubiquitinated Rip2 mediates Tak1 
or IKK activation remain unclear. Our data suggests that Tak1 and IKK are activated by 
K63 specific ubiquitin chain attached in Rip2 protein in the Nod2-Rip2 pathway, 
consistent with a well established model that preferential binding to K63 polyubiquitin 
chains leads to the activation of Tak1, perhaps by triggering Tak1 autophosphorylation 
[14,226]. However, the role of K63-linked polyubiquitination chains in Tak1/IKK 
activation has been challenged recently. Several different groups show that the ubiquitin 
ligase complex LUBAC (linear ubiquitin chain assembly complex) composed of two 
RING domain proteins, RNF31 (also known as HOIP) and RBCK1 (also known as 
HOIL-1L); along with UbcH5C catalyze the synthesis of linear ubiquitin chains on the 
substrate. LUBAC has been shown to bind to NEMO in the IKK complex after TNF 
treatment and to catalyze the addition of linear ubiquitin chains onto lysine 285 and/or 
309 of NEMO. Importantly, the involvement of LUBAC in NF-B activation was 
confirmed in genetically modified mice lacking the regulatory subunit HOIL-1L. TNF 
induced NF-B activation was impaired in primary hepatocytes and MEFs from 
HOIL-1L null mice [19]. Additional support for the linear ubiquitination model of IKK 
activation comes from work demonstrating that the UBAN (ubiquitin binding in ABIN 
and NEMO) motif of NEMO selectively binds linear ubiquitin chains, but not K63 
ubiquitin chains. Binding of these linear ubiquitin chains to NEMO is hypothesized to 
trigger a conformational change in the IKK complex, resulting in IKK activation [20]. 
These studies suggest that in addition to K63-linked ubiquitin chains, linear ubiquitin 
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chains may also have specific signaling functions.  
      In contrast, work by Xia et al indicated that the RNF31-RBCK1 synthesized 
linear polyubiquitin chains failed to activate IKK or Tak1, and that only K63-linked 
polyubiquitin chains result in IKK and Tak1 activation [21]. Moreover, RNF31 or 
RBCK1 silencing in human cells had no effect on TNF induced IKK activation, and some 
studies found that under physiological conditions, NEMO preferentially binds K63 linked 
ubiquitin chains rather than linear ubiquitin chains [227]. Using an ubiquitin replacement 
strategy in human cells, only K63 linked ubiquitin chains, but not linear ubiquitin chains, 
appear capable of activating the IKK in the TNF pathway [227]. Crystal structure studies 
support a K63 polyubiquitination activation model, as they show that the Tab2 NZF 
domain specifically binds K63-linked di- and tri-ubiquitin [228]. Collectively, these 
published data support the K63 ubiquitination model of IKK activation.  
In our studies, we demonstrated that the Rip2 protein is K63 ubiquitin modified 
in MDP treated cells (Figure 7). However, the contribution of the LUBAC system to Rip2 
and NEMO ubiquitination has not been tested. The recent work done by Xu et al 
indicates that Rip1 was not modified by linear ubiquitin chains [227]. Using siRNA to 
knock down the expression of HOIP-1L, Xu et al failed to observe a change in Rip1 
polyubiquitination. These data are consistent with the previous finding that the 
HOIP-HOIL-1L E3 complex does not ubiquitinate Rip1 in vitro [19]. However, it 
remains to be tested whether the HOIP-HOIL-1L E3 complex contributes to Nod 
-mediated NF-B or IRF5 activation and Rip2/NEMO ubiquitination.  
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Another unanswered question in Nod2 mediated signaling, is the precise role of 
the E3 ligase Traf6. We and others found that Traf6 contributes to Nod2 induced NF-B 
activation, and that MDP treatment stimulates formation of a complex consisting of Traf6, 
Rip2 and Tak1 (Figure 9 and 10, [113,172]). In Hek293 cells, Traf6 silencing impairs 
Rip2 polyubiquitination upon MDP treatment. But currently there is no evidence that 
Traf6 is the direct E3 ligase for Rip2. Additionally, the effect of Traf6 on Rip2 
polyubiquitination has not been examined in vivo or in immune related cell types.  
Two published studies have implicated other E3 ligases including cIAP1/cIAP2 
and ITCH in Rip2 polyubiquitination [229,230]. It is possible that Rip2 may have 
multiple E3 ligases in the Nod pathway potentially for activation of different signaling 
pathways. Indeed, the E3 ligase ITCH was proposed to modify Rip2 and promote p38 
MAPK and JNK activation, and to inhibit NF-B activation [230]. It is also possible that 
multiple E3s work together to achieve optimal ligase activity, which is the case for the 
Rip1 protein modification. Traf6 and the IAP family protein XIAP function 
collaboratively in the TGF pathway [231,232]. Thus, Traf6, cIAP1/cIAP2 and ITCH 
may all contribute to Nod pathway regulation. 
       Similarly, multiple E3 ligases have been shown to regulate Rip1 
polyubiquitination in the TNF and TLR pathways. The kelliher lab, together with Vishva 
Dixit and colleagues, demonstrated that TNF induced Rip1 polyubiquitination is impaired 
in Traf2/5 deficient MEFs and in Traf2 silenced Hek293 cells [34,36]. However, several 
groups have since reported that cIAP1/2 is the physiological E3 ligase that promotes Rip1 
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ubiquitination [38,233,234].  Traf2 does not appear to be directly involved in the 
ubiquitin modification of Rip1, but may be required for the stable recruitment of cIAP1/2 
to the TNFR1 complex. In this case, Traf2 mainly serves as a critical adapter protein 
recruiting cIAPs to Rip1 to promote Rip1 polyubiquitination. Recent structural studies 
have provided evidence that the ring domain of Traf2 lacks the interacting interfaces 
required for interaction with Ubc13 or UbcH5 yet retains the ability to bind cIAPs and 
Rip1[235]. Thus, Traf2 and Traf6 may function as scaffold proteins to bring cIAPs to Rip 
substrates.   
       In addition to Ubc13, another E2 enzyme Ubc5HA has been shown to promote 
K63-specific ubiquitination [227,236]. TNF-induced IKK activation requires Ubc5HA, 
which functions with the E3 cIAP1 to catalyze the polyubiquitination of Rip1 [227]. 
Ubc13, previously thought to be required for Rip1 polyubiquitination, does not appear to 
be required for NF-B activation in TNF pathway [227]. Although we did not address the 
contribution of Ubc5HA in our Nod2-Rip2 studies, it is possible that Ubc5HA could also 
contribute to Rip2 polyubiquitination and NF-B activation in the Nod pathway.  
      Although our initial studies revealed that the Nod2 pathway is ubiquitin regulated, 
whether this modification occurs in vivo under conditions of pathogen infection was 
unclear. Our studies using the bacterial pathogen Mycobacterium tuberculosis (Mtb) 
demonstrated that Rip2 is ubiquitin modified in Mtb infected cells and that Rip2 
polyubiquitination is required for the host type I interferon response to Mtb. We showed 
that Mtb infection of macrophages triggers Rip2 polyubiquitination in a TLR and MyD88 
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independent manner (Figure 11 and 14), and that this stimulation is due to the 
ESX1-dependent entry of bacterial products into the cytosol where they are recognized 
by Nod2, implicating MDP as the relevant PAMP (Figure 15 and 16).  Unexpectedly, 
Mtb infection stimulates IFN/ production that is dependent on a novel pathway 
consisting of Nod2, Rip2, TBK1, and IRF5 (Figure 17 and 21). This work is the first to 
implicate NLRs in IRF activation and to suggest a role for Irf5 in anti-bacterial innate 
immune responses. Thus, the mammalian Nod2 pathway appears to be remarkably 
sensitive to mycobacterial MDP and responds to infection by triggering the production of 
type I interferon, which is responsible for a significant component of the transcriptional 
response to Mtb infection.  
      Infection with a variety of bacterial pathogens induces a type I IFN response, yet 
how this pathway is activated remains unknown. One current model suggests that 
bacterial DNA that translocates into the host cytosol is the major eliciting agent.  This 
model is based largely on the observations that infection with L. monocytogenes or L. 
pneumophilla, or transfection of DNA into the cytosol induces a IFN response that is 
TBK1- and IRF3-dependent [183]. Our results showed that both IRF3 and the related 
IRF5 transcription factor, previously shown to be activated by the MyD88-dependent 
TLR7 and TLR9 pathways [237], contribute to IFN expression in Mtb infected cells 
(Figure 21 and 23). We provide genetic evidence that the Nod2-, Rip2- dependent type I 
interferon response is IRF5 -dependent and IRF3 independent (Figure 25). Although the 
majority of the IFN response may be through IRF3, a significant amount of the type I 
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interferon response to Mtb occurs via Rip2 and IRF5.   
 The Nod2-Rip2-IRF5 pathway differs from the response triggered by other 
bacteria such as L. monocytogenes, which depend entirely on IRF3. Thus, our data do not 
imply that Mtb is stimulating type I interferon in a fundamentally different manner from 
other bacteria.  Instead, it is possible that the balance of these pathways might be 
affected by the activation state of the macrophage. Also, it is likely that bacterial 
pathogens stimulate the IFN response via multiple, partially redundant pathways, and that 
the relative importance of each is determined by the unique biology of the infection. In 
the case of Mtb, we speculate that the N-glycolylation of its peptidoglycan, and perhaps a 
paucity of other ligands such as DNA, favor recognition via Nod2.  We demonstrated 
that the N-Glycolylated form of MDP is a more potent stimulator for Rip2 
polyubiquitination and type I IFN response than the more common N-Acetylated 
derivative (Figure 20).  
      Are IRF3 and IRF5 the only IRFs required for Mtb induced type I IFN response? 
Our studies in IRF3/IRF5 double knockout macrophages demonstrated that Mtb infection 
fails to result in any type I interferon response in the absence of IRF3 and IRF5 (Figure 
27). However, the nature of the Mtb ligand responsible for IRF3 activation in Mtb 
infected cells is unknown. We proposed that bacterial DNA translocated into the host 
cytosol might be the ligand that stimulates IRF3 activation; based on studies that 
transfection of L. monocytogenes DNA into the cytosol induces IRF3 activation [183]. If 
true, a specific cytosolic DNA sensor may contribute to type I interferon response. 
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      A Rip2 point mutant that cannot be stably ubiquitin modified is unable to mediate 
IFN/ induction in response to Mtb infection (Figure 26), suggesting that 
polyubiquitinated Rip2 is required for Mtb-induced type I IFN production. One possible 
mechanism is that Rip2 polyubiquitination may regulate TBK1 activity. Indeed, other 
studies have indicated that the TBK1 mediated type I IFN response is K63-ubiquitination 
regulated [238]. Traf3, a ring domain containing E3 ligase, is K63 specific and undergoes 
K63-linked auto-ubiquitination upon viral infection. K63 ubiquitin modified Traf3 
recruits TBK1 in a ubiquitin dependent manner and activates TBK1. The deubiquitinase 
DUBA cleaves the K63 polyubiquitin chains on TRAF3, resulting in its dissociation from 
the downstream signaling complex containing TBK1 and terminating the type I IFN 
response upon viral infection. Thus K63 ubquitin may be a general mechanism of kinase 
activation in the innate immune signaling pathway. 
      A ubiquitin-like domain (UBL) was identified in TBK1 and IKK. The TBK1 
UBL domain binds to its kinase domain and is required for kinase activation. Deletion or 
mutations of the UBL in TBK1 impairs kinase activation, and results in an inability to 
phosphorylate IRF3 [239]. In our studies, we observed an interaction between TBK1 and 
polyubiquitinated Rip2 (data not shown), raising the possibility that Rip2 
polyubiquitination triggers TBK1 recruitment and activation upon Mtb infection. 
      What is the biological role of Nod2-Rip2 induced Type I interferon response in 
Mtb pathogenesis? While the importance of IFN/ in viral defense is clear and virtually 
universal, the role of type I interferon in antibacterial immunity appears to vary.  Mice 
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deficient in the type I IFN receptor, Ifnar1, are significantly more susceptible to several 
Gram-positive and -negative bacterial infections [202,203,204,205], indicating that 
IFN/ are important for immunity to many bacteria.  However, an Ifnar1-deficiency 
has the opposite effect on the outcome of L. monocytogenes infection [206], suggesting 
that IFN/ can also exacerbate disease.   
       The role played by IFN/ in Mtb infection remains somewhat uncertain and 
there is conflicting evidence regarding the role of type I IFN in the infection. Initially, M. 
tuberculosis was shown to have a slight growth advantage in the lungs of Ifnar1-/- mice 
following aerosol infection, although growth in other organs was not examined [240]. 
This study suggests a protective role for type I IFNs during infection with M. tuberculosis. 
Consistent with this, it was shown that signaling through the type I IFN receptor during M. 
tuberculosis infection of macrophages was required for the production of a number of 
immunologically important products, including inducible NO synthase, IFN--inducible 
protein-10 (IP-10), RANTES, and IRG1 [139]. It has also been shown that M. 
tuberculosis may actively inhibit type I IFN signaling related to pathogenicity by 
increasing the association of protein tyrosine phosphatase 1c with the IFNAR1 [212]. 
However, other Mtb infection studies in Ifnar1-/- mice showed increased splenic 
resistance to infection with decreased bacterial burden in the spleen [169]. Consistent 
with this, a hypervirulent clinical isolate of M. tuberculosis was found to induce 
significantly higher levels of type I IFN [210]. Moreover, exogenous addition of type I 
IFNs to macrophages infected with Mtb, enhanced bacterial growth, providing further 
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evidence for a detrimental role of type I IFNs during Mtb infection [209].  
       The ultimate influence of IFN/ on Mtb infection appears to depend on a 
number of experimental factors, including host genetic background, bacterial strain, route 
of infection and dose. Most importantly, the effect of IFN/ is most apparent after the 
onset of adaptive immunity and not before, suggesting that type I IFNs may instruct the 
priming and /or maintenance of the adaptive immune response, and perhaps control the 
differentiation of regulatory T cells [208]. 
       Mtb infection of Nod2-deficient mice revealed similar bacterial counts but 
reduced inflammatory responses during the early phase of disease. However, 
Nod2-deficient mice succumbed to the disease at 6 months post infection with a half-log 
increase in bacterial load compared to wild-type controls, potentially due to an impaired 
adaptive response to Mtb [241]. This result, suggests that the Nod2 pathway has a 
protective role in Mtb pathogenesis and may promote the adaptive immune response. 
However, this delayed susceptibility phenotype could result from impaired cytokine 
production in Nod2 deficient mice upon Mtb infection, such as IL-12 and IL-6. The Rip2 
deficient mouse susceptibility studies upon Mtb infection are ongoing in our lab.  
      The Nod2 pathway described in this work might play a major role in determining 
the effectiveness of tuberculosis vaccines, since Type I IFN production is required for 
complete Freund's adjuvant (CFA) to promote antigen-specific immune responses [55]. 
Our work suggests that a particularly potent form of MDP is translocated into the host 
cell cytosol upon Mtb infection, leading to robust induction of the type I IFN response.  
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This may at least be partially responsible for the poor protection against pulmonary TB in 
adults provided by the attenuated vaccine strain M. bovis BCG, which produces the same 
PAMPs present in CFA but lack ESX1 function, and is therefore unable to activate the 
Nod2 pathway or induce Rip2 polyubiquitination [216,217]. Understanding both the 
details of PAMP trafficking, as well as the precise specificity of PAMP recognition, 
promises to aid in both the design of improved adjuvants and more effective tuberculosis 
vaccines. 
     In addition, Rip2 polyubiquitination might serve as a sign of cytosolic Nod2 
pathway activation. In vitro studies have identified a variety of pathogens that activate 
Nod2, including S. pneumoniae, S. aureus, Salmonella typhimurium, L. monocytogenes, S. 
flexneri and Mycobacterium tuberculosis [120,121,122,123]. Thus, it is reasonable to 
think other pathogens may also activate Nod2 in vivo and induce Rip2 polyubiquitination. 
A recent study has revealed that infection of HT-29 cells with L. monocytogenes also 
triggers Rip2 polyubiquitination [241]. This result correlates with the previous work that 
L. monocytogenes infection activates the Nod2 pathway in vivo and that Nod2-/- and 
Rip2-/- mice are more resistance to L. monocytogenes infection [64,100]. Indeed, our 
recently unpublished studies also suggest that Neiserria Gonnorhea induces Nod2 
activation and Rip2 polyubiquitination in vivo. 
      In the past few years, research has revealed that the Rip protein family integrates 
many diverse upstream signals and mediates MAPK, IKK or IRF activation. Collectively, 
they share the capacities to transmit intracellular responses to various cellular stresses. 
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Our work in this thesis presents a new regulatory mechanism where the Rip2 protein, 
similar to Rip1, is K63-linked polyubiquitination modified, and this modification is 
essential for a Rip2 mediated innate immune response. This study reveals critical roles 
for polyubiquitinated Rip proteins in innate immune recognition of bacterial and 
potentially viral pathogens. The E3 ubiquitin ligases or deubiquitinases that regulate 
innate immune responses may therefore serve as a new drug targets for human 
inflammatory disease.  
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Figure 1. MDP induced NF-B activation requires the expression of Ubc-13. The 
mouse macrophage cell line RAW 264.7 was infected with lentiviruses containing 
shRNA sequences specific for Ubc13 or GFP as a control and stable puromycin resistant 
pools selected.  These lines were left untreated or stimulated with MDP (10g/ml) for 
the time periods indicated.  Cells were lysed and NF-B activation was measured by 
immunoblotting with a phospho-IB antibody (Cell Signaling Techology). Ubc-13 and 
-actin levels were determined by immunoblotting with the indicated antibodies.  
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Figure 2. Expression of wild type NOD2, but not the Crohn’s Disease associated 
alleles, stimulates the stable polyubiquitination of Rip2. A. NOD2 mutants 
associated with Crohn’s Disease fail to stimulate Rip2 polyubiquitination. 
Omni-tagged wild type NOD2 or the Crohn’s disease-associated NOD2 mutants 
L1007insC and D291N were expressed with FLAG-tagged Rip2 in the presence of 
HA-tagged ubiquitin in HEK293T cells. Rip2 was immnoprecipitated with an anti-Rip2 
antibody (Santa Cruz), and western blots were performed with the indicated antibody.  
Expression levels of Rip2 and wild type NOD2 and mutants were measured by 
immunoblotting the total cell lysate with anti-FLAG or anti-Omni antibodies.  B.  
L1007insC interacts with Rip2 whereas D291N is impaired in its ability to stably 
interact with Rip2.  Omni-tagged wild type NOD2 and the CD-associated mutants 
L1007insC or D291N were expressed with Flag-tagged Rip2 in HEK293 cells.  Wild 
type or CD-associated NOD2 alleles were immunoprecipitated with anti-Omni antibody 
followed by immunoblotting with an anti-Flag antibody.  Expression levels of Rip2, 
wild type and mutant forms of NOD2 were monitored by immunoblotting the total cell 
lysate with anti-Flag or anti-Omni antibodies, respectively. 
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Figure 3. Co-expression of RIP2 and IRF5 stimulate ISRE luciferase reporter 
activity. HEK293T cells were co-transfected with ISRE-luciferase reporter plasmid 
(40ng) together with the indicated concentrations of IRF5 and RIP2 expression plasmids.  
Luciferase activity was measured 24h later using Dual Luciferase reporter assay system 
(Promega).  Renilla luciferase gene (40ng) was co-transfected and used as an internal 
control.  Each experiment was repeated three times. Data are expressed as mean ± s.d. 
of three replicates. 
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Figure 4. Irf7 is not required for an optimal type I IFN response upon Mtb infection. 
BMDM from Irf7-/- or control littermates were infected with ESX1 wt Mtb H37Rv (Rv) 
at an MOI of 10, or left uninfected for 4 hours. RNA was harvested, and IFN mRNA 
level was quantified by real time-PCR. Gene expression of IFN is reported as copy 
number per 1,000 copies of -actin. Samples were assayed in triplicate; error bars 
represent standard deviation. Data shown is representative of at least three independent 
experiments. 
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Figure 5.    Rip2 and TBK1 interact in transfected cells.  Flag-tagged TBK1 and 
Myc-tagged Rip2 were either co-expressed or expressed alone in HEK293T cells.  
TBK1 was immunoprecipitated with an anti-Flag antibody and Rip2 detected by 
immunoblotting with anti-Myc antibody or Rip2 was immunoprecipitated with an 
anti-Myc antibody followed by immunoblotting with anti-Flag antibody to detect 
associated TBK1 proteins.  Relative expression of each construct was measured by 
immunoblotting the total cell lysate with anti-Myc or -Flag antibodies.  
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A cytosolic NEMO/RIP1 complex recruits TAK1 
to mediate the NF-B and p38 MAP 
kinase/MAPKAP-2 responses to DNA damage 
 
 
 
 
  Yang et al, 2010 
2 
Summary 
 
Genotoxic stress triggers translocation of the regulatory subunit of the IKK complex 
NEMO I γ from the nucleus to the cytosol, following a series of post-translational 
modifications that lead to IκB kinase activation. RIP1 has been implicated in this response and 
found modified in DNA damaged cells; however, the nature of the RIP1 modification and its 
precise role in the pathway remain unclear.  Here we demonstrate that RIP1 and the ubiquitin-
activated kinase TAK1 are principal mediators of the genotoxic stress response. We find RIP1 
SUMO- and ubiquitin-modified in response to DNA damage and show that a RIP1 deficiency 
sensitizes cells to DNA damage due to an inability to induce survival gene expression. DNA 
damage stimulates TAK1 kinase activity and formation of a cytosolic complex containing ATM, 
NEMO I γ, RIP1 and TA 1.  We demonstrate that a TA 1 deficiency or inhibition sensitizes 
tumor cells to DNA damage due to an inability to activate NF-κB and the alternative DNA 
damage response pathway mediated by p38 MAPK-MAPKAP-2 kinases. This study has 
translational implications and reveals TAK1 as a potential therapeutic target in chemoresistance. 
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DNA damage stimulates formation of a cytosolic NEMO, RIP1, TAK1 and IKK complex 
RIP1 is SUMO-and ubiquitin-modified and TAK1 binds ubiquitinated RIP1 
A TAK1 deficiency impairs the NF-B response and sensitizes tumor cells to DNA damage 
TAK1 mediates the p38 MAPK/MK2 checkpoint in DNA damaged, p53-deficient tumor cells 
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Introduction 
 
The DNA damage response activates cell cycle checkpoint and survival pathways that 
function to prevent DNA replication until damaged DNA is repaired. These pathways include the 
well-characterized ATM (Ataxia telangiectasia mutated)/CHK2 and ATR (Ataxia telangiectasia 
and Rad-3-related)/CHK1 pathways and the more recently identified 
ATM/ATR/p38MAPK/MAPKAP-2 checkpoint active in p53-deficient tumor cells (Lavin, 2008; 
Reinhardt et al., 2007). The transcription factor NF-B regulates apoptosis induced by genotoxic 
stress and is an attractive therapeutic target in tumor cells whose response to DNA damaging 
agents is impaired due to compromised p53 function.  Moreover, constitutive NF-B activity is a 
hallmark of several cancers and mutations in NF-B pathway components have been associated 
with the activated B cell (ABC) subtype of diffuse large B cell lymphoma (DLBCL), breast 
cancer and multiple myeloma (Annunziata et al., 2007; Boehm et al., 2007; Demchenko et al., 
2010; Hideshima et al., 2009). Thus the inclusion of NF-B inhibitors in cancer therapy could 
have anti-oncogenic activities as well as augment the tumor chemotherapeutic response. 
NF-B is normally held in the cytoplasm in an inactive form bound to inhibitor proteins such 
as IB.  Diverse stimuli such as infection, pro-inflammatory cytokine production or treatment 
with agents that induce DNA damage illicit NF-B mediated transcriptional activity by 
activating the cytosolic IKK complex, consisting of IKK and IKK and a regulatory subunit 
designated IKK or NEMO (hereafter referred to as NEMO).   IKK activation results in IB 
phosphorylation, ubiquitination and subsequent degradation.  The NF-B (p65/p50) heterodimer 
is then free to enter the nucleus and stimulate gene expression (Hayden and Ghosh, 2008).  
DNA double strand breaks are also sensed by the poly (ADP-ribosy)lating enzyme PARP-1.  
Upon recognition of DNA double strand breaks, PARP-1 catalyzes the attachment of poly(ADP-
ribose) (PAR) chains to glutamic acid residues on PARP-1 itself, as well as other substrates.  
PAR-modified PARP-1 recruits the ATM kinase and the inhibitor of activated STATy (PIASy) 
which sumoylates the IKK regulatory subunit, NEMO at lysines K277 and K309 (Mabb et al., 
2006; Stilmann et al., 2009; Wu et al., 2006b). DNA damage also stimulates interactions in the 
nucleus between NEMO, the receptor-interacting protein (RIP1) and the p53-induced protein 
with death domain (PIDD) (Janssens et al., 2005).  PIDD has been shown to translocate to the 
  Yang et al, 2010 
4 
nucleus in response to genotoxic stress and either PIDD or RIP1 depletion abolishes DNA 
damage-induced NF-B activation and NEMO sumoylation (Janssens et al., 2005).  Once 
sumoylated, NEMO is phosphorylated by ATM and mono-ubiquitinated potentially by the 
inhibitor of apoptosis protein, cIAP1 in the nucleus (Huang et al., 2003; Jin et al., 2009).  These 
events trigger the translocation of ATM and NEMO into the cytosol, however the mechanism by 
which NEMO mono-ubiquitination leads to IKK activation is unknown. 
Ubiquitin modification has been linked to cytosolic IKK activation by the pro-inflammatory 
cytokines IL-1 and TNF-.  In the IL-1 pathway, the E3 ubiquitin ligase TRAF6 and the 
UBC13/UEV1A E2 complex catalyze the K63-linked polyubiquitination of TRAF6, IRAK1 and 
NEMO and stimulate the recruitment of the ubiquitin-activated TAK1 kinase complex. The 
TAK1 kinase complex consists of TAB2 and TAB3 proteins that contain NZF-type ubiquitin 
binding domains that bind polyubiquitinated TRAF6 and NEMO (Ea et al., 2006; Kanayama et 
al., 2004). In the TNF pathway, the E3 ubiquitin ligases cIAP1/2 and TRAF2/5 mediate the K63-
polyubiquitination of RIP1, TRAF2 and NEMO, which in turn recruits TAK1 and IKK 
complexes to the TNF receptor through the ubiquitin binding domains present in TAB2/3 and 
NEMO (Ea et al., 2006; Lee et al., 2004; Mahoney et al., 2008). Thus, in cytokine signaling, the 
polyubiquitin chains serve as a scaffold to recruit the IKK complex, allowing TAK1 to 
phosphorylate and activate IKK.  Deubiquitinases such as CYLD and A20 disassemble K63 
polyubiquitin chains from the signal transducers to abrogate these inflammatory responses 
(Trompouki et al., 2003; Wertz et al., 2004). K63-polyubiquitin chains contribute to IKK and 
TBK-1 kinase activation in additional pathways including the T cell receptor, NOD-like 
receptors and RIG-I cytosolic receptors (Bhoj and Chen, 2009).  
In the present study, we demonstrate that the NF-B response to DNA damage may also be 
ubiquitin-regulated and mediated by the ubiquitin-activated kinase TAK1. Our studies reveal that 
DNA damage stimulates TAK1 kinase activity and formation of a large cytosolic complex that 
includes NEMO, RIP1, TAK1 and IKK.  We reveal that RIP1, like NEMO, is SUMO-1 
modified by the SUMO E3 ligase PIASy and that modified RIP1 forms a complex with NEMO, 
TAK1 and IKK.  RIP1 is also K63-ubiquitin modified in response to DNA damage and TAK1 
binds polyubiquitinated RIP1 in DNA damaged cells. We provide evidence that a RIP1 or TAK1 
deficiency abrogates NF-B activity and sensitizes mouse fibroblasts and multiple human tumor 
cell lines to DNA damaging agents. This study also reveals novel roles for TAK1 as a critical 
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mediator of the p38 MAP kinase/MAPKAP-2(MK-2) checkpoint in p53-deficient human tumor 
cells. Thus, TAK1 silencing or inhibition in human tumor cells interferes with both the NF-B- 
and p38 MAP kinase/MK2-mediated survival pathways, raising TAK1 as a potential therapeutic 
target in chemotherapeutic resistance. 
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Results 
A Rip1- or Nemo-deficiency impairs the NF-B response and sensitizes MEFs to genotoxic 
stress 
The RIP1 protein has been implicated in the NF-B response to DNA damage and its role in 
the DNA damage response has been shown to be independent of its kinase activity and effects on 
the TNF pathway (Hur et al., 2003; Janssens et al., 2005).  Although implicated in DNA damage-
induced NF-B activity, the exact function and relative position(s) of RIP1 in this NF-B 
pathway remain unclear. Previous studies suggested a nuclear role for RIP1, demonstrating that 
RIP1 is required for formation of the PIDDosome and the SUMO-modification of NEMO in 
DNA damaged cells (Janssens et al., 2005).  Although not tested, these findings predict that cells 
deficient for RIP1 or NEMO would be equivalently sensitive to DNA damage.  To test this 
prediction, we compared the sensitivity of Rip1-deficient and Nemo-deficient murine embryonic 
fibroblasts to doxorubicin treatment.  We found Rip1-deficient and Nemo-deficient cells 
equivalently hypersensitive to doxorubicin treatment (Figure 1A), supporting the idea that both 
RIP1 and NEMO contribute to the DNA damage response.  We also found IB degradation 
impaired in both Rip1- and Nemo-deficient MEFs treated with doxorubicin (Figure 1B), 
consistent with published studies (Huang et al., 2002; Hur et al., 2003; Stilmann et al., 2009).  
 To determine why a Rip1 deficiency results in sensitivity to DNA damaging agents, we 
used gene expression profiling to compare the responses of wild type and Rip1-deficient MEFs 
to etoposide treatment. Ingenuity pathway analysis revealed a failure to induce survival gene 
expression when cells lacking Rip1 were exposed to DNA damage.  Specifically, induction of 
Xiap, Bcl2l1 (Bcl-xL), and Birc3 (cIap2) mRNAs was impaired in Rip1- as well as in Nemo-
deficient cells (Figure 1C).  Thus, the absence of Rip1 or Nemo, sensitizes cells to DNA damage 
due to a failure to activate NF-B and induce survival gene expression.   
 
DNA damage stimulates the SUMO- and K63-ubiquitin modification of RIP1  
 Previous studies detected a modified form of RIP1 in etoposide-treated cells (Janssens et 
al., 2005). However, the precise nature and functional significance of the RIP1 modification(s) 
remain unclear.  We detect a modified form of RIP1 in etoposide-treated cells that migrates at 
approximately 95-100 kDa.  The 20-25 kDa increase in the apparent molecular weight suggested 
that RIP1, like NEMO, might be SUMO-1 (small ubiquitin-like modifier) modified in DNA 
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damaged cells.  To determine whether DNA damage leads to RIP1 sumoylation, we treated 
U2OS cells with etoposide, immunoprecipitated RIP1 and examined the immunoprecipitates for 
the presence of sumolyated forms.  We detected sumolyated forms of RIP1 40 min following 
etoposide treatment (Figure 2A, upper panel). Consistently, the detection of sumoylated RIP1 
appears co-incident with phospho-IB reactivity detected at 30 min following etoposide 
exposure (Figure 2A, lower panel).  The SUMO ligase PIASy mediates NEMO sumoylation in 
response to genotoxic stress and RIP1 and NEMO interact in the nucleus of DNA damaged cells 
(Janssens et al., 2005; Wu et al., 2006a).  To examine whether PIASy can function as a direct 
SUMO E3 ligase for RIP1, we introduced 2 individual PIASy siRNA oligonucleotides into 
U2OS cells and tested whether the etoposide-induced modification of RIP1 was affected. We 
were unable to detect sumoylated RIP1 in the etoposide-treated, PIASy-depleted cells, indicating 
that in response to genotoxic stress PIASy may modify both NEMO and RIP1 (Figure 2B, 
Supplementary Figure 1A and B). 
In addition to the SUMO-1 modification, RIP1 was also found stably modified with K63-
linked polyubiquitin chains (Figure 2C and D).  K63-ubiquitin modified RIP1 was detected at 30 
min following etoposide treatment and steadily increased for 2 hours, consistent with the 
maintenance of NF-B activity in DNA damaged cells (Figure 2A, lower panel).  However, the 
amount of polyubiquitinated RIP1 was significantly less in DNA damaged cells, than in those 
treated with TNF- for 10 min (Figure 2C), suggesting that only a fraction of the total RIP1 is 
modified in DNA damaged cells. These findings indicate that in addition to its nuclear role(s), 
RIP1 and potentially K63-ubiquitin-modified RIP1 may function in the cytosol to assemble an 
IKK activating complex in response to genotoxic stress.   
 
DNA damage induces the formation of a large cytosolic complex containing ATM, NEMO, 
RIP1, TAK1 and IKK 
DNA damage stimulates the formation of complexes in the nucleus consisting of ATM, 
PARP-1, PIASy and NEMO as well as a PIDD, RIP1 and NEMO complex (Janssens et al., 2005; 
Stilmann et al., 2009).  However, cytosolic complexes induced by DNA damage have been less 
well studied and as a result, how a nuclear damage signal is conveyed to the cytosolic IKK and 
MAK kinases remains unresolved. We utilized size exclusion chromatography and co-
immunoprecipitation to uncover the cytosolic complexes induced in DNA damaged cells. Size 
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exclusion chromatography of cytosolic lysates from untreated or etoposide-treated cells revealed 
that DNA damage causes a shift in the migration of both NEMO and RIP1 into overlapping 
fractions corresponding to a MW of ~500-700 kDa (Figure 3A, fractions 17-21). In contrast to 
NEMO, only a fraction of the total RIP1 protein appears to shift to the higher molecular weight 
complex. We then examined the complexes for the presence of TAK1.  TAK1 migrates in three 
apparent complexes in DNA damaged cells.  One complex (fractions 17-21) migrates with an 
apparent molecular weight that overlaps with the NEMO- and RIP1-containing complex. To 
determine whether this complex contains NEMO, RIP1 and TAK1 in one complex, we 
immunoprecipitated TAK1 from fractions 17-21 and then examined the immunoprecipitates for 
the presence of NEMO and RIP1.  In the untreated cells, interactions between RIP1, NEMO and 
TAK1 were not observed (Figure 3B).  However, when these column fractions were 
immunoprecipitated from etoposide-treated cells, RIP1 and TAK1 and TAK1 and NEMO 
associations were readily detected in the cytosol (Figure 3B).  Interestingly, the DNA damage-
induced cytosolic complex that contains NEMO and TAK1 appears to also contain a modified 
form of RIP1 (Figure 3A, marked with asterisk).  Further analysis revealed that the RIP1 
associated with this complex ran as a smear on a 3-8% gradient SDS-PAGE gel, suggesting that 
the complex contains ubiquitinated forms of RIP1 (Supplementary Figure 2).  We also examined 
the column fractions for the presence of the catalytic IKK subunit, IKK.  DNA damage induced 
a shift in IKK into a similar sized complex, suggesting that DNA double strand breaks stimulate 
formation of a cytosolic complex consisting of RIP1, NEMO, TAK1 and IKK (Figure 3A). 
These data are consistent with the hypothesis that DNA damage stimulates the SUMO- and 
ubiquitin-modification of RIP1, which in turn recruits and activates TAK1 and IKK to achieve 
IKK activation. 
 To investigate whether K63-polyubiquitinated RIP1 triggers the recruitment of the 
ubiquitin-activated TAK1 kinase, we asked whether the mobility of the TAK1-associated RIP1 
protein was altered in DNA damaged cells, as it is in TNF--treated cells (Kanayama et al., 
2004; Lee et al., 2004).  We immunoprecipitated TAK1 from cells treated with TNF- for 10 
min or from cells exposed to etoposide for 30 min to 2 hours.  We then analyzed the nature of the 
RIP1 protein found associated with TAK1 by immunoblotting.  Etoposide or TNF- treatment 
stimulated TAK1 interactions with higher molecular weight forms of RIP1 (Figure 3C), 
consistent with our model that ubiquitinated RIP1 stimulates TAK1 recruitment and activation in 
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response to DNA damage. Consistently, expression of a K63-only form of ubiquitin is sufficient 
to trigger the association of TAK1 with RIP1 in the absence of additional stimuli, indicating that 
ubiquitinated RIP1 is a preferred TAK1 binding partner (Supplementary Figure 3).  
We also prepared nuclear and cytoplasmic fractions from cells treated with etoposide for 
various times and examined each for the presence of ATM, PARP1 and CASPASE 3. Although 
ATM is predominantly a nuclear kinase, a small quantity of ATM can be detected in the cytosol 
(Figure 3D and Wu et al., 2006b). When TAK1 was immunoprecipitated from the cytosolic 
fractions, we found that etoposide treatment induced interactions between TAK1 and cytosolic 
ATM (Figure 3E).  We then examined the nuclear and cytoplasmic extracts for the presence of 
RIP1.  A transient and weak RIP1/NEMO interaction was observed in the nucleus of cells treated 
with etoposide for 30 min, similar to previously published work (Janssens et al., 2005).   In 
contrast, a more robust and sustained RIP1/NEMO interaction was readily detected in the cytosol 
of doxorubicin- or etoposide-treated cells (Figure 3E and Supplementary Figure 4). Moreover, 
RIP1 also associated with TAK1, by co-immunoprecipitation (Figure 3E).  Thus, TAK1 
associates with ATM and RIP1, while RIP1 also interacts with NEMO about 1 hour following 
DNA damage (Figure 3E).  The cytosolic gel filtration experiment suggests that these proteins 
associate in one complex.  These interactions are co-incident with the induction of NF-B 
activity as measured by phospho-IB reactivity or IB degradation (Figure 2A, lower panel), 
suggesting that a cytosolic ATM, RIP1, NEMO and TAK1 complex recruits and activates IKK.  
 
DNA double strand breaks stimulate TAK1 kinase activity and TAK1 inhibition impairs 
the NF-B response and sensitizes cells to genotoxic stress 
 Treatment with the pro-inflammatory cytokines TNF- or IL-1 has been shown to 
stimulate TAK1 kinase activity, which can be detected using an in vitro kinase assay or by 
probing cell lysates with an anti-phospho-TAK1 antibody to measure TAK1 autophosphorylation 
(Singhirunnusorn et al., 2005; Xia et al., 2009).  To determine whether DNA damage stimulates 
TAK1 kinase activity, we treated the human tumor cell line U2OS with doxorubicin, etoposide 
or -irradiation for the time periods indicated and measured anti-phospho-TAK1 levels. We 
detected a modest increase in phospho-TAK1 reactivity in doxorubicin-treated cells (Figure 4A).  
Treatment of U2OS cells with etoposide or -irradiation, treatments known to induce numerous 
DNA double strand breaks, significantly increased and sustained phospho-TAK1 reactivity; 
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indicating that like TNF- treatment, DNA double strand breaks are potent inducers of TAK1 
kinase activity (Figure 4A).   
 To further test the contribution of TAK1 to the genotoxic stress response, we examined 
NF-B activity and sensitivity to doxorubicin in Tak1-deficient, SV40T antigen immortalized 
MEFs.  A Tak1-deficiency results in an inability to activate NF-B in response to TNF-, IL-
1 or TLR3/4 ligands (Shim et al., 2005). We found the NF-B response to TNF- and 
doxorubicin treatment impaired in the absence of Tak1 (Figure 4B) and found Tak1-deficient 
cells hypersensitive to doxorubicin treatment compared to wild type controls (Figure 4C; p < 
0.01).  
 We then tested whether TAK1 kinase activity was required for the NF-B response to 
DNA damage.  To examine a requirement for the kinase activity of TAK1, we pretreated cells 
with vehicle or with 5Z-7-oxozeaenol, a potent and highly selective inhibitor of TAK1 
(Bioaustralis) (Takaesu et al., 2003; Windheim et al., 2007).  The cells were left untreated, 
exposed to the proinflammatory cytokine TNF- for 10 min or to doxorubicin for the time 
periods indicated. We examined the cell lysates for evidence of IB degradation and measured 
cell viability.  As expected, TNF- or doxorubicin treatment induced IB degradation in the 
vehicle treated cells. Pretreatment with the TAK1 kinase selective inhibitor 5Z7 reduced the 
IB degradation observed in cells treated with TNF- or doxorubicin (Figure 4D).  Consistent 
with the impaired NF-B response, TAK1 kinase inhibition additionally sensitized the cells to 
doxorubicin-induced cell death (Figure 4E; p<0.05), indicating that the kinase activity of TAK1 
is required for NF-B activation and survival in response to DNA damage.  
 
DNA damage fails to activate TAK1 or NF-B in the absence of ATM, NEMO or RIP1 
 The formation of a large cytosolic complex containing modified RIP1, NEMO, TAK1 
and IKK in DNA damaged cells reveals ubiquitin-modified RIP1 and the ubiquitin-activated 
kinase TAK1 as critical links between nuclear damage and cytosolic IKK activation. Our 
biochemical studies suggest that ATM, NEMO and RIP1 are sensors and transducers of the DNA 
damage signal and lie upstream of TAK1 and IKK-  To genetically test this model, we asked 
whether Atm, Nemo or Rip1 are each required for DNA damage-induced Tak1 activation. Wild 
type, Atm-/-, Nemo-/- and Rip1-/- mouse embryonic fibroblasts were treated with the pro-
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inflammatory cytokines IL-1 or TNF- for 10-15 min or exposed to etoposide for the time 
periods indicated.  We measured Tak1 kinase activity using an in vitro kinase assay with a His-
tagged, kinase-inactive MKK6 as a substrate.  Additionally, the cell lysates were examined for 
phospho-Tak1 and phospho-IB levels.   
 As expected, the IL-1 or TNF--induced Tak1 kinase activity appeared unaffected by 
an Atm deficiency (Figure 5A and B) and consistent with the role of Nemo downstream of Tak1 
in the IL-1 pathway, similar phospho-Tak1 levels were detected in the IL-1-treated Nemo-
deficient cells (Figure 5D).  However, Tak1 kinase and NF-B activity was significantly reduced 
in the etoposide-treated fibroblasts lacking Atm, Nemo or Rip1 (Figure 5A-F).  A Rip1 
deficiency impaired the NF-B response to both TNF- and etoposide, as reduced IB and 
Tak1 phosphorylation levels were observed when Rip1-deficient MEFs or RIP1-silenced human 
tumor cells were treated with TNF- or etoposide (Figure 5E, F).  Collectively, these data 
support a model whereby Atm/Nemo and Rip1 are each required for Tak1 kinase activation and 
for an optimal NF-B response to DNA damage.   
 
TAK1 silencing impairs the tumor NF-B response to multiple DNA damaging agents 
Our studies in mouse fibroblasts implicate Tak1 in the NF-B response to genotoxic 
stress and raise the possibility that TAK1 may protect human tumor cell lines from the effects of 
DNA damaging agents and thereby contribute to chemotherapeutic resistance.  To determine 
whether TAK1 silencing sensitizes human tumor cells to DNA damage, we transfected human 
U2OS cells with control or TAK1-specific siRNAs and then exposed the cells to the pro-
inflammatory cytokine TNF- or to the DNA damaging agents doxorubicin, etoposide or -
irradiation.  In the U2OS cells transfected with the control siRNA, TNF- treatment or exposure 
to DNA damaging agents induced IB phosphorylation and IB degradation whereas, TAK1 
depletion impaired the tumor NF-B response to TNF- and to DNA damage-induced by 
doxorubicin, etoposide or -irradiation (Figure 6 A-C).  We examined multiple human tumor cell 
lines including the human cervical adenocarcinoma cell line HeLa, the human breast 
adenocarcinoma cell line MCF7 and the human lung adenocarcinoma cell line H1299.  We found 
that TAK1 silencing impaired the NF-B response to DNA damage in all the human tumor cell 
lines examined (Figure 6 and data not shown). 
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Failure to induce NF-B-dependent survival gene expression and sensitivity to DNA 
damage in RIP1- or TAK1-depleted human tumor cells 
 The impaired NF-B response to DNA damage predicts that TAK1 silencing should 
sensitize human tumor cells to DNA damaging agents. To test this prediction, we knocked down 
TAK1 expression in human U2OS cells and exposed the cells to DNA damaging agents. The 
TAK1-depleted tumor cells exhibited significantly more cell death than control cells treated with 
etoposide or exposed to -irradiation (Figure 7A and B; p<0.05). Collectively, these data indicate 
that TAK1 contributes to the NF-B response to DNA damage and TAK1 depletion increases 
tumor sensitivity to treatment with chemotherapeutic agents or radiation.  
 We demonstrated that Rip1-, Nemo- and Tak1-deficient MEFs are sensitive to DNA 
damage due to an inability to induce NF-B-dependent gene expression (Figures 1 and 4).  To 
determine whether TAK1- or RIP1-silencing in human tumor cells affects NF-B-dependent, 
survival gene expression, we quantified XIAP and BCL2L1(BCL-xL) mRNA levels in human 
tumor cells transfected with control, TAK1- or RIP1-specific siRNA oligonucleotides.  
Etoposide treatment of cells expressing the control siRNA stimulated a 2.5-fold increase in XIAP 
and BCL2L1(BCL-xL) mRNA levels at 30 min, followed by a 5-fold increase in mRNA levels at 
1 and 2 hours.  However, we observed little to no induction of XIAP or BCL2L1(BCL-xL) 
expression in the etoposide-treated RIP1- or TAK1-silenced cultures (Figure 7C and D), 
revealing that both RIP1 and TAK1 contribute to NF-B-mediated survival gene expression in 
tumor cells exposed to DNA damage. 
 Although our biochemical studies support a model whereby TAK1 lies downstream of 
the ATM/NEMO/RIP1 complex in this NF-B pathway, it remains plausible that RIP1 and 
TAK1 mediate independent survival pathways. To perform an epistatic analysis, we silenced 
RIP1 and/or TAK1 expression in HeLa cells and then measured sensitivity to DNA damaging 
agents.  As in mouse fibroblasts and in the human U2OS tumor cell line, TAK1- or RIP1 
depletion sensitized HeLa cells to doxorubicin treatment with an average of 47% viable cells 
(Figure 7E; TAK1-knockdown: 50.9 ± 2.3% RIP1-knockdown: 42.7 ± 3.0%) recovered 12 hours 
following treatment, compared to 83.2 ± 3.5% viability in the control cultures.  Silencing both 
TAK1 and RIP1 had no added effect on tumor cell viability following doxorubicin treatment 
(Figure 7E).  Consistent with induction of apoptosis, PARP1 and CASPASE 3 cleavage was 
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detected in the RIP1-, TAK1- and in the RIP1- and TAK1-silenced cells at 12 hours, but not in 
doxorubicin treated control cells (not shown).  The fact that RIP1 or TAK1 silencing had similar 
effects on cell viability and that no increase or acceleration in cell death was observed when both 
TAK1 and RIP1 were silenced supports a model where RIP1 and TAK1 function in the same 
pathway to mediate tumor cell survival. 
 
TAK1 mediates the p38 MAP kinase-MK2 checkpoint in p53-deficient human tumor cells 
 The DNA damage response is primarily mediated by the kinases ATR and ATM, which 
signal to the checkpoint kinases CHK1 and CHK2. Yet in the absence of a functional ATM-
CHK2 or an ATR-CHK1-TSP53 pathway, DNA damage activates a third pathway that involves 
ATM/ATR signaling to p38 MAP kinase which activates a newly identified checkpoint mediated 
by MAPKAP Kinase 2 (MK2) (Reinhardt et al., 2007).  Tumor cells that inactivate p53 depend 
on this alternative pathway to mediate cell cycle arrest and survival following treatment with 
chemotherapeutic drugs that cause DNA damage. Pre-treatment with the p38 MAPK selective 
inhibitor SB203580 prior to the administration of DNA damaging agents abolishes MK2 
activation and fails to result in cell cycle arrest (Reinhardt et al., 2007).  Although this alternative 
DNA damage pathway is active in most p53-deficient human tumor cells, how DNA damage 
results in p38 MAP kinase activation was unknown.  To investigate whether this alternative 
survival and repair pathway may be mediated by TAK1, we infected the p53-deficient, human 
lung adenocarcinoma cell line H1299 with a control GFP or a TAK1-specific shRNA lentivirus.  
Alternatively, we pre-treated H1299 tumor cells with the TAK1 selective kinase inhibitor prior to 
etoposide exposure.  Both TAK1 depletion and TAK1 kinase inhibition impaired the p38 MAP 
kinase and JNK responses to DNA damage (Figure 8A and B and not shown).  We then directly 
examined the cell lysates for evidence of MK2 activation.  DNA damage-induced MK2 
phosphorylation was significantly impaired in the TAK1-silenced cells, but not in the control 
cultures (Figure 8C), suggesting that TAK1 contributes to the p38 MAPK/MK2-mediated DNA 
damage response pathway. 
To determine whether a TAK1-deficiency interferes with p38 MAPK/MK2 checkpoint 
signaling, we compared the cell cycle profiles of control or TAK1-silenced cells left untreated or 
treated with etoposide for 24 or 48 hours.  Treatment of the control infected cells with etoposide 
for 24h led to the accumulation of cells with 4N DNA content, indicative of an intact checkpoint.  
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In contrast, when TAK1 expression is limiting, etoposide-induced cell cycle arrest is impaired 
with half as many cells detected with 4N DNA content (Figure 8D; Control: 70.3 ± 3.7% vs. 
TAK1-knockdown: 42.3 ± 5.4% in three independent experiments; p<0.05). Consistently, an 
impaired p38 MAPK/MK2 response to DNA damage reduced phospho-CDC2 levels detected in 
the TAK1-depleted tumor cells compared to cells expressing the control GFP shRNA.  These 
data demonstrate that TAK1 mediates the NF-B genotoxic stress response and the p38 MAPK-
MK2 checkpoint.  These findings have translational implications and raise the TAK1 kinase as a 
potential therapeutic target for tumors refractory to conventional chemo/radiation therapy.  
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Discussion 
In the present study, we reveal how nuclear DNA damage signals are conveyed to the 
cytosolic IKK and p38 MAPK/MK2 kinases to mediate cell survival.  We demonstrate crucial 
cytosolic roles for RIP1 and TAK1 in the NF-B response, demonstrating that ubiquitin-
modified RIP1 triggers recruitment of the ubiquitin-activated kinase TAK1. These findings 
indicate that in addition to its nuclear role(s), RIP1 has cytosolic functions and contributes 
downstream of the nuclear ATM/NEMO/RIP1 complex. Our studies also reveal a requirement 
for TAK1 in the genotoxic stress-induced NF-B pathway and the alternative survival pathway 
mediated by the p38 MAPK/MK2 kinases.  We demonstrate that DNA damage stimulates TAK1 
kinase activity and importantly, that TAK1 kinase inhibition impairs both NF-B and 
p38MAP/MK2 kinase activation and thereby sensitizes p53-deficient human tumor cells to DNA 
damaging agents.  These findings have implications for translational cancer research and predict 
that TAK1 kinase inhibition may sensitize p53-deficient, chemoresistant tumors to DNA 
damaging agents.  
Our co-immunoprecipitation studies reveal that DNA damage stimulates interactions 
between ATM, NEMO, RIP1 and TAK1 in the cytosol of etoposide-treated cells.  These findings 
led us to interrogate the nature of the cytosolic complexes formed in response to DNA damage.  
Size exclusion chromatography revealed that DNA damage causes shifts in RIP1, NEMO, TAK1 
and IKK proteins into overlapping fractions corresponding to a MW range of 500-700 kDa.  
Co-immunoprecipitation of column fractions confirmed that DNA damage induces formation of 
a NEMO, RIP1 and TAK1 complex. Interestingly, these studies suggest that ubiquitinated RIP1 
shifts into the NEMO/TAK1 complex in response to DNA damage.  Surprisingly, only a fraction 
of the total RIP1 protein appears ubiquitin-modified and shifts into the 500-700 kDa complex in 
DNA damaged cells (Figures 2C; 3A and 3C and Supplementary Figure 2). This is in contrast to 
the amount of polyubiquitinated RIP1 detected when the same cells are treated with TNF- for 
10 min (Figure 2C). The reasons for these differences are unclear, but may reflect the nature of 
the NF-B responses. Although the TNF-induced NF-B response is rapid and robust, occurring 
within minutes of receptor activation; DNA damaging agents induce a weaker, more sustained 
NF-B response, detected at 30 minutes and lasting several hours.  The delay observed in the 
damage response may reflect the time required to relay the nuclear damage signal to the cytosol. 
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Whereas the duration of the DNA damage NF-B response may reflect how the pathway is 
negatively regulated. Cytokine-induced NF-B responses are terminated in part by the rapid de-
ubiquitination of cytosolic components such as RIP1, TRAF6 and NEMO. In contrast, the DNA 
damage-induced NF-B pathway may be regulated in the nucleus potentially at the level of the 
SUMO proteases that control NEMO and/or RIP1 sumoylation.  
We provide evidence that NEMO, RIP1 and TAK1 mediate NF-B activation and function 
to protect normal cells against DNA damage-induced cell death.  Consistently, Rip1- and Nemo-
deficient mouse embryonic fibroblasts fail to activate NF-B and were equivalently sensitive to 
doxorubicin-induced apoptosis (Figure 1A and B).   In the absence of Rip1 or Nemo, we found 
the induction of anti-apoptotic gene expression (Xiap, Birc3 and Bcl2l1) significantly impaired 
(Figure 1C).  Similarly, in the absence of Tak1 or upon treatment with a Tak1-selective kinase 
inhibitor, DNA damage fails to activate NF-B and sensitizes SV40-immortalized, Tak1-
deficient cells to DNA damage (Figure 4).  The NF-B and cell death studies in genetically 
modified mouse fibroblasts support a model whereby cytosolic RIP1, NEMO and TAK1 
function in the same pathway to mediate the NF-B response to DNA damage. 
In addition to RIP1 and NEMO, the p53-induced protein with death domain (PIDD) was 
also shown to interact with RIP1 to facilitate NEMO sumoylation (Janssens et al., 2005). Yet in 
contrast to a Rip1-, Nemo- or Tak1-deficiency, Pidd-deficient fibroblasts appear to respond 
normally to DNA damage (Manzl et al., 2009). These findings indicate that either PIDD is not 
absolutely required for the NF-B response or that redundant pathways exist in certain cell types. 
Consistent with this idea, the requirement for PARylation in DNA damage-induced NF-B 
activation appears cell type-dependent (Stilmann et al., 2009).  In contrast to the Janssens’ study 
which identified PIDD, RIP1 and NEMO in the nucleus of DNA damaged HEK293 cells, 
Stillman et al., failed to detect PIDD or RIP1 as components of the nuclear PARP-1 complex 
induced in mouse embryonic fibroblasts following -irradiation (Stilmann et al., 2009). These 
seemingly disparate findings could indicate that the composition of the DNA damage-induced 
nuclear complexes vary among cell types or that the PIDD/RIP1/NEMO nuclear complex 
functions downstream of the PARP-1 signalsome.  
Consistent with this model, the PARP-1 signalsome is detected 10 minutes after DNA 
damage, prior to the formation of the cytosolic RIP1, NEMO and TAK1 complex which 
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becomes detectable between 30 min and 1 hour following etoposide treatment (Stilmann et al., 
2009) and Figure 3).  Hence, a delay exists between PARP-1 signalsome (10 min) formation and 
RIP1 and NEMO sumoylation (>30 min), suggesting that sumoylation is downstream of the 
PARP-1 signalsome.  This study detects modified RIP1 in the cytosolic complex coincident with 
the detection of phospho-IB reactivity, thereby temporally linking the post-translational 
modification(s) of RIP1 to IKK activation (Figures 2A and 3).  
In the present study, we reveal the nature of the RIP1 modifications observed in DNA 
damaged cells. We find RIP1 SUMO- and ubiquitin-modified and demonstrate that PIASy 
silencing impairs our ability to detect both sumolyated RIP1 and NEMO in etoposide-treated 
cells (Figure 2B and Supplementary Figure 1B). Moreover, we detect sumoylated RIP1 and 
NEMO at similar time points following DNA damage (Figure 2A and Supplementary Figure 
1A), suggesting that PIASy modifies both NEMO and RIP1.  
DNA damage also stimulates the K63-linked ubiquitin modification of RIP1, which in turn 
signals the recruitment of the ubiquitin-activated kinase TAK1.  Consistent with this model, 
expression of a K63-only form of ubiquitin stimulates a Rip1/Tak1 interaction in unstimulated 
cells and TAK1 binds a modified form of RIP1 in DNA damaged cells (Supplementary Figure 3 
and Figure 3C).  Moreover, silencing of the E2 conjugating enzyme UBC13 responsible for K63-
linked polyubiquitination diminishes the NF-B response to doxorubicin (Supplementary Figure 
5). Collectively, these data reinforce a critical role for K63-ubiquitin in the stabilization and 
assembly of the cytosolic DNA damage response complex and reveal that this NF-B response 
utilizes ubiquitin-dependent signaling mechanisms to mediate cell cycle arrest and survival. 
The sensitivity to DNA damage observed in mouse embryonic fibroblasts deficient for 
Nemo, Rip1 or Tak1 prompted us to test whether RIP1 and TAK1 contribute to the DNA 
damage response in human tumor cells. We demonstrate that RIP1- and/or TAK1-silencing in 
multiple human tumor cell lines results in an impaired NF-B-dependent, anti-apoptotic response 
and sensitivity to DNA damage.  In addition to the DNA damage-induced NF-B response, our 
studies reveal that TAK1 also mediates the alternative p38 MAP kinase/MK-2 checkpoint found 
active in human tumor cells that lack functional p53 (Reinhardt et al., 2007).  We demonstrate 
that TAK1 silencing or TAK1 kinase inhibition impairs both the p38 MAP kinase/MK2 and JNK 
responses to DNA damage, interferes with cell cycle arrest and sensitizes tumor cells to 
etoposide treatment.  
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The present study reveals the RIP1 and TAK1 kinases as critical mediators of the genotoxic 
stress response. Although the kinase activity of RIP1 has been shown to be dispensable for TNF- 
and DNA damage-induced NF-B activation (Hur et al., 2003; Lee et al., 2004; Ting et al., 
1996), we demonstrate that TAK1 kinase activity is required for optimal NF-B, p38 MAP 
kinase/MK2 and JNK responses to DNA damage.  Importantly, these findings have translational 
implications for chemoresistance and predict that TAK1 kinase inhibition may sensitize resistant, 
mutant p53 human tumor cells to chemo/radiation therapies. 
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Experimental Procedures 
 
Cell culture and Biological Reagents 
Targeted disruption of the rip1 loci and generation of rip1-/- mouse embryonic fibroblasts 
has been described previously (Kelliher et al., 1998). Nemo- and Tak1-deficient fibroblasts and  
fibroblasts from wild type littermate controls were generously provided by Manolis Pasparakis 
(Institute for Genetics, University of Cologne) and Sankar Ghosh (Columbia University, NYC), 
respectively. Human U2OS, HeLa, MCF7 and H1299 cell lines were obtained from ATCC and 
grown in DMEM containing 10% FBS.  For some experiments, U2OS and H1299 cells were 
infected with a lentivirus expressing a control GFP- or TAK1-specific shRNA (Open 
Biosystems), selected with 2.0g/ml puromycin and TAK1 protein levels determined by 
immunoblotting. Doxorubicin was obtained from Sigma and etoposide purchased from Alexis. 
TAK1 kinase inhibitor 5Z-7-oxozeaenol was obtained from Bioaustralis.  Recombinant TNF- 
and IL1- was obtained from Sigma and eBioscience, respectively.  
 
Preparation and Transfection of siRNA 
siRNA oligonucleotides against human RIP1 (CCGACATTTCCTGGCATTGAA) and 
(CAGCTTGATTTACGTCAGCCA), PIASy (AACAAGACAGGTGGAGTTGAT) and 
(AAAAGCTGCCGTTCTTTAATA), UBC13 (GATCCGCACAGTTCTGCTATC) or TAK1  
(UGGCUUAUCUUACACUGGA) were purchased  from QIAGEN and Dharmacon respectively.   
A scrambled siRNA was purchased from Dharmacon. U2OS or HeLa cells were transfected 
using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions and as 
described previously (Yang et al., 2007).  
 
Western Blotting, Coimmunoprecipitation and Kinase Assays   
The RIP1 and NEMO antibodies were obtained from BD Bioscience. The ATM antibody 
was obtained from Calbiochem. The UBC13 and SUMO-1 antibodies were purchased from 
Zymed and the -actin antibody from Sigma. The Tak1, PIASy, IKK, PARP-1, ubiquitin, 
IB, p38 MAP kinase and JNK antibodies were all obtained from Santa Cruz Biotechnology.  
The phospho-specific antibodies for TAK1, MKK6, MK2, CDC2, IB, p38 MAP kinase and 
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JNK were obtained from Cell Signaling Technology. Anti total MK2, CDC2, CASPASE-3 and 
MKK6 antibodies were obtained from Cell Signaling Technology. The K63-ubiquitin antibody 
was obtained from Millipore. 
For coimmunoprecipitation, cells were lysed in an endogenous lysis buffer (0.5M Tris-HCl 
pH 7.6, 0.5M NaCl, 0.1M EDTA, 1% Triton X-100, 0.5M NaF, and 0.5M sodium 
pyrophosphate) supplemented with complete protease inhibitor cocktail (Roche).  
For ubiquitination and sumoylation assays, cells were boiled 10 mins in 1% SDS before 
immunoprecipitation. Boiled lysates were diluted to 0.1% SDS with a modified RIPA buffer 
(50mM Tris-HCl pH 7.5, 150mM NaCl, 1% NP40, 0.25% deoxycholic acid, 1mM EDTA, 
supplemented with protease inhibitors and 5mM N-ethylmaleimide (Sigma)). Cleared lysates 
were incubated overnight with anti-RIP1, anti-NEMO or anti-K63 ubiquitin antibody.  
Immunoprecipitates were washed 3 times with lysis buffer, separated by SDS-PAGE, transferred 
to nitrocellulose and analyzed by immunoblotting with an anti-ubquitin, anti-SUMO-1 or anti-
RIP1 antibodies.    
For western blot analysis to detect either total protein or phosphorylated protein, cells were 
lysed in kinase lysis buffer (10mM/10mM KPO4/EDTA pH 7.05, 5mM EGTA pH 7.2, 10mM 
MgCl2, 50mM -glycerophosphate pH 7.2, 0.5% NP-40, 0.1% Brij-35) supplemented with a 
protease inhibitor mixture (Roche), 1mM DTT, 1mM Na3VaO4, 1mM PMSF.  
For the TAK1 in vitro kinase assays, cell lysates were immunoprecipitated with an anti-
TAK1 antibody and then incubated with protein A–conjugated beads.  Immunoprecipitates were 
washed 3 times with lysis buffer and kinase reactions were allowed to proceed for 60 min at 
30°C in 20 l kinase buffer (20 mM HEPES pH 7.2, 10 mM MgCl2, 0.1mg/ml BSA, 3mM 2-
mercaptoethanol) containing 1g of His-tagged-kinase inactive MKK6(K82A). The reaction 
samples were separated by SDS-PAGE and MKK6 phosphorylation determined by 
immunoblotting with a phospho-specific MKK6 antibody (Cell Signaling).   
 
Biochemical Fractionation 
Cytoplasmic and nuclear fractions were prepared as described in (Dignam et al., 1983).  
Briefly, treated or untreated U2OS cells were lysed in a cytosolic lysis buffer containing 10 mM 
HEPES (pH 7.9), 1.5 mM MgCl2, 300 mM sucrose, 0.5% NP-40, 10 mM KCl supplemented 
with DTT and protease inhibitors. Nuclei were pelleted by a short centrifugation and lysed in a 
  Yang et al, 2010 
21 
nuclear buffer containing 20 mM HEPES (pH 7.9), 100 mM NaCl, 0.2 mM EDTA, 20% 
glycerol, 100 mM KCl supplemented with DTT and protease inhibitors. Nuclear pellets were 
subjected to a freeze-thaw cycle, sonicated, and centrifuged to obtain a solubilized nuclear 
fraction. In coimmunoprecipitation and gel filtration chromatography experiments, both cytosol 
and nuclear fraction were added or diluted to 150 mM NaCl.  
        For gel filtration chromatography, U2OS cytosolic extracts were fractionated using FPLC 
protein purification system (Pharmacia) on a Superose 6 column (Amersham Biosciences) at 4°C 
equilibrated with buffer A (20 mM Hepes-KOH, 10 mM KCl, 1 mM MgCl2, 1 mM EDTA, 1 
mM EGTA, 1 mM DTT pH 7.9, 150mM NaCl and 0.5% NP-40). Cytosolic (5mg) extract was 
loaded and eluted from the column in buffer A at a flow rate of 0.4 ml/min and 500 l fractions 
were collected. The column was calibrated with gel filtration standards (Bio-Rad Laboratories). 
 
Flow Cytometry  
For cell cycle analysis, human U2OS or H1299 cells infected with lentiviruses expressing a 
GFP or TAK1-specific shRNA were left untreated or treated with etoposide for 24 and 48 hours.  
The cells were then fixed in 70% ethanol, stained with propidium iodide (PI), and analyzed for 
DNA content. 
 
Real time quantitative PCR analysis  
Total RNA was isolated from untreated and etoposide treated mouse wild type, RIP1- or NEMO-
deficient cells or U2OS cells using Trizol reagent (Invitrogen) and cDNA was generated with 
Mo-MLV RT (Invitrogen).  Real time PCR primers used in this study are listed in 
Supplementary Table 1. Product accumulation was monitored by SYBR green fluorescence, with 
the relative expression levels determined from a standard curve of serial dilutions of cDNA.  All 
samples were normalized to -actin values and results were displayed as fold induction from 
untreated control.  
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Figure legends 
 
Figure 1.  A Rip1- or Nemo- deficiency impairs NF-B response and sensitizes cells to 
genotoxic stress.  (A) Wild type, Rip1- or Nemo-deficient MEF were left untreated or treated 
with doxorubicin (2g/ml) and cell viability determined at 24 and 48 hours.  Samples were done 
in triplicate; error bars represent the standard deviation. Statistical evaluation was performed 
using an unpaired student's t test and * indicates p<0.05. (B) DNA damage-induced NF-B 
activation is impaired in the absence of Rip1 and Nemo.  Wild type, Rip1- or Nemo-deficient 
MEFs were left untreated, treated with TNF- ng/ml) for 10min or treated with doxorubicin 
(10g/ml) for the time periods indicated. NF-B activity was monitored by immunoblotting with 
an IB antibody. (C) NF-B-dependent survival gene expression is impaired in Rip1- and 
Nemo-deficient MEF.  Wild type, Rip1-deficient and Nemo-deficient MEFs were left untreated 
or treated with etoposide (40M) for 6 hours and Birc3 (cIap2), Xiap and Bcl2l1(Bcl-xL) mRNA 
levels were quantified using real time PCR. Gene expression was normalized to -actin then 
normalized to untreated control to estimate fold induction. Samples were assayed in triplicate; 
error bars represent the standard deviation. 
 
Figure 2.  DNA damage stimulates the SUMO- and ubiquitin-modification of RIP1.  (A) 
DNA damage stimulates the SUMO-1 modification of RIP1.  Human U2OS cells were left 
untreated or treated with etoposide (40M) for the time periods indicated.  Protein extracts were 
boiled and then immunoprecipitated with an anti-RIP1 antibody and sumolyated proteins 
detected by immunoblotting with a SUMO-1 antibody.  (B) A PIASy-deficiency reduces SUMO-
RIP1 levels in etoposide-treated cells. Human U2OS cells were transfected with control or 
PIASy-specific siRNAs and then left untreated or treated with etoposide (40M) for one hour. 
Protein extracts were boiled and then immunoprecipitated with an anti-RIP1 antibody followed 
by immunoblotting with an anti-SUMO-1 antibody. (C) DNA damage stimulates RIP1 
polyubiquitination. Human U2OS cells were left untreated or treated with TNF- (10 ng/ml) for 
10 min or etoposide (40M) for the time periods indicated. Protein extracts were boiled and then 
immunoprecipitated with an anti-RIP1 antibody followed by immunoblotting with anti-ubiquitin. 
(D) DNA damage stimulates the K63 specific ubiquitin-modification of RIP1. Human U2OS 
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cells were left untreated or treated with human TNF- (10ng/ml) for 10 min or etoposide 
(40M) for the time periods indicated.  Protein extracts were boiled and then 
immunoprecipitated with K63-ubiquitin-specific antibodies and analyzed by immunoblotting 
with an anti RIP1 antibody.  
 
Figure 3.  DNA damage induces the formation of a large cytosolic complex containing 
ATM, NEMO, RIP1, TAK1 and IKK.  (A) A RIP1/NEMO/TAK1/IKK complex is detected 
in the cytosol of DNA damaged cells. U2OS cytosolic extracts were fractionated using FPLC 
protein purification system (Pharmacia) on a Superose 6 column (Amersham Biosciences). 
Fractions 10-37 were separated by SDS-PAGE and immunoblotted with NEMO, Rip1, Tak1 and 
IKK antibodies. The column was calibrated with gel filtration standards (Bio-Rad Laboratories) 
(B). Fractions 17-21 from untreated or etoposide treated cells were immunoprecipitated with a 
Tak1 antibody followed by immunoblotting with either a RIP1, NEMO or Tak1 antibody. (C) 
TAK1 binds modified RIP1 in etoposide treated cells.  Human U2OS were left untreated, treated 
with TNF- (10ng/ml) or etoposide (40M) and cell lysates were immunoprecipitated with a 
TAK1 antibody followed by immunoblotting with a RIP1 antibody. (D) ATM levels in the 
nuclear and cytosolic extracts were examined by immunoblotting with an ATM antibody. 
Lysates were also probed with anti-PARP, anti-caspase3 and -actin antibodies to monitor the 
purity of the nuclear/cytosolic lysates and the total protein levels. (E) DNA damage stimulates 
interactions between ATM and TAK1, RIP1 and TAK1 and RIP1 and NEMO. Human U2OS 
cells were left untreated or treated with etoposide (40M) for the time periods indicated.  
Nuclear and cytosolic extracts were immunoprecipitated with a TAK1 or NEMO antibody 
followed by immunoblotting with either an ATM or RIP1 antibody. 
 
Figure 4. DNA double strand breaks stimulate TAK1 kinase activity and TAK1 inhibition 
impairs the NF-B response and sensitizes cells to genotoxic stress. (A) Multiple DNA 
damaging agents stimulate TAK1 kinase activity. Human U2OS tumor cells were left untreated 
or treated with doxorubicin (10g/ml), etoposide (40M) or exposed to 10Gy -irradiation for 
the time periods indicated. TAK1 activity was measured by immunoblotting with a phospho-
specific TAK1 antibody.  Total TAK1 levels were measured by immunoblotting with a TAK1 
antibody. (B) NF-B response to genotoxic stress is impaired in Tak1-deficient MEFs.  SV40T 
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antigen-immortalized wild type or Tak1-deficient murine embryonic fibroblasts were left 
untreated, treated with 10ng/ml TNF- for 10 min or treated with 10g/ml doxorubicin (Dox) 
for the time periods indicated and NF-B activity was measured by monitoring IB 
degradation.  Cell lysates were probed with anti--actin antibody to insure equal amounts of total 
protein were loaded.  (C) Tak1-deficient MEFs are hypersensitive to doxorubicin treatment.  
Wild type or Tak1-deficient MEFs were treated with 2g/ml doxorubicin for 24 and 48 hours 
and viable cells were quantified by trypan blue exclusion. Samples were assayed in triplicate; 
error bars represent the standard deviation. The experiment shown is representative of at least 
three. Statistical evaluation was performed using an unpaired student's t test and ** indicates 
p<0.01.  (D) Treatment with a TAK1 kinase inhibitor impairs the NF-B response to DNA 
damage. Human U2OS cells were pretreated with the TAK1 kinase inhibitor 5Z7 (Bioaustralis) 
(1M) or DMSO for 2 hours. The cells were left untreated or treated with doxorubicin (10g/ml) 
for the time periods indicated or treated with TNF- (10ng/ml) for 10 min. NF-B activity was 
measured by immunoblotting the cell lysates with an IB antibody. Total protein levels were 
determined by immunoblotting with an anti--actin antibody.  (E) TAK1 kinase inhibition 
sensitizes human tumor cells to doxorubicin treatment.  Human MCF7 tumor cells were 
pretreated with the TAK1 kinase inhibitor 5Z7 (1M) or DMSO control for 2 hours. Cells were 
then left untreated or treated with doxorubicin (10g/ml) for 24 and 48 hours. Viable cells were 
quantified by trypan blue exclusion. Samples were assayed in triplicate; error bars represent the 
standard deviation. The experiment shown is representative of at least three. Statistical 
evaluation was performed using an unpaired student's t test and * indicates p<0.05. 
 
Figure 5.  DNA damage fails to activate TAK1 or NF-B in the absence of ATM, NEMO or 
RIP1.   Murine embryonic fibroblasts from Atm-, Nemo- or Rip1-deficient mice and control 
littermates were left untreated, treated with TNF- or IL-1 (10ng/ml) for 10 min or treated with 
etoposide (40M) for the time periods indicated. TAK1 was immunoprecipitated from the cell 
lysates and TAK1 kinase activity measured using an in vitro kinase assay with a His-tagged, 
kinase-inactive MKK6 as a substrate. MKK6 phosphorylation was then measured using a 
phospho-specific MKK6 antibody as described in (Xia et al., 2009). Total MKK6 input levels 
were measured by immunoblotting with an anti-MKK6 antibody (A and C). Alternatively, 
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TAK1 activity was measured by immunoblotting cell lysates with a phospho-specific TAK1 
antibody (B, D and E).  Total TAK1 levels were measured by immunoblotting with a TAK1 
antibody.  (F) RIP1 is also required for TAK1 and NF-B activation in etoposide-treated human 
tumor cells. To determine if acute RIP1 ablation altered the tumor NF-kB response, human 
U2OS cells were transfected with a control or RIP1 specific siRNA oligonucleotides.  Forty-
eight hours later, cells were treated with human TNF- for 10 min or with etoposide for the time 
periods indicated and phospho-TAK1 and -IB reactivity measured.  TAK1 and RIP1 levels 
were measured by immunoblotting. 
 
Figure 6.  TAK1 silencing impairs the tumor NF-B response to multiple DNA damaging 
agents. Human U2OS tumor cells were transfected with a control siRNA or a TAK1 siRNA, 
cells were left untreated or treated with doxorubicin (10g/ml) (A), or etoposide (40M) (B). 
Alternatively, human U2OS tumor cells were infected with a control GFP shRNA or TAK1-
specific shRNA lentivirus and following selection, cells were left untreated or exposed to 10Gy 
-irradiation (C). Cells were lysed and NF-B activity measured by immunoblotting with 
phospho-IB antibody or total IB antibody. To monitor knockdown and to insure that equal 
amounts of total protein are compared, the cell lysates were probed with an anti-TAK1 or anti--
actin antibody. Numbers under the blot indicate the relative abundance of phospho-IB or 
total-IB in each sample compare to -actin as determined by densitometry.  
 
Figure 7. Failure to induce NF-B-dependent survival gene expression and sensitivity to 
DNA damage in RIP1- or TAK1-depleted human tumor cells.  (A and B) A TAK1 deficiency 
sensitizes human tumor cell lines to etoposide treatment or -irradiation. Human U2OS cells 
were infected with a control GFP shRNA or TAK1-specific shRNA lentivirus and following 
selection, cells were left untreated, treated with etoposide (40M) for 24 and 48 hours, or 
exposed to 10Gy -irradiation. Viable cells were quantified by trypan blue exclusion. Samples 
were assayed in triplicate; error bars represent the standard deviation. The experiment shown is 
representative of at least three. Statistical evaluation was performed using an unpaired student's t 
test and * indicates p<0.05. (C and D) DNA damage fails to induce expression of NF-B-
dependent survival genes in TAK1- or RIP1-silenced human tumor cell lines. Human U2OS cells 
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were transfected with a control siRNA, a TAK1 siRNA or a RIP1 siRNA for 48 hours.  Cells 
were then left untreated or treated with etoposide (40M) for 0.5, 1 or 2 hours and RNA was 
harvested. XIAP and BCL2L1(BCL-xL) mRNA levels were quantified using real time PCR. Gene 
expression is reported as copy number per 1,000 copies of -actin. Samples were assayed in 
triplicate; error bars represent the standard deviation. (E) A RIP1 and TAK1 deficiency does not 
result in increased doxorubicin sensitivity. Human HeLa cells were left untransfected or 
transfected with a control siRNA, a TAK1 siRNA, RIP1 siRNA or TAK1 plus RIP1 siRNA 
oliognucleotides for 48 hours.  Cells were then left untreated or treated with doxorubicin 
(2g/ml) for 12 and 24 hours. Viable cells were quantified by trypan blue exclusion. Samples 
were assayed in triplicate; error bars represent the standard deviation. Statistical evaluation was 
performed using an unpaired student's t test and * indicates p<0.05, ns indicates not significant.  
(F)  RIP1 and/or TAK1 knockdown efficiency was monitored by immunoblotting the cell lysates 
with RIP1 or TAK1 antibodies. 
 
Figure 8. TAK1 mediates the p38 MAP kinase-MK-2 checkpoint in p53-deficient human 
tumor cells.  (A and C) A TAK1 deficiency impairs p38 MAP kinase, MK2 and JNK activation 
in response to DNA damage.   Human U2OS cells were infected with a control GFP or TAK1 
shRNA lentivirus.  The cells were left untreated, treated with TNF- (10ng/ml) for 10 min or 
treated with etoposide (40M) for the time periods indicated.   Cell lysates were probed with a 
phospho-specific p38 MAP kinase, -MK2 or -JNK1/2 antibodies.  Total p38 MAP kinase, MK2 
and JNK1/2 levels were measured by immunoblotting the cell lysates with total p38 MAP 
kinase, MK2 or JNK1/2 antibodies.  (B) Inhibiting TAK1 kinase activity impairs the p38 MAP 
kinase and JNK1/2 response to DNA damage. U2OS cells were pretreated with vehicle (DMSO) 
or the TAK1-selective kinase inhibitor 5Z7 (Bioaustralis) and cells were left untreated, treated 
with TNF- for 10 min or treated with etoposide for various time periods. JNK and p38 MAP 
kinase activation was measured by immunoblotting the cell lysates with phospho-JNK1/2 or 
phospho-p38 MAP kinase antibodies. Total p38 MAP kinase and JNK1/2 levels were measured 
by immunoblotting the cell lysates with p38 MAP kinase or JNK1/2 antibodies. (D) Impaired 
cell cycle arrest upon DNA damage in TAK1-deficient, p53-deficient human tumor cells.   
H1299 lung adenocarcinoma cells were infected with a control GFP shRNA or TAK1 shRNA 
lentivirus and selected cells were left untreated or treated with etoposide (40M) for 24 or 48 
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hours.  Cell cycle analysis was performed by staining the cells with PI followed by flow 
cytometry.  To confirm the flow cytometry data, phospho-CDC2 levels were compared by 
immunoblotting the cell lysates with phospho-specific CDC2 antibodies.  Total protein levels 
were determined by immunoblotting with an anti--actin antibody. 
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Figure Legends for Supplementary Data 
 
Supplementary Figure 1. DNA damage stimulates the SUMO-1-modification of 
NEMO. (A) DNA damage stimulates the SUMO-1 modification of NEMO.  Human 
U2OS cells were left untreated or treated with etoposide (40M) for the time periods 
indicated.  Protein extracts were boiled and then immunoprecipitated with an anti-NEMO 
antibody and sumolyated proteins detected by immunoblotting with a SUMO-1 antibody.  
(B) A PIASy-deficiency reduces sumoylated NEMO levels in etoposide-treated cells. 
Human U2OS cells were transfected with control or PIASy-specific siRNAs and the cells 
left untreated or treated with etoposide (40M) for one hour. Protein extracts were boiled 
and then immunoprecipitated with an anti-NEMO antibody followed by immunoblotting 
with an anti-SUMO-1 antibody. 
 
Supplementary Figure 2.  The DNA damage-induced cytosolic complex contains 
modified RIP1. U2OS cytosolic extracts from untreated or etoposide-treated cells were 
fractionated using FPLC protein purification system (Pharmacia) on a Superose 6 column 
(Amersham Biosciences).  Fractions 17-22 from the etoposide-treated cells were 
separated on a 3-8% gradient SDS-PAGE gel, transferred to nitrocellulose and 
immunoblotted with a RIP1 antibody. 
 
Supplementary Figure 3.  Expression of a K63-only form of ubiquitin is sufficient to 
stimulate a RIP1/TAK1 interaction in human tumor cells.  Human U2OS cells were 
left untreated, transfected with a K63-only form of ubiquitin, or treated with etoposide for 
the time periods indicated.  Cell lysates were immunoprecipitated with a TAK1 antibody 
followed by immunoblotting with a RIP1 antibody. Immunoprecipitates were also 
immunoblotted with a TAK1 antibody (lower panel) to insure that an equal amount of 
TAK1 protein was immunoprecipitated. 
Supplemental Text and Figures
 Supplementary Figure 4. TNF- or doxorubicin treatment stimulates interactions 
between NEMO and RIP1 and TAK1 and RIP1.  Human U2OS cells were left 
untreated, treated with 10ng/ml TNF- for 5-15 min or treated with 10g/ml doxorubicin 
(Dox) for the time periods indicated. Cell lysates were immunoprecipitated with a NEMO 
(A) or TAK1 (B) antibody followed by immunoblotting with a RIP1 antibody. 
Immunoprecipitates were also immunoblotted with a NEMO or TAK1 antibody (lower 
panel) to insure that equal amounts of protein were immunoprecipitated. 
 
Supplementary Figure 5. UBC13 contributes to the NF-B response to DNA damage. 
(A) The human U373 astrocytoma cell line was infected with a lentivirus expressing a 
control GFP- or UBC13-specific shRNA (Open Biosystems), selected with 2.0g/ml 
puromycin and UBC13 protein levels determined by immunoblotting. Cells were left 
untreated, treated with 10ng/ml TNF-  or treated with 10g/ml doxorubicin (Dox) for the 
time periods indicated. Cells were lysed and NF-B activity measured by immunoblotting 
with total IB antibody. To monitor knockdown and to insure that equal amounts of total 
protein are compared, the cell lysates were probed with an anti-UBC13 or anti--actin 
antibody. (B) Human U2OS tumor cells were transfected with control siRNA or UBC13 
siRNA oligonucleotides. Cells were left untreated, treated with 10ng/ml TNF-  or treated 
with 10g/ml doxorubicin (Dox) for the time periods indicated. Cells were lysed and 
NF-B activity measured by immunoblotting with total IB antibody. To monitor 
knockdown and to insure that equal amounts of total protein are compared, the cell lysates 
were probed with an anti-UBC13 or anti--actin antibody.  
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 Supplementary Table 1. Real time PCR primers used in this study 
Real time PCR primer Sequences 
Mouse -actin-F 5'-CGAGGCCCAGAGCAAGAGAG 
Mouse -actin-R 5'-CGGTTGGCCTTAGGGTTCAG 
Mouse Birc3-F 5’-GCTGTGGCCTAATGCTAGACA 
Mouse Birc3-R 5’-GGACAATCTTGATTTGCTCGGAA 
Mouse Xiap-F 5’-CGAGCTGGGTTTCTTTATACCG 
Mouse Xiap-R 5’-GATAGCACAGCCTGGATAGCAAC 
Mouse Bcl2l1-F 5’-GACAAGGAGATGCAGGTATTGG 
Mouse Bcl2l1-R 5’-TCCCGTAGAGATCCACAAAAGT 
Human -ACTIN-F 5'-CGCGAGAAGATGACCCAGAT  
Human -ACTIN-R 5'-GATAGGACAGCCTGGATAGCAAC 
Human BCL2L1-F 5’-GGCCTTTTTCTCCTTCGGTG 
Human BCL2L1-R 5’-CTCTCGGCTGCTGCATTGTT 
Human XIAP-F 5’-GCAGGTTGGGTGTACGATGT 
Human XIAP-R 5’-GCTGCCACAGTAGGACTCG 
